# Official Journal C 233/2006

| | ISSN 1725-2423 |
| --- | --- |
| Official Journal
  of the European Union | C 233 |
| | |
| English edition | Information and Notices | Volume 4928 September 2006 |

ISSN 1725-2423

Official Journal

of the European Union

C 233

English edition

Information and Notices

Volume 4928 September 2006

---

| Notice No | Contents | page |
| --- | --- | --- |
| | I   Information |
| | Commission |
| 2006/C 233/1 | Euro exchange rates | 1 |
| 2006/C 233/2 | Prior notification of a concentration (Case COMP/M.4242 — Thermo Electron Corporation/Fisher Scientific International) (
  1
  ) | 2 |
| 2006/C 233/3 | Prior notification of a concentration (Case COMP/M.4379 — Remondis/Cronimet/Alfa Acciai/TSR Group) — Candidate case for simplified procedure (
  1
  ) | 3 |
| 2006/C 233/4 | Prior notification of a concentration (Case COMP/M.4390 — PHL/IBFF) — Candidate case for simplified procedure (
  1
  ) | 4 |
| 2006/C 233/5 | State aid — Italy — State aid No C 31/2006 (ex N 612/2005) — Urgent measures to prevent bird flu — Invitation to submit comments pursuant to Article 88(2) of the EC Treaty | 5 |
| 2006/C 233/6 | Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid (
  1
  ) | 9 |
| 2006/C 233/7 | Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid (
  1
  ) | 17 |
| | EUROPEAN ECONOMIC AREA |
| | Standing Committee of the EFTA States |
| 2006/C 233/8 | List of marketing authorisations granted by the EEA EFTA States for the first half of 2003 | 21 |
| 2006/C 233/9 | List of marketing authorisations granted by the EEA EFTA States for the second half of 2003 | 28 |
| 2006/C 233/0 | List of marketing authorisations granted by the EEA EFTA States for the first half of 2004 | 37 |
| 2006/C 233/1 | List of marketing authorisations granted by the EEA EFTA States for the second half of 2004 | 45 |
| 2006/C 233/2 | List of marketing authorisations granted by the EEA EFTA States for the first half of 2005 | 54 |

Notice No

Contents

page

I   Information

Commission

2006/C 233/1

Euro exchange rates

1

2006/C 233/2

Prior notification of a concentration (Case COMP/M.4242 — Thermo Electron Corporation/Fisher Scientific International) (
  1
  )

1

2

2006/C 233/3

Prior notification of a concentration (Case COMP/M.4379 — Remondis/Cronimet/Alfa Acciai/TSR Group) — Candidate case for simplified procedure (
  1
  )

1

3

2006/C 233/4

Prior notification of a concentration (Case COMP/M.4390 — PHL/IBFF) — Candidate case for simplified procedure (
  1
  )

1

4

2006/C 233/5

State aid — Italy — State aid No C 31/2006 (ex N 612/2005) — Urgent measures to prevent bird flu — Invitation to submit comments pursuant to Article 88(2) of the EC Treaty

5

2006/C 233/6

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid (
  1
  )

1

9

2006/C 233/7

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid (
  1
  )

1

17

EUROPEAN ECONOMIC AREA

Standing Committee of the EFTA States

2006/C 233/8

List of marketing authorisations granted by the EEA EFTA States for the first half of 2003

21

2006/C 233/9

List of marketing authorisations granted by the EEA EFTA States for the second half of 2003

28

2006/C 233/0

List of marketing authorisations granted by the EEA EFTA States for the first half of 2004

37

2006/C 233/1

List of marketing authorisations granted by the EEA EFTA States for the second half of 2004

45

2006/C 233/2

List of marketing authorisations granted by the EEA EFTA States for the first half of 2005

54

| | III   Notices |
| --- | --- |
| | Commission |
| 2006/C 233/3 | Notice of invitation to tender for the reduction in the import duty on maize imported from non-member countries | 61 |

III   Notices

Commission

2006/C 233/3

Notice of invitation to tender for the reduction in the import duty on maize imported from non-member countries

61

| | |
| --- | --- |
| | (1)   Text with EEA relevance |

---

(1)   Text with EEA relevance

1

| EN | |
| --- | --- |

EN

---

I Information

Commission

| 28.9.2006 | EN | Official Journal of the European Union | C 233/1 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/1

---

Euro exchange rates (1)

27 September 2006

(2006/C 233/01)

1 euro=

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,2684 |
| JPY | Japanese yen | 148,90 |
| DKK | Danish krone | 7,4595 |
| GBP | Pound sterling | 0,67105 |
| SEK | Swedish krona | 9,2770 |
| CHF | Swiss franc | 1,5796 |
| ISK | Iceland króna | 88,77 |
| NOK | Norwegian krone | 8,2650 |
| BGN | Bulgarian lev | 1,9558 |
| CYP | Cyprus pound | 0,5767 |
| CZK | Czech koruna | 28,413 |
| EEK | Estonian kroon | 15,6466 |
| HUF | Hungarian forint | 273,63 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,6960 |
| MTL | Maltese lira | 0,4293 |
| PLN | Polish zloty | 3,9782 |
| RON | Romanian leu | 3,5350 |
| SIT | Slovenian tolar | 239,59 |
| SKK | Slovak koruna | 37,443 |
| TRY | Turkish lira | 1,8965 |
| AUD | Australian dollar | 1,6915 |
| CAD | Canadian dollar | 1,4143 |
| HKD | Hong Kong dollar | 9,8784 |
| NZD | New Zealand dollar | 1,9264 |
| SGD | Singapore dollar | 2,0156 |
| KRW | South Korean won | 1 196,86 |
| ZAR | South African rand | 9,6795 |
| CNY | Chinese yuan renminbi | 10,0229 |
| HRK | Croatian kuna | 7,3945 |
| IDR | Indonesian rupiah | 11 681,96 |
| MYR | Malaysian ringgit | 4,670 |
| PHP | Philippine peso | 63,693 |
| RUB | Russian rouble | 33,9790 |
| THB | Thai baht | 47,603 |

Currency

Exchange rate

USD

US dollar

1,2684

JPY

Japanese yen

148,90

DKK

Danish krone

7,4595

GBP

Pound sterling

0,67105

SEK

Swedish krona

9,2770

CHF

Swiss franc

1,5796

ISK

Iceland króna

88,77

NOK

Norwegian krone

8,2650

BGN

Bulgarian lev

1,9558

CYP

Cyprus pound

0,5767

CZK

Czech koruna

28,413

EEK

Estonian kroon

15,6466

HUF

Hungarian forint

273,63

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,6960

MTL

Maltese lira

0,4293

PLN

Polish zloty

3,9782

RON

Romanian leu

3,5350

SIT

Slovenian tolar

239,59

SKK

Slovak koruna

37,443

TRY

Turkish lira

1,8965

AUD

Australian dollar

1,6915

CAD

Canadian dollar

1,4143

HKD

Hong Kong dollar

9,8784

NZD

New Zealand dollar

1,9264

SGD

Singapore dollar

2,0156

KRW

South Korean won

1 196,86

ZAR

South African rand

9,6795

CNY

Chinese yuan renminbi

10,0229

HRK

Croatian kuna

7,3945

IDR

Indonesian rupiah

11 681,96

MYR

Malaysian ringgit

4,670

PHP

Philippine peso

63,693

RUB

Russian rouble

33,9790

THB

Thai baht

47,603

---

(1)

Source: reference exchange rate published by the ECB.

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/2 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/2

---

Prior notification of a concentration

(Case COMP/M.4242 — Thermo Electron Corporation/Fisher Scientific International)

(2006/C 233/02)

(Text with EEA relevance)

| 1. | On 19 September 2006, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Thermo Electron Corporation (‘Thermo’, USA) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Fisher Scientific International (‘Fisher’, USA) by way of purchase of shares. |
| --- | --- |

1.

On 19 September 2006, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Thermo Electron Corporation (‘Thermo’, USA) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking Fisher Scientific International (‘Fisher’, USA) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for Thermo: manufacture and supply of instruments, equipment and related software and services for life science, drug discovery, clinical, environmental and industrial laboratories; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Thermo: manufacture and supply of instruments, equipment and related software and services for life science, drug discovery, clinical, environmental and industrial laboratories;

| — | for Fisher: manufacturer, supplier and distributor of product and services for life science, medical research, university and hospital laboratories. |
| --- | --- |

—

for Fisher: manufacturer, supplier and distributor of product and services for life science, medical research, university and hospital laboratories.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4242 — Thermo Electron Corporation/Fisher Scientific International, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4242 — Thermo Electron Corporation/Fisher Scientific International, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/3 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/3

---

Prior notification of a concentration

(Case COMP/M.4379 — Remondis/Cronimet/Alfa Acciai/TSR Group)

Candidate case for simplified procedure

(2006/C 233/03)

(Text with EEA relevance)

| 1. | On 20 September 2006, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings ALFA Acciai s.p.a. (‘ALFA Acciai’, Italy), Cronimet Holding GmbH (‘Cronimet’, Germany), and Remondis AG & Co. KG (‘Remondis’, Germany) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the undertaking TSR Group (‘TSR’, Germany) by way of purchase of shares. |
| --- | --- |

1.

On 20 September 2006, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings ALFA Acciai s.p.a. (‘ALFA Acciai’, Italy), Cronimet Holding GmbH (‘Cronimet’, Germany), and Remondis AG & Co. KG (‘Remondis’, Germany) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of the undertaking TSR Group (‘TSR’, Germany) by way of purchase of shares.

| 2. | The business activities of the undertakings concerned are:






  — | for undertaking ALFA Acciai: production of reinforcing steel; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for undertaking ALFA Acciai: production of reinforcing steel;

| — | for undertaking Cronimet: trade in raw material for the production of steel; |
| --- | --- |

—

for undertaking Cronimet: trade in raw material for the production of steel;

| — | for undertaking Remondis: water and recycling management; |
| --- | --- |

—

for undertaking Remondis: water and recycling management;

| — | for undertaking TSR:trade in and processing of secondary raw material for the steel industries. |
| --- | --- |

—

for undertaking TSR:trade in and processing of secondary raw material for the steel industries.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4379 — Remondis/Cronimet/Alfa Acciai/TSR Group, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4379 — Remondis/Cronimet/Alfa Acciai/TSR Group, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/4 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/4

---

Prior notification of a concentration

(Case COMP/M.4390 — PHL/IBFF)

Candidate case for simplified procedure

(2006/C 233/04)

(Text with EEA relevance)

| 1. | On 20 September 2006 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Liberator Bidco Ltd (‘Liberator’, UK), part of Permira Holdings, acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the European frozen food business of the Unilever Group (‘IBFF’, UK) by way of purchase of shares and assets. |
| --- | --- |

1.

On 20 September 2006 the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Liberator Bidco Ltd (‘Liberator’, UK), part of Permira Holdings, acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the European frozen food business of the Unilever Group (‘IBFF’, UK) by way of purchase of shares and assets.

| 2. | The business activities of the undertakings concerned are:






  — | Liberator: private equity investment; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

Liberator: private equity investment;

| — | IBFF: production and marketing of branded frozen food. |
| --- | --- |

—

IBFF: production and marketing of branded frozen food.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4390 — PHL/IBFF to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Brussels |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4390 — PHL/IBFF to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Brussels

---

(1)  OJ L 24, 29.1.2004, p. 1.

(2)  OJ C 56, 5.3.2005, p. 32.

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/5 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/5

---

STATE AID — ITALY

State aid No C 31/2006 (ex N 612/2005) — Urgent measures to prevent bird flu

Invitation to submit comments pursuant to Article 88(2) of the EC Treaty

(2006/C 233/05)

By means of the letter dated of 4 July 2006, reproduced in the authentic language on the pages following this summary, the Commission notified Italy of its decision to initiate the procedure laid down in Article 88(2) of the EC Treaty concerning the abovementioned aid.

Interested parties may submit their comments on the aid in respect of which the Commission is initiating the procedure within one month of the date of publication of this summary and the following letter, to:

| European Commission |
| --- |
| Directorate-General for Agriculture and Rural Development |
| Directorate H2 |
| Office: Loi 130 5/128 |
| B-1049 Brussels |
| Fax: (32-2) 296 76 72 |

European Commission

Directorate-General for Agriculture and Rural Development

Directorate H2

Office: Loi 130 5/128

B-1049 Brussels

Fax: (32-2) 296 76 72

These comments will be communicated to Italy. Confidential treatment of the identity of the interested party submitting the comments may be requested in writing, stating the reasons for the request.

SUMMARY

| — | The Italian authorities adopted urgent measures to prevent bird flu which will be in force until 1 January 2007 under the following legislation:






  a) | Article 5 of Legislative Decree No 202 of 1 October 2005 (LD 202/05) implemented by Law No 244 of 30 November 2005 (Law 244/06) (1), as amended by Article 1a(7) of Law No 81 of 11 March 2006 (Law 81/06) on the ratification of Legislative Decree No 2 of 10 January 2006. |
| --- | --- | --- |

—

The Italian authorities adopted urgent measures to prevent bird flu which will be in force until 1 January 2007 under the following legislation:

a)

Article 5 of Legislative Decree No 202 of 1 October 2005 (LD 202/05) implemented by Law No 244 of 30 November 2005 (Law 244/06) (1), as amended by Article 1a(7) of Law No 81 of 11 March 2006 (Law 81/06) on the ratification of Legislative Decree No 2 of 10 January 2006.

| b) | Decree of the Ministry of Agricultural Policy of 13 January 2006 (Decree of 13 January 2006) on methods for implementing the measures to withdraw from the poultry meat market in accordance with Article 5(1) and (2) of Law 244/2005 (2). |
| --- | --- |

b)

Decree of the Ministry of Agricultural Policy of 13 January 2006 (Decree of 13 January 2006) on methods for implementing the measures to withdraw from the poultry meat market in accordance with Article 5(1) and (2) of Law 244/2005 (2).

| c) | Article 1a(8), (10), (11) and (12) of Law 81/06 (3). |
| --- | --- |

c)

Article 1a(8), (10), (11) and (12) of Law 81/06 (3).

| — | Poultry farms, slaughterhouses and poultry meat processing companies, poultry meat warehouses and poultry-feed manufacturers may benefit from these measures. |
| --- | --- |

—

Poultry farms, slaughterhouses and poultry meat processing companies, poultry meat warehouses and poultry-feed manufacturers may benefit from these measures.

| — | Article 5 of LD 202/05, last amended by Article 1a(7) of Law 81/06 provides for:






  a) | the purchase by AGEA of 17 000 tonnes of poultry meat and other poultry products for humanitarian aid (paragraphs 1 and 2); |
| --- | --- | --- |

—

Article 5 of LD 202/05, last amended by Article 1a(7) of Law 81/06 provides for:

a)

the purchase by AGEA of 17 000 tonnes of poultry meat and other poultry products for humanitarian aid (paragraphs 1 and 2);

| b) | the suspension of tax payments, social security contributions and payments for operators in the poultry sector (paragraph 3a); |
| --- | --- |

b)

the suspension of tax payments, social security contributions and payments for operators in the poultry sector (paragraph 3a);

| c) | granting aid for reconversion and restructuring loans for poultry businesses affected by the emergency situation in the poultry sector (paragraph 3c). |
| --- | --- |

c)

granting aid for reconversion and restructuring loans for poultry businesses affected by the emergency situation in the poultry sector (paragraph 3c).

| — | Article 1a, paragraphs 8, 10, 11 and 12 of Law 81/06 provides for an Emergency Poultry Fund (‘the Fund’) to be set up under the Ministry of Agricultural Policy for use in 2006:






  a) | for rescue and restructuring aid for the poultry sector (in accordance with Community guidelines on state aid for rescuing and restructuring firms in difficulty); |
| --- | --- | --- |

—

Article 1a, paragraphs 8, 10, 11 and 12 of Law 81/06 provides for an Emergency Poultry Fund (‘the Fund’) to be set up under the Ministry of Agricultural Policy for use in 2006:

a)

for rescue and restructuring aid for the poultry sector (in accordance with Community guidelines on state aid for rescuing and restructuring firms in difficulty);

| b) | to compensate farmers for loss of revenue or additional expenditure incurred as a result of implementing the Community, national or regional plans for preventing and eradicating bird flu and indirect damages resulting from restrictions on handling animals or production stoppages imposed by the health authorities; |
| --- | --- |

b)

to compensate farmers for loss of revenue or additional expenditure incurred as a result of implementing the Community, national or regional plans for preventing and eradicating bird flu and indirect damages resulting from restrictions on handling animals or production stoppages imposed by the health authorities;

| c) | for aid for the cessation of production (in accordance with point 9 of the Community Guidelines on state aid for the agriculture sector — guidelines); |
| --- | --- |

c)

for aid for the cessation of production (in accordance with point 9 of the Community Guidelines on state aid for the agriculture sector — guidelines);

| d) | for investments in poultry farms for biosecurity and health measures; |
| --- | --- |

d)

for investments in poultry farms for biosecurity and health measures;

| e) | for the slaughter of animals on the order of the health authority or for the well being of animals in the event of overpopulation of production structures or a ban on handling animals. |
| --- | --- |

e)

for the slaughter of animals on the order of the health authority or for the well being of animals in the event of overpopulation of production structures or a ban on handling animals.

| — | Article 1a(12) of Law 81/06 states that the implementing measures for aid funded by the Fund are to be adopted by a decree from the Ministry for Agricultural policy and the Ministry for Health. The Italian authorities undertook, in an e-mail dated 20 April 2006, to notify the above decrees to the Commission under Article 88(3) of the Treaty. The Commission notes that this Law does not constitute state aid ex se. Consequently these measures are not liable to distort competition or affect trade between Member States. The Italian authorities notified the Commission in an e-mail dated 23 May 2006 of a draft Ministerial Decree on the implementing measures for the aid financed by the Fund. As a result, this file in the dossier will examined as part of state aid No 322/2006. |
| --- | --- |

—

Article 1a(12) of Law 81/06 states that the implementing measures for aid funded by the Fund are to be adopted by a decree from the Ministry for Agricultural policy and the Ministry for Health. The Italian authorities undertook, in an e-mail dated 20 April 2006, to notify the above decrees to the Commission under Article 88(3) of the Treaty. The Commission notes that this Law does not constitute state aid ex se. Consequently these measures are not liable to distort competition or affect trade between Member States. The Italian authorities notified the Commission in an e-mail dated 23 May 2006 of a draft Ministerial Decree on the implementing measures for the aid financed by the Fund. As a result, this file in the dossier will examined as part of state aid No 322/2006.

| — | At this stage, the Commission has doubts regarding the compatibility with the internal market of the measures provided for in Article 5 of Legislative Decree No 202/05, last amended by Article 1a(7) of Law No 81/06, as the Italian authorities have not provided any information justifying these measures in the light of the rules applicable to state aid, and in particular point 11.4 of the Community guidelines on state aid in the poultry sector (4), as well as the Community guidelines for state aid for rescuing and restructuring firms in difficulty (5). |
| --- | --- |

—

At this stage, the Commission has doubts regarding the compatibility with the internal market of the measures provided for in Article 5 of Legislative Decree No 202/05, last amended by Article 1a(7) of Law No 81/06, as the Italian authorities have not provided any information justifying these measures in the light of the rules applicable to state aid, and in particular point 11.4 of the Community guidelines on state aid in the poultry sector (4), as well as the Community guidelines for state aid for rescuing and restructuring firms in difficulty (5).

TEXT OF THE LETTER

‘Con la presente mi pregio informarLa che la Commissione, dopo aver esaminato le informazioni trasmesse dalle autorità italiane sulla misura di cui all'oggetto, ha deciso di avviare il procedimento previsto dall'articolo 88, paragrafo 2, del trattato CE.

1.   PROCEDIMENTO

| 1) | Con lettera del 9 dicembre 2005, protocollata il 13 dicembre 2005, la Rappresentanza permanente d'Italia presso l'Unione europea ha notificato alla Commissione le misure in oggetto a norma dell'articolo 88, paragrafo 3, del trattato. |
| --- | --- |

1)

Con lettera del 9 dicembre 2005, protocollata il 13 dicembre 2005, la Rappresentanza permanente d'Italia presso l'Unione europea ha notificato alla Commissione le misure in oggetto a norma dell'articolo 88, paragrafo 3, del trattato.

| 2) | Con messaggio di posta elettronica del 2 marzo 2006, protocollato il 3 marzo 2006, le autorità italiane hanno notificato alla Commissione l'articolo 1 bis, paragrafi 8, 10, 11 e 12 del progetto di legge di conversione del decreto legge 10 gennaio 2006, n. 2 . |
| --- | --- |

2)

Con messaggio di posta elettronica del 2 marzo 2006, protocollato il 3 marzo 2006, le autorità italiane hanno notificato alla Commissione l'articolo 1 bis, paragrafi 8, 10, 11 e 12 del progetto di legge di conversione del decreto legge 10 gennaio 2006, n. 2 .

| 3) | Con fax rispettivamente del 14 febbraio 2006 (rif. AGR 4535) e del 20 marzo 2006 (rif. AGR 7800) la Commissione ha chiesto informazioni complementari. |
| --- | --- |

3)

Con fax rispettivamente del 14 febbraio 2006 (rif. AGR 4535) e del 20 marzo 2006 (rif. AGR 7800) la Commissione ha chiesto informazioni complementari.

| 4) | Con messaggio di posta elettronica del 20 aprile 2006, protocollato il 25 aprile 2005, le autorità italiane hanno trasmesso alcune informazioni complementari. |
| --- | --- |

4)

Con messaggio di posta elettronica del 20 aprile 2006, protocollato il 25 aprile 2005, le autorità italiane hanno trasmesso alcune informazioni complementari.

2.   DESCRIZIONE DETTAGLIATA DELLA MISURA

Titolo

| 5) | Misure urgenti per la prevenzione dell'influenza aviaria |
| --- | --- |

5)

Misure urgenti per la prevenzione dell'influenza aviaria

Fondamento giuridico

| 6) | Articolo 5 del decreto-legge 1o ottobre 2005, n. 202 (DL 202/05) convertito in legge 30 novembre 2005, n. 244 (legge 244/06) (6), modificato dall'articolo 1 bis, paragrafo 7, della legge 11 marzo 2006, n. 81 (legge 81/06) di conversione del decreto-legge 10 gennaio 2006, n. 2. |
| --- | --- |

6)

Articolo 5 del decreto-legge 1o ottobre 2005, n. 202 (DL 202/05) convertito in legge 30 novembre 2005, n. 244 (legge 244/06) (6), modificato dall'articolo 1 bis, paragrafo 7, della legge 11 marzo 2006, n. 81 (legge 81/06) di conversione del decreto-legge 10 gennaio 2006, n. 2.

| 7) | Decreto del Ministero delle politiche agricole e forestali del 13 gennaio 2006 (decreto 13 gennaio 2006) recante modalità per l'applicazione delle disposizioni in materia di ritiro dal mercato di carne avicola ai sensi dell'articolo 5, commi 1 e 2, della legge 244/2005 (7). |
| --- | --- |

7)

Decreto del Ministero delle politiche agricole e forestali del 13 gennaio 2006 (decreto 13 gennaio 2006) recante modalità per l'applicazione delle disposizioni in materia di ritiro dal mercato di carne avicola ai sensi dell'articolo 5, commi 1 e 2, della legge 244/2005 (7).

| 8) | Articolo 1 bis, paragrafi 8, 10, 11 e 12 della legge 81/06 (8). |
| --- | --- |

8)

Articolo 1 bis, paragrafi 8, 10, 11 e 12 della legge 81/06 (8).

Stanziamento

| 9) | Le risorse cui attingere per il finanziamento delle diverse misure provengono dal bilancio nazionale. Le autorità italiane hanno menzionato una dotazione finanziaria di 120 milioni di EUR così distribuiti: 20 milioni di EUR destinati agli aiuti alimentari e 100 milioni di EUR destinati all'istituzione del Fondo per l'emergenza avicola. |
| --- | --- |

9)

Le risorse cui attingere per il finanziamento delle diverse misure provengono dal bilancio nazionale. Le autorità italiane hanno menzionato una dotazione finanziaria di 120 milioni di EUR così distribuiti: 20 milioni di EUR destinati agli aiuti alimentari e 100 milioni di EUR destinati all'istituzione del Fondo per l'emergenza avicola.

Durata

| 10) | Fino al 1o gennaio 2007. |
| --- | --- |

10)

Fino al 1o gennaio 2007.

Beneficiari

| 11) | Allevamenti avicoli, imprese di macellazione e di trasformazione di carne avicola, esercenti attività di commercio all'ingrosso di carni avicole e imprese di produzione di alimenti per il pollame. |
| --- | --- |

11)

Allevamenti avicoli, imprese di macellazione e di trasformazione di carne avicola, esercenti attività di commercio all'ingrosso di carni avicole e imprese di produzione di alimenti per il pollame.

Misure

| 12) | L'articolo 5 del DL 202/05, modificato dall'articolo 1 bis, paragrafo 7, della legge 81/06, prevede:






  a) | l'acquisto, da parte dell'AGEA, di 17 000 tonnellate di carne di pollame e di altri prodotti avicoli da destinare agli aiuti umanitari (commi 1 e 2); |
| --- | --- | --- |

12)

L'articolo 5 del DL 202/05, modificato dall'articolo 1 bis, paragrafo 7, della legge 81/06, prevede:

a)

l'acquisto, da parte dell'AGEA, di 17 000 tonnellate di carne di pollame e di altri prodotti avicoli da destinare agli aiuti umanitari (commi 1 e 2);

| b) | la sospensione del pagamento delle imposte, dei contributi di assistenza sociale e delle rate delle operazioni creditizie e di finanziamento per gli operatori del settore avicolo (comma 3 bis); |
| --- | --- |

b)

la sospensione del pagamento delle imposte, dei contributi di assistenza sociale e delle rate delle operazioni creditizie e di finanziamento per gli operatori del settore avicolo (comma 3 bis);

| c) | la concessione di contributi destinati a mutui per il salvataggio e la riconversione e la ristrutturazione delle imprese avicole coinvolte nella situazione di emergenza della filiera avicola (comma 3 quater). |
| --- | --- |

c)

la concessione di contributi destinati a mutui per il salvataggio e la riconversione e la ristrutturazione delle imprese avicole coinvolte nella situazione di emergenza della filiera avicola (comma 3 quater).

| 13) | L'articolo 1 bis, commi 8, 10, 11 e 12, della legge 81/06 prevede l'istituzione presso il Ministero delle politiche agricole e forestali di un “Fondo per l'emergenza avicola” (il Fondo) con dotazione pari a 100 milioni di EUR per l'anno 2006, avente le seguenti finalità:






  a) | erogazione di contributi per il salvataggio e la ristrutturazione del settore avicolo (conformemente agli Orientamenti comunitari sugli aiuti di Stato per il salvataggio e la ristrutturazione di imprese in difficoltà); |
| --- | --- | --- |

13)

L'articolo 1 bis, commi 8, 10, 11 e 12, della legge 81/06 prevede l'istituzione presso il Ministero delle politiche agricole e forestali di un “Fondo per l'emergenza avicola” (il Fondo) con dotazione pari a 100 milioni di EUR per l'anno 2006, avente le seguenti finalità:

a)

erogazione di contributi per il salvataggio e la ristrutturazione del settore avicolo (conformemente agli Orientamenti comunitari sugli aiuti di Stato per il salvataggio e la ristrutturazione di imprese in difficoltà);

| b) | indennizzo degli allevatori per la perdita di reddito o per le spese supplementari sostenute in occasione dell'attuazione dei programmi di prevenzione ed eradicazione dell'influenza aviaria realizzati a livello comunitario, nazionale e regionale nonché per i danni indiretti provocati dalle restrizioni della movimentazione degli animali e/o dai periodi di fermo produttivo imposti dalle autorità sanitarie; |
| --- | --- |

b)

indennizzo degli allevatori per la perdita di reddito o per le spese supplementari sostenute in occasione dell'attuazione dei programmi di prevenzione ed eradicazione dell'influenza aviaria realizzati a livello comunitario, nazionale e regionale nonché per i danni indiretti provocati dalle restrizioni della movimentazione degli animali e/o dai periodi di fermo produttivo imposti dalle autorità sanitarie;

| c) | erogazione di contributi a seguito della cessazione dell'attività produttiva (conformemente al punto 9 degli Orientamenti comunitari per gli aiuti di Stato nel settore agricolo); |
| --- | --- |

c)

erogazione di contributi a seguito della cessazione dell'attività produttiva (conformemente al punto 9 degli Orientamenti comunitari per gli aiuti di Stato nel settore agricolo);

| d) | realizzazione di investimenti nelle aziende avicole per l'attuazione di misure di biosicurezza e delle misure sanitarie; |
| --- | --- |

d)

realizzazione di investimenti nelle aziende avicole per l'attuazione di misure di biosicurezza e delle misure sanitarie;

| e) | macellazione degli animali imposta con provvedimento dell'autorità sanitaria per il benessere degli animali in caso di sovrappopolazione delle strutture produttive o al divieto di movimentazione del bestiame. |
| --- | --- |

e)

macellazione degli animali imposta con provvedimento dell'autorità sanitaria per il benessere degli animali in caso di sovrappopolazione delle strutture produttive o al divieto di movimentazione del bestiame.

| 14) | L'articolo 1 bis, comma 12, della legge 81/06 stabilisce che le disposizione attuative degli aiuti finanziati dal Fondo saranno adottate con decreti del Ministero delle politiche agricole e forestali e del Ministero della sanità. Con messaggio di posta elettronica del 20 aprile 2006 le autorità italiane si sono impegnate a notificare alla Commissione i suddetti decreti, in applicazione dell'articolo 88, paragrafo 3, del trattato. |
| --- | --- |

14)

L'articolo 1 bis, comma 12, della legge 81/06 stabilisce che le disposizione attuative degli aiuti finanziati dal Fondo saranno adottate con decreti del Ministero delle politiche agricole e forestali e del Ministero della sanità. Con messaggio di posta elettronica del 20 aprile 2006 le autorità italiane si sono impegnate a notificare alla Commissione i suddetti decreti, in applicazione dell'articolo 88, paragrafo 3, del trattato.

| 15) | Con e-mail del 24 maggio 2006 le autorità italiane hanno notificato alla Commissione un progetto di decreto ministeriale comportante le misure attuative degli aiuti finanziati dal Fondo. Pertanto le misure previste dall'articolo 1-bis, comma 12, della legge 81/06 saranno esaminate dalla Commissione nell'ambito del fascicolo di aiuti di Stato N 322/2006. |
| --- | --- |

15)

Con e-mail del 24 maggio 2006 le autorità italiane hanno notificato alla Commissione un progetto di decreto ministeriale comportante le misure attuative degli aiuti finanziati dal Fondo. Pertanto le misure previste dall'articolo 1-bis, comma 12, della legge 81/06 saranno esaminate dalla Commissione nell'ambito del fascicolo di aiuti di Stato N 322/2006.

| 16) | La Commissione ha a più riprese raccomandato alle autorità italiane di non dare seguito alla misura prevista dall'articolo 5 del DL 202/05 in merito all'acquisto di carni congelate da destinare ad aiuti alimentari (9). Il decreto 13 gennaio 2006, che disciplina le modalità alle quali l'AGEA deve attenersi per l'acquisto dei prodotti avicoli di origine comunitaria, prevede i seguenti prezzi minimi d'acquisto:







  Carcasse e tagli di carne | EUR/kg per le carni fresche | EUR/kg per le carni congelate |
| --- | --- | --- | --- |
| Galletti Golden e/o livornesi | 2,40 | 2,10 |
| Galletti “Vallespluga” | 2,40 | 2,10 |
| Polli | 1,40 | 1,20 |
| Quarti posteriori di pollo | 1,40 | 1,20 |
| Ali di pollo | 1,00 | 0,80 |
| Cosce di tacchina femmina | 1,00 | 0,80 |
| Cosce di tacchino maschio | 1,10 | 0,90 |
| Ali di tacchino maschio | 1,00 | 0,80 |
| Tacchino maschio (busti) | 1,30 | 1,10 |
| Galline faraone ed anatre | 2,40 | 2,10 |

16)

La Commissione ha a più riprese raccomandato alle autorità italiane di non dare seguito alla misura prevista dall'articolo 5 del DL 202/05 in merito all'acquisto di carni congelate da destinare ad aiuti alimentari (9). Il decreto 13 gennaio 2006, che disciplina le modalità alle quali l'AGEA deve attenersi per l'acquisto dei prodotti avicoli di origine comunitaria, prevede i seguenti prezzi minimi d'acquisto:

Carcasse e tagli di carne

EUR/kg per le carni fresche

EUR/kg per le carni congelate

Galletti Golden e/o livornesi

2,40

2,10

Galletti “Vallespluga”

2,40

2,10

Polli

1,40

1,20

Quarti posteriori di pollo

1,40

1,20

Ali di pollo

1,00

0,80

Cosce di tacchina femmina

1,00

0,80

Cosce di tacchino maschio

1,10

0,90

Ali di tacchino maschio

1,00

0,80

Tacchino maschio (busti)

1,30

1,10

Galline faraone ed anatre

2,40

2,10

| 17) | Può offrire i propri prodotti ad AGEA qualsiasi persona fisica o giuridica attiva nel settore dell'allevamento e della trasformazione delle carni avicole da più di dodici mesi a decorrere dall'entrata in vigore del decreto 13 gennaio 2006 ed iscritta, per le suddette attività, nel registro delle imprese tenuto dalla Camera di commercio. |
| --- | --- |

17)

Può offrire i propri prodotti ad AGEA qualsiasi persona fisica o giuridica attiva nel settore dell'allevamento e della trasformazione delle carni avicole da più di dodici mesi a decorrere dall'entrata in vigore del decreto 13 gennaio 2006 ed iscritta, per le suddette attività, nel registro delle imprese tenuto dalla Camera di commercio.

3.   VALUTAZIONE DELLA MISURA

| 18) | In virtù dell'articolo 87, paragrafo 1, del trattato, sono incompatibili con il mercato comune, nella misura in cui incidano sugli scambi tra Stati membri, gli aiuti concessi dagli Stati, ovvero mediante risorse statali, sotto qualsiasi forma che, favorendo talune imprese o talune produzioni, falsino o minaccino di falsare la concorrenza. |
| --- | --- |

18)

In virtù dell'articolo 87, paragrafo 1, del trattato, sono incompatibili con il mercato comune, nella misura in cui incidano sugli scambi tra Stati membri, gli aiuti concessi dagli Stati, ovvero mediante risorse statali, sotto qualsiasi forma che, favorendo talune imprese o talune produzioni, falsino o minaccino di falsare la concorrenza.

| 19) | L'articolo 1 bis, commi 8, 10, 11 e 12 della legge 81/06 prevede l'istituzione del Fondo da utilizzare per finanziare le misure descritte al punto 13, lettere a) — e), le cui modalità di concessione saranno fissate da decreti ad hoc del Ministero delle politiche. Le autorità italiane hanno notificato alla Commissione un progetto di decreto ministeriale comportante le misure attuative degli aiuti finanziati dal Fondo. Pertanto le misure previste dall'articolo 1-bis, comma 12, della legge 81/06 saranno esaminate dalla Commissione nell'ambito del fascicolo di aiuti di Stato N 322/2006. |
| --- | --- |

19)

L'articolo 1 bis, commi 8, 10, 11 e 12 della legge 81/06 prevede l'istituzione del Fondo da utilizzare per finanziare le misure descritte al punto 13, lettere a) — e), le cui modalità di concessione saranno fissate da decreti ad hoc del Ministero delle politiche. Le autorità italiane hanno notificato alla Commissione un progetto di decreto ministeriale comportante le misure attuative degli aiuti finanziati dal Fondo. Pertanto le misure previste dall'articolo 1-bis, comma 12, della legge 81/06 saranno esaminate dalla Commissione nell'ambito del fascicolo di aiuti di Stato N 322/2006.

| 20) | Nella fase attuale le misure descritte ai punti 12, 16 e 17 sembrano invece corrispondere alla definizione di aiuto di Stato sopra menzionata nel senso che esse sono concesse mediante risorse statali sia sotto forma di mancato guadagno in termini di gettito fiscale per i pubblici poteri sia sotto forma di prezzi da corrispondere per l'acquisto di carni di pollame e nel senso che esse possono incidere sugli scambi a causa della posizione che l'Italia occupa nel comparto produttivo in parola (nel 2004 l'Italia era il quarto paese produttore di carni avicole nell'Unione). |
| --- | --- |

20)

Nella fase attuale le misure descritte ai punti 12, 16 e 17 sembrano invece corrispondere alla definizione di aiuto di Stato sopra menzionata nel senso che esse sono concesse mediante risorse statali sia sotto forma di mancato guadagno in termini di gettito fiscale per i pubblici poteri sia sotto forma di prezzi da corrispondere per l'acquisto di carni di pollame e nel senso che esse possono incidere sugli scambi a causa della posizione che l'Italia occupa nel comparto produttivo in parola (nel 2004 l'Italia era il quarto paese produttore di carni avicole nell'Unione).

| 21) | Tuttavia, nei casi previsti dall'articolo 87, paragrafi 2 e 3, del trattato, alcune misure possono essere considerate, in deroga, compatibili con il mercato comune. |
| --- | --- |

21)

Tuttavia, nei casi previsti dall'articolo 87, paragrafi 2 e 3, del trattato, alcune misure possono essere considerate, in deroga, compatibili con il mercato comune.

| 22) | Nel caso in specie, tenuto conto delle informazioni disponibili, l'unica deroga che si potrebbe invocare è quella dell'articolo 87, paragrafo 3, lettera c), del trattato, secondo cui possono essere considerati compatibili con il mercato comune gli aiuti destinati ad agevolare lo sviluppo di talune attività o di talune regioni economiche, sempre che non alterino le condizioni degli scambi in misura contraria al comune interesse. |
| --- | --- |

22)

Nel caso in specie, tenuto conto delle informazioni disponibili, l'unica deroga che si potrebbe invocare è quella dell'articolo 87, paragrafo 3, lettera c), del trattato, secondo cui possono essere considerati compatibili con il mercato comune gli aiuti destinati ad agevolare lo sviluppo di talune attività o di talune regioni economiche, sempre che non alterino le condizioni degli scambi in misura contraria al comune interesse.

| 23) | Affinché tale deroga sia applicabile, è necessario che la Commisione non nutra alcun dubbio in merito alla problematica della compatibilità delle misure previste. |
| --- | --- |

23)

Affinché tale deroga sia applicabile, è necessario che la Commisione non nutra alcun dubbio in merito alla problematica della compatibilità delle misure previste.

| 24) | Poiché attualmente le autorità italiane non hanno trasmesso nessuna informazione che giustifichi le suddette misure alla luce delle norme applicabili in materia di aiuti di Stato — segnatamente il punto 11.4 degli Orientamenti comunitari per gli aiuti di Stato nel settore agricolo (10) — e degli Orientamenti comunitari sugli aiuti di Stato per il salvataggio e la ristrutturazione di imprese in difficoltà (11), la Commissione nutre effettivamente dei dubbio per quanto riguarda la compatibilità della misura proposta con il mercato comune. |
| --- | --- |

24)

Poiché attualmente le autorità italiane non hanno trasmesso nessuna informazione che giustifichi le suddette misure alla luce delle norme applicabili in materia di aiuti di Stato — segnatamente il punto 11.4 degli Orientamenti comunitari per gli aiuti di Stato nel settore agricolo (10) — e degli Orientamenti comunitari sugli aiuti di Stato per il salvataggio e la ristrutturazione di imprese in difficoltà (11), la Commissione nutre effettivamente dei dubbio per quanto riguarda la compatibilità della misura proposta con il mercato comune.

| 25) | La Commissione ha pertanto deciso di avviare il procedimento di indagine previsto dall'articolo 88, paragrafo 2, del trattato. |
| --- | --- |

25)

La Commissione ha pertanto deciso di avviare il procedimento di indagine previsto dall'articolo 88, paragrafo 2, del trattato.

| 26) | Tenuto conto delle considerazioni sopra esposte, la Commissione invita le autorità italiane, nell'ambito del procedimento di cui all'articolo 88, paragrafo 2, del trattato, a presentare le proprie osservazioni ed a trasmettere qualsiasi informazione utile ai fini della valutazione della misura entro un mese a decorrere dalla data di ricezione della presente. Essa invita altresì le autorità del Suo paese a trasmettere immediatamente copia della presente ai potenziali beneficiari dell'aiuto. |
| --- | --- |

26)

Tenuto conto delle considerazioni sopra esposte, la Commissione invita le autorità italiane, nell'ambito del procedimento di cui all'articolo 88, paragrafo 2, del trattato, a presentare le proprie osservazioni ed a trasmettere qualsiasi informazione utile ai fini della valutazione della misura entro un mese a decorrere dalla data di ricezione della presente. Essa invita altresì le autorità del Suo paese a trasmettere immediatamente copia della presente ai potenziali beneficiari dell'aiuto.

| 27) | La Commissione rammenta alle autorità italiane l'effetto sospensivo dell'articolo 88, paragrafo 3, del trattato CE e si richiama all'articolo 14 del regolamento (CE) n. 659/1999 del Consiglio secondo cui ogni aiuto illegale può costituire oggetto di recupero presso il beneficiario. |
| --- | --- |

27)

La Commissione rammenta alle autorità italiane l'effetto sospensivo dell'articolo 88, paragrafo 3, del trattato CE e si richiama all'articolo 14 del regolamento (CE) n. 659/1999 del Consiglio secondo cui ogni aiuto illegale può costituire oggetto di recupero presso il beneficiario.

| 28) | Con la presente, la Commissione avvisa le autorità italiane che informerà gli interessati tramite la pubblicazione della presente lettera e di un riepilogo della medesima nella Gazzetta ufficiale dell'Unione europea. Essa informerà altresì gli interessati nei paesi dell'EFTA che hanno firmato l'Accordo SEE tramite la pubblicazione nel supplemento SEE della Gazzetta ufficiale nonché l'Autorità di vigilanza EFTA tramite copia della presente. Tutti gli interessati sopra citati saranno invitati a presentare le proprie osservazioni entro un mese a decorrere dalla data della presente pubblicazione.’ |
| --- | --- |

28)

Con la presente, la Commissione avvisa le autorità italiane che informerà gli interessati tramite la pubblicazione della presente lettera e di un riepilogo della medesima nella Gazzetta ufficiale dell'Unione europea. Essa informerà altresì gli interessati nei paesi dell'EFTA che hanno firmato l'Accordo SEE tramite la pubblicazione nel supplemento SEE della Gazzetta ufficiale nonché l'Autorità di vigilanza EFTA tramite copia della presente. Tutti gli interessati sopra citati saranno invitati a presentare le proprie osservazioni entro un mese a decorrere dalla data della presente pubblicazione.’

---

(1)  Official Gazette of the Italian Republic of 30.11.2005, general series No 279, p. 44.

1

(2)  Official Gazette of the Italian Republic of 26.1.2006, general series No 21, p. 50.

2

(3)  Official Gazette of the Italian Republic of 11.3.2006, ordinary supplement No 58.

3

(4)  OJ C 28, 1.2.2000, p. 2.

4

(5)  OJ C 244, 1.10.2004, p. 2.

5

(6)  Gazzetta ufficiale della Repubblica italiana del 30.11.2006 — serie generale — n. 279, pag. 44.

6

(7)  Gazzetta ufficiale della Repubblica italiana del 26.1.2006 — serie generale — n. 21, pag. 50.

7

(8)  Gazzetta ufficiale della Repubblica italiana dell'11.3.2006; supplemento ordinario n. 58.

8

(9)  Segnatamente con lettera D(2005)38372 del 12.12.2005 (rif. AGR 31606), con fax D(2006)9256 del 20.3.2006 (rif. AGRI 7800), entrambe della direzione generale dell'Agricoltura e dello sviluppo rurale e con lettera B4* D(2006)1927 del 12.4.2006 della direzione generale dello Sviluppo.

9

(10)  GU C 28 dell'1.2.2000, pag. 2.

10

(11)  GU C 244 dell'1.10.2004, pag. 2.

11

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/9 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/9

---

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid

(2006/C 233/06)

(Text with EEA relevance)

| Aid No | XT 3/06 |
| --- | --- |
| Member State | Germany |
| Region | Brandenburg |
| Title of aid scheme or name of company receiving individual aid | INNOPUNKT 13 ‘Prospects for qualified young women in the Land of Brandenburg’ |
| Legal basis | §§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg |
| Annual expenditure planned or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | EUR 0,35 million |
| Loans guaranteed | |
| Individual aid | Overall aid amount | |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | 5/2005 |
| Duration of the scheme or individual aid award | Until 5.5.2007
  (The adjustment period provided for in Article 8(2) of Regulation 68/2001 is being used in order to make any adjustment needed to bring the scheme into line with the block exemption regulation then applicable) |
| Objective of aid | General training | Yes |
| Specific training | |
| Economic sectors concerned | All sectors eligible for training aid | Yes |
| Name and address of the granting authority | Name:
  Landesagentur für Struktur und Arbeit Brandenburg GmbH |
| Address:





  Wetzlarer Str. 54 |
| D-14482 Potsdam |

Aid No

XT 3/06

Member State

Germany

Region

Brandenburg

Title of aid scheme or name of company receiving individual aid

INNOPUNKT 13 ‘Prospects for qualified young women in the Land of Brandenburg’

Legal basis

§§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

EUR 0,35 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

5/2005

Duration of the scheme or individual aid award

Until 5.5.2007

(The adjustment period provided for in Article 8(2) of Regulation 68/2001 is being used in order to make any adjustment needed to bring the scheme into line with the block exemption regulation then applicable)

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Landesagentur für Struktur und Arbeit Brandenburg GmbH

Address:

Wetzlarer Str. 54

D-14482 Potsdam

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 4/06 |
| --- | --- |
| Member State | Germany |
| Region | Brandenburg |
| Title of aid scheme or name of company receiving individual aid | INNOPUNKT 12 ‘Future prospects due to cluster-based regional interaction processes’ |
| Legal basis | §§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg |
| Annual expenditure planned or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | EUR 0,8 million |
| Loans guaranteed | |
| Individual aid | Overall aid amount | |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | 11.2004 |
| Duration of the scheme or individual aid award | Until 30.11.2006 |
| Objective of aid | General training | Yes |
| Specific training | |
| Economic sectors concerned | All sectors eligible for training aid | Yes |
| Name and address of the granting authority | Name:
  Landesagentur für Struktur und Arbeit Brandenburg GmbH |
| Address:





  Wetzlarer Str. 54 |
| D-14482 Potsdam |

Aid No

XT 4/06

Member State

Germany

Region

Brandenburg

Title of aid scheme or name of company receiving individual aid

INNOPUNKT 12 ‘Future prospects due to cluster-based regional interaction processes’

Legal basis

§§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

EUR 0,8 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

11.2004

Duration of the scheme or individual aid award

Until 30.11.2006

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Landesagentur für Struktur und Arbeit Brandenburg GmbH

Address:

Wetzlarer Str. 54

D-14482 Potsdam

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 5/06 |
| --- | --- |
| Member State | Germany |
| Region | Brandenburg |
| Title of aid scheme or name of company receiving individual aid | INNOPUNKT 14 ‘Alliances between the cultural and business sectors promote growth and employment in Brandenburg’ |
| Legal basis | §§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg |
| Annual expenditure planned or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | EUR 0,58 million |
| Loans guaranteed | |
| Individual aid | Overall aid amount | |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | 8.2005 |
| Duration of the scheme or individual aid award | Until 30.8.2007
  (The adjustment period provided for in Article 8(2) of Regulation 68/2001 is being used in order to make any adjustment needed to bring the scheme into line with the block exemption regulation then applicable. Steps are being taken to ensure that after the deadline the scheme is in keeping with the block exemption regulation or corresponding rules then in force) |
| Objective of aid | General training | Yes |
| Specific training | |
| Economic sectors concerned | All sectors eligible for training aid | Yes |
| Name and address of the granting authority | Name:
  Landesagentur für Struktur und Arbeit Brandenburg GmbH |
| Address:





  Wetzlarer Str. 54 |
| D-14482 Potsdam |

Aid No

XT 5/06

Member State

Germany

Region

Brandenburg

Title of aid scheme or name of company receiving individual aid

INNOPUNKT 14 ‘Alliances between the cultural and business sectors promote growth and employment in Brandenburg’

Legal basis

§§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

EUR 0,58 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

8.2005

Duration of the scheme or individual aid award

Until 30.8.2007

(The adjustment period provided for in Article 8(2) of Regulation 68/2001 is being used in order to make any adjustment needed to bring the scheme into line with the block exemption regulation then applicable. Steps are being taken to ensure that after the deadline the scheme is in keeping with the block exemption regulation or corresponding rules then in force)

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Landesagentur für Struktur und Arbeit Brandenburg GmbH

Address:

Wetzlarer Str. 54

D-14482 Potsdam

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 10/06 |
| --- | --- |
| Member State | United Kingdom of Great Britain and Northern Ireland |
| Region | Scotland (Local Authorities) |
| Title of aid scheme or name of company receiving individual aid | Support for SMEs for training |
| Legal basis | Section 20 of Local Government in Scotland Act 2003 |
| Annual expenditure planned under the scheme or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | GBP 2 million |
| Loans guaranteed | |
| Individual aid | Overall aid amount | |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | From 1.1.2006 |
| Duration of scheme or individual aid award | Until 31.12.2006 |
| Objective of aid | General training | Yes |
| Specific training | Yes |
| Economic sectors concerned | All sectors eligible for training aid | Yes |
| Name and address of the granting authority | Name:
  Scottish Executive |
| Address:





  State Aid Unit |
| Meridian Court |
| 5 Cadogan Street |
| Glasgow G2 6AT |
| United Kingdom |

Aid No

XT 10/06

Member State

United Kingdom of Great Britain and Northern Ireland

Region

Scotland (Local Authorities)

Title of aid scheme or name of company receiving individual aid

Support for SMEs for training

Legal basis

Section 20 of Local Government in Scotland Act 2003

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

GBP 2 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 1.1.2006

Duration of scheme or individual aid award

Until 31.12.2006

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Scottish Executive

Address:

State Aid Unit

Meridian Court

5 Cadogan Street

Glasgow G2 6AT

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 11/06 |
| --- | --- |
| Member State | United Kingdom |
| Region | West Wales & The Valleys Objective 1 Region |
| Title of aid scheme or name of company receiving individual aid | Energy Tech Limited |
| Legal basis | Council Regulation (EC) No. 1260/99
  The Structural Funds (National Assembly for Wales) Regulations 2000 (no./906/2000)
  The Structural Funds (National Assembly for Wales) Designation2000 |
| Annual expenditure planned under the scheme or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | |
| Loans guaranteed | |
| Individual aid | Overall aid amount | GBP 19 600 |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | From 17.1.2006 |
| Duration of scheme or individual aid award | Until 31.12.2006

  NB. As noted above, the grant was committed prior to 31 December 2006. Payments against this commitment will, potentially (in line with N+2) continue until 30 April 2008 |
| Objective of aid | General training | Yes |
| Specific training | No |
| Economic sectors concerned | Limited to specific sectors | Yes |
| Other services (Renewable Energy) | Yes |
| Name and address of the granting authority | Name:
  National Assembly for Wales |
| Address:





  C/o Welsh European Funding Office |
| Cwm Cynon Business Park |
| Mountain Ash CF45 4ER |
| United Kingdom |

Aid No

XT 11/06

Member State

United Kingdom

Region

West Wales & The Valleys Objective 1 Region

Title of aid scheme or name of company receiving individual aid

Energy Tech Limited

Legal basis

Council Regulation (EC) No. 1260/99

The Structural Funds (National Assembly for Wales) Regulations 2000 (no./906/2000)

The Structural Funds (National Assembly for Wales) Designation2000

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

GBP 19 600

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 17.1.2006

Duration of scheme or individual aid award

Until 31.12.2006

NB. As noted above, the grant was committed prior to 31 December 2006. Payments against this commitment will, potentially (in line with N+2) continue until 30 April 2008

Objective of aid

General training

Yes

Specific training

No

Economic sectors concerned

Limited to specific sectors

Yes

Other services (Renewable Energy)

Yes

Name and address of the granting authority

Name:

National Assembly for Wales

Address:

C/o Welsh European Funding Office

Cwm Cynon Business Park

Mountain Ash CF45 4ER

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 12/06 |
| --- | --- |
| Member State | United Kingdom |
| Region | London |
| Title of aid scheme or name of company receiving individual aid | Kessler Limited (Lean Learning Academy) |
| Legal basis | Section 4 RDA Act 1998 |
| Annual expenditure planned under the scheme or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | |
| Loans guaranteed | |
| Individual aid | Overall aid amount | GBP 123 000 |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | From 21.3.2006 |
| Duration of scheme or individual aid award | Until 17.7.2006 |
| Objective of aid | General training | Yes |
| Specific training | |
| Economic sectors concerned | All sectors eligible for training aid | Yes |
| Name and address of the granting authority | Name:
  London Development Agency |
| Address:





  Devon House, 58 |
| 60 St Katherines Way |
| London. E1W 15X |
| United Kingdom |

Aid No

XT 12/06

Member State

United Kingdom

Region

London

Title of aid scheme or name of company receiving individual aid

Kessler Limited (Lean Learning Academy)

Legal basis

Section 4 RDA Act 1998

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

GBP 123 000

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 21.3.2006

Duration of scheme or individual aid award

Until 17.7.2006

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

London Development Agency

Address:

Devon House, 58

60 St Katherines Way

London. E1W 15X

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 14/06 |
| --- | --- |
| Member State | Deutschland |
| Region | Brandenburg |
| Title of aid scheme or name of company receiving individual aid | IHK Projektgesellschaft mbH |
| Legal basis | §§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg |
| Annual expenditure planned or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | |
| Loans guaranteed | |
| Individual aid | Overall aid amount | EUR 0,28 million |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | 23.2.2006 |
| Duration of the scheme or individual aid award | Until 15.12.2007
  (The adjustment period provided for in Article 8(2) of Regulation 68/2001 is being used in order to make any adjustment needed to bring the scheme into line with the block exemption regulation then applicable. Steps are being taken to ensure that after the deadline the scheme is in keeping with the block exemption regulation or corresponding rules then in force) |
| Objective of aid | General training | Yes |
| Specific training | No |
| Economic sectors concerned | All sectors eligible for training aid | Yes |
| Name and address of the granting authority | Name:
  Landesagentur für Struktur und Arbeit Brandenburg GmbH |
| Address:





  Wetzlarer Str. 54 |
| D-14482 Potsdam |

Aid No

XT 14/06

Member State

Deutschland

Region

Brandenburg

Title of aid scheme or name of company receiving individual aid

IHK Projektgesellschaft mbH

Legal basis

§§ 23, 44 Landeshaushaltsordnung des Landes Brandenburg

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

EUR 0,28 million

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

23.2.2006

Duration of the scheme or individual aid award

Until 15.12.2007

(The adjustment period provided for in Article 8(2) of Regulation 68/2001 is being used in order to make any adjustment needed to bring the scheme into line with the block exemption regulation then applicable. Steps are being taken to ensure that after the deadline the scheme is in keeping with the block exemption regulation or corresponding rules then in force)

Objective of aid

General training

Yes

Specific training

No

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Landesagentur für Struktur und Arbeit Brandenburg GmbH

Address:

Wetzlarer Str. 54

D-14482 Potsdam

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 19/06 |
| --- | --- |
| Member State | United Kingdom |
| Region | London |
| Title of aid scheme or name of company receiving individual aid | Richard Edward Limited (Lean Learning Academy) |
| Legal basis | Section 4 RDA Act 1998 |
| Annual expenditure planned under the scheme or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | |
| Loans guaranteed | |
| Individual aid | Overall aid amount | GBP 72 700 |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | From 21.3.2006 |
| Duration of scheme or individual aid award | Until 17.7.2006 |
| Objective of aid | General training | Yes |
| Specific training | |
| Economic sectors concerned | All sectors eligible for training aid | Yes |
| Name and address of the granting authority | Name:
  London Development Agency |
| Address:





  Devon House, 58 |
| 60 St Katherines Way |
| London. E1W 15X |
| United Kingdom |

Aid No

XT 19/06

Member State

United Kingdom

Region

London

Title of aid scheme or name of company receiving individual aid

Richard Edward Limited (Lean Learning Academy)

Legal basis

Section 4 RDA Act 1998

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

GBP 72 700

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 21.3.2006

Duration of scheme or individual aid award

Until 17.7.2006

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

London Development Agency

Address:

Devon House, 58

60 St Katherines Way

London. E1W 15X

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 22/06 |
| --- | --- |
| Member State | United Kingdom |
| Region | West Midlands |
| Title of aid scheme or name of company receiving individual aid | Accelerate — Training Support for the West Midlands Automotive Cluster |
| Legal basis | Employment Act 1973 — Section 2(1) and 2(2) as substantiated by Section 25 of the Employment and Training Action1998 and the Industrial Development Act 1982, Section 7 & 11
  Regional Development Agencies Act 1998 — Section 5 & 6
  Greater London Authority Action 1999
  Leasehold and Reform, Housing and Urban Act 1993
  National Lottery Act, 1998
  Local Government Act, 2000 — Section 2
  Housing Grant Construction and Regeneration Act 1996 — Section 126
  Employment and Training Act 1993 — Section 2
  Leasehold, Housing and Urban Development Act 1993 — Part 3
  Learning and Skills Council Act 2000 |
| Annual expenditure planned under the scheme or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | GBP 25 million |
| Loans guaranteed | |
| Individual aid | Overall aid amount | GBP 150 000 |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | From 1.1.2006 |
| Duration of scheme or individual aid award | Until 31.12.2006 |
| Objective of aid | General training | Yes |
| Specific training | Yes |
| Economic sectors concerned | All sectors eligible for training aid | No |
| Limited to specific sectors | Yes |
| — | All manufacturing |

Aid No

XT 22/06

Member State

United Kingdom

Region

West Midlands

Title of aid scheme or name of company receiving individual aid

Accelerate — Training Support for the West Midlands Automotive Cluster

Legal basis

Employment Act 1973 — Section 2(1) and 2(2) as substantiated by Section 25 of the Employment and Training Action1998 and the Industrial Development Act 1982, Section 7 & 11

Regional Development Agencies Act 1998 — Section 5 & 6

Greater London Authority Action 1999

Leasehold and Reform, Housing and Urban Act 1993

National Lottery Act, 1998

Local Government Act, 2000 — Section 2

Housing Grant Construction and Regeneration Act 1996 — Section 126

Employment and Training Act 1993 — Section 2

Leasehold, Housing and Urban Development Act 1993 — Part 3

Learning and Skills Council Act 2000

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

GBP 25 million

Loans guaranteed

Individual aid

Overall aid amount

GBP 150 000

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 1.1.2006

Duration of scheme or individual aid award

Until 31.12.2006

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

All sectors eligible for training aid

No

Limited to specific sectors

Yes

—

All manufacturing

Yes

Name and address of the granting authority

Name:

Birmingham Chamber of Commerce and Industry

Address:

| 75 Harborne Road, Edgbaston |
| --- |
| Birmingham, B15 3DH |
| United Kingdom |

75 Harborne Road, Edgbaston

Birmingham, B15 3DH

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 24/06 |
| --- | --- |
| Member State | Belgium |
| Region | Vlaanderen |
| Title of aid scheme or name of company receiving individual aid | Van Hool |
| Bernard van Hoolstraat 58 |
| B-2500 Lier |

Aid No

XT 24/06

Member State

Belgium

Region

Vlaanderen

Title of aid scheme or name of company receiving individual aid

Van Hool

Bernard van Hoolstraat 58

B-2500 Lier

Legal basis

Decreet van 31 januari 2003

Annual expenditure planned or overall amount of aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

EUR 953 063

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

12.5.2006

Duration of scheme or individual aid award

Until 30.7.2008

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

Limited to specific sectors

Yes

Motor vehicles

Yes

Name and address of the granting authority

Name:

Vlaamse Gewest

Address:

| Markiesstraat 1 |
| --- |
| B-1000 Brussel |

Markiesstraat 1

B-1000 Brussel

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 25/06 |
| --- | --- |
| Member State | Belgium |
| Region | Vlaanderen |
| Title of aid scheme or name of company receiving individual aid | P&O Ports Antwerp |
| Nieuwe Westweg — Haven 742 |
| B-2040 Antwerpen |

Aid No

XT 25/06

Member State

Belgium

Region

Vlaanderen

Title of aid scheme or name of company receiving individual aid

P&O Ports Antwerp

Nieuwe Westweg — Haven 742

B-2040 Antwerpen

Legal basis

Decreet van 31 januari 2003

Annual expenditure planned or overall amount of aid granted to the company

Aid scheme

Annual overall amount

Loans guaranteed

Individual aid

Overall aid amount

EUR 999 261

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

19.5.2006

Duration of scheme or individual aid award

Until 30.8.2008

Objective of aid

General training

Yes

Specific training

Economic sectors concerned

Limited to specific sectors

Yes

Maritime transport services

Yes

Name and address of the granting authority

Name:

Vlaamse Gewest

Address:

| Markiesstraat 1 |
| --- |
| B-1000 Brussel |

Markiesstraat 1

B-1000 Brussel

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/17 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/17

---

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 of 12 January 2001 on the application of Articles 87 and 88 of the EC Treaty to training aid

(2006/C 233/07)

(Text with EEA relevance)

| Aid No | XT 16/06 |
| --- | --- |
| Member State | Hungary |
| Region | Entire country |
| Title of aid scheme or name of company receiving an individual aid | Training aid from the regional development appropriation |
| Legal basis | A területfejlesztési célelőirányzat felhasználásának részletes szabályairól szóló, a 17/2006. (I. 26.) Korm. rendelettel módosított 26/2003. (III. 4.) Korm. rendelet 24/A. § |
| Annual expenditure planned or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount (2006) | EUR 3 958 300 |
| Annual overall amount (2007) | EUR 1 227 985 |
| Loans guaranteed | |
| Individual aid | Overall aid amount | |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(6) of the Regulation | Yes | |
| Date of implementation | 29.1.2006 |
| Duration of the scheme or individual aid award | 30.6.2007 |
| Objective of aid | General training | Yes |
| Specific training | Yes |
| Economic sectors concerned | All sectors eligible for training aid | Yes |
| Name and address of the granting authority | Name:
  Országos Területfejlesztési Hivatal, Regionális Fejlesztés Operatív Program és INTERREG Közösségi Kezdeményezés Irányító Hatósága |
| Address:
  H-Budapest — 1015. Hattyú u. 14.
  Contact person:
  Szigeti Ferenc Albert |
| Large individual aid grants | In conformity with Article 5 of the Regulation | Yes |

Aid No

XT 16/06

Member State

Hungary

Region

Entire country

Title of aid scheme or name of company receiving an individual aid

Training aid from the regional development appropriation

Legal basis

A területfejlesztési célelőirányzat felhasználásának részletes szabályairól szóló, a 17/2006. (I. 26.) Korm. rendelettel módosított 26/2003. (III. 4.) Korm. rendelet 24/A. §

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount (2006)

EUR 3 958 300

Annual overall amount (2007)

EUR 1 227 985

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(6) of the Regulation

Yes

Date of implementation

29.1.2006

Duration of the scheme or individual aid award

30.6.2007

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Országos Területfejlesztési Hivatal, Regionális Fejlesztés Operatív Program és INTERREG Közösségi Kezdeményezés Irányító Hatósága

Address:

H-Budapest — 1015. Hattyú u. 14.

Contact person:

Szigeti Ferenc Albert

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 21/06 |
| --- | --- |
| Member State | Republic of Hungary |
| Region | Entire country |
| Title of aid scheme or name of company receiving an individual aid | EQUAL Community Initiative |
| Legal basis | Az EQUAL Közösségi Kezdeményezés fejezeti kezelésű előirányzat felhasználásával kapcsolatos szabályokról szóló 33/2004. (XII. 23.) FMM rendelet |
| Annual expenditure planned or overall amount of individual aid granted to the company | For 2005: EUR 13 649 200 (1) |
| Maximum aid intensity | For general education gross aid intensity cannot exceed 60% for large companies and 80% for micro-, small- and medium-sized enterprises.
  For special education gross aid intensity cannot exceed 35% for large companies and 45% for micro-, small- and medium-sized enterprises.
  For both general and special education aid intensity can be increased by a further 10% if it is for the education of a disadvantaged person |
| Date of implementation | Start of the aid programme: 1.1.2005 |
| Duration of the scheme or individual aid award | 31.12.2006 |
| Objective of aid | The aim of the EQUAL Community Initiative is to develop innovative methods to tackle discrimination and inequalities on the labour market via the Development Partnership and with the help of economic operators, including undertakings.
  EQUAL helps to implement the European Employment Strategy |
| Economic sectors concerned | All sectors |
| Name and address of the granting authority | Name:
  Foglalkoztatáspolitikai és Munkaügyi Minisztérium Humánerőforrás-fejlesztési Operatív Program és EQUAL Program Irányító Hatóság |
| Address:
  H-1054 Budapest, Alkotmány u. 3. |

Aid No

XT 21/06

Member State

Republic of Hungary

Region

Entire country

Title of aid scheme or name of company receiving an individual aid

EQUAL Community Initiative

Legal basis

Az EQUAL Közösségi Kezdeményezés fejezeti kezelésű előirányzat felhasználásával kapcsolatos szabályokról szóló 33/2004. (XII. 23.) FMM rendelet

Annual expenditure planned or overall amount of individual aid granted to the company

For 2005: EUR 13 649 200 (1)

Maximum aid intensity

For general education gross aid intensity cannot exceed 60% for large companies and 80% for micro-, small- and medium-sized enterprises.

For special education gross aid intensity cannot exceed 35% for large companies and 45% for micro-, small- and medium-sized enterprises.

For both general and special education aid intensity can be increased by a further 10% if it is for the education of a disadvantaged person

Date of implementation

Start of the aid programme: 1.1.2005

Duration of the scheme or individual aid award

31.12.2006

Objective of aid

The aim of the EQUAL Community Initiative is to develop innovative methods to tackle discrimination and inequalities on the labour market via the Development Partnership and with the help of economic operators, including undertakings.

EQUAL helps to implement the European Employment Strategy

Economic sectors concerned

All sectors

Name and address of the granting authority

Name:

Foglalkoztatáspolitikai és Munkaügyi Minisztérium Humánerőforrás-fejlesztési Operatív Program és EQUAL Program Irányító Hatóság

Address:

H-1054 Budapest, Alkotmány u. 3.

| Aid No | XT 23/06 |
| --- | --- |
| Member State: | Italy |
| Region | Molise, with differing aid intensities according to the area where the measure is implemented |
| Title of aid scheme or name of company receiving individual aid Regional Economic Development Plan: | Multiannual programme of measures designed to promote economic recovery in Molise following disasters — Open notice concerning the granting of aid to give integrated support to firms |
| Legal basis | Ordinanza del Presidente del Consiglio dei Ministri n. 3268 del 12 marzo 2003, e successive, che ha nominato il Presidente della Regione Molise Commissario Delegato per gli eccezionali eventi sismici del 31 ottobre 2002 e per quelli meteorologici del gennaio 2003 ed ha previsto, all'art. 15, la predisposizione di un Programma pluriennale d'interventi diretti a favorire la ripresa produttiva nel territorio della Regione Molise.
  Tale Programma è stato approvato dalla Giunta regionale del Molise con Deliberazione n. 841 del 9 giugno 2004 e dal Comitato Interministeriale per la Programmazione Economica con Deliberazione n. 32 del 29 settembre 2004 (pubblicata nella Gazzetta Ufficiale della Repubblica Italiana n. 289 del 10 dicembre 2004). |
| For the legal basis, see the specific section on the multiannual economic regeneration programme for Molise, on the region's official website (www.regione.molise.it) |
| Annual expenditure planned or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount
  Average over three years | EUR 0,53 million |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation: | 16.2.2006 |
| Duration of scheme or individual aid award | Until 30.6.2008 |
| Objective of aid | General training | Yes |
| Specific training | Yes |
| Economic sectors concerned | Limited to specific sectors | Yes |
| Other manufacturing | Yes |
| Other services | Yes |
| Name and address of the granting authority | Name:
  Commissario Delegato per l'Attuazione Operativa del Programma ex art. 15 |
| Address:





  via XXIV Maggio, 130 |
| I-86100 Campobasso |

Aid No

XT 23/06

Member State:

Italy

Region

Molise, with differing aid intensities according to the area where the measure is implemented

Title of aid scheme or name of company receiving individual aid Regional Economic Development Plan:

Multiannual programme of measures designed to promote economic recovery in Molise following disasters — Open notice concerning the granting of aid to give integrated support to firms

Legal basis

Ordinanza del Presidente del Consiglio dei Ministri n. 3268 del 12 marzo 2003, e successive, che ha nominato il Presidente della Regione Molise Commissario Delegato per gli eccezionali eventi sismici del 31 ottobre 2002 e per quelli meteorologici del gennaio 2003 ed ha previsto, all'art. 15, la predisposizione di un Programma pluriennale d'interventi diretti a favorire la ripresa produttiva nel territorio della Regione Molise.

Tale Programma è stato approvato dalla Giunta regionale del Molise con Deliberazione n. 841 del 9 giugno 2004 e dal Comitato Interministeriale per la Programmazione Economica con Deliberazione n. 32 del 29 settembre 2004 (pubblicata nella Gazzetta Ufficiale della Repubblica Italiana n. 289 del 10 dicembre 2004).

For the legal basis, see the specific section on the multiannual economic regeneration programme for Molise, on the region's official website (www.regione.molise.it)

Annual expenditure planned or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

Average over three years

EUR 0,53 million

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation:

16.2.2006

Duration of scheme or individual aid award

Until 30.6.2008

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

Limited to specific sectors

Yes

Other manufacturing

Yes

Other services

Yes

Name and address of the granting authority

Name:

Commissario Delegato per l'Attuazione Operativa del Programma ex art. 15

Address:

via XXIV Maggio, 130

I-86100 Campobasso

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

| Aid No | XT 56/04 |
| --- | --- |
| Member State | United Kingdom |
| Region | Northern Ireland |
| Title of aid scheme or name of company receiving individual aid | Company Development Programme |
| Legal basis | The Industrial Development (NI) Order 1982 |
| Annual expenditure planned under the scheme or overall amount of individual aid granted to the company | Aid scheme | Annual overall amount | GBP 7,5 million |
| Loans guaranteed | |
| Individual aid | Overall aid amount | |
| Loans guaranteed | |
| Maximum aid intensity | In conformity with Article 4(2)-(7) of the Regulation | Yes | |
| Date of implementation | From 2.2.2001 |
| Duration of scheme or individual aid award | Until 31.12.2006 |
| Objective of aid | General training | Yes |
| Specific training | Yes |
| Economic sectors concerned | All sectors eligible for training aid | Yes |
| Name and address of the granting authority | Name:
  Invest NI |
| Address:





  44-58 May Street |
| Belfast BT1 4NN |
| United Kingdom |

Aid No

XT 56/04

Member State

United Kingdom

Region

Northern Ireland

Title of aid scheme or name of company receiving individual aid

Company Development Programme

Legal basis

The Industrial Development (NI) Order 1982

Annual expenditure planned under the scheme or overall amount of individual aid granted to the company

Aid scheme

Annual overall amount

GBP 7,5 million

Loans guaranteed

Individual aid

Overall aid amount

Loans guaranteed

Maximum aid intensity

In conformity with Article 4(2)-(7) of the Regulation

Yes

Date of implementation

From 2.2.2001

Duration of scheme or individual aid award

Until 31.12.2006

Objective of aid

General training

Yes

Specific training

Yes

Economic sectors concerned

All sectors eligible for training aid

Yes

Name and address of the granting authority

Name:

Invest NI

Address:

44-58 May Street

Belfast BT1 4NN

United Kingdom

Large individual aid grants

In conformity with Article 5 of the Regulation

Yes

---

(1)  Data contains the total annual budget for the EQUAL programme for 2005. The budget also contains measures not constituting State aid. (Calculated with exchange rate HUF 250 = EUR 1.)

---

EUROPEAN ECONOMIC AREA

Standing Committee of the EFTA States

| 28.9.2006 | EN | Official Journal of the European Union | C 233/21 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/21

---

List of marketing authorisations granted by the EEA EFTA States for the first half of 2003

(2006/C 233/08)

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note, at the meeting on 10 March 2006, the following lists concerning marketing authorisations for medicinal products for the period 1 January — 30 June 2003:

| Annex I | List of new marketing authorisations |
| --- | --- |

Annex I

| Annex II | List of renewed marketing authorisations |
| --- | --- |

Annex II

| Annex III | List of extended marketing authorisations |
| --- | --- |

Annex III

| Annex IV | List of withdrawn marketing authorisations |
| --- | --- |

Annex IV

---

ANNEX I

1.   New Marketing Authorisations:

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January — 30 June 2003:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/131/031-050 | PegIntron | Liechtenstein | 31.1.2003 |
| EU/1/00/134/013-021 | Lantus | Liechtenstein | 31.5.2003 |
| EU/1/00/146/027 | Keppra | Liechtenstein | 31.3.2003 |
| EU/1/00/147/001/NO-008/NO | Hexavac | Norway | 30.1.2003 |
| EU/1/01/171/009-010 | Rapamune | Liechtenstein | 31.1.2003 |
| EU/1/01/176/004-006 | Zometa | Liechtenstein | 31.5.2003 |
| EU/1/01/179/001/NO | Osteogent Protein 1 | Norway | 24.4.2003 |
| EU/1/01/183/001/NO-017/NO | HBVAXPRO | Norway | 5.3.2003 |
| EU/1/01/188/004-006 | Fabrazyme | Liechtenstein | 31.1.2003 |
| EU/1/01/195/008-015 | Liprolog | Liechtenstein | 31.3.2003 |
| EU/1/02/201/005-006 | Protopic | Liechtenstein | 31.5.2003 |
| EU/1/02/202/005-006 | Protopy | Liechtenstein | 31.5.2003 |
| EU/1/02/216/002 | Invanz | Liechtenstein | 31.5.2003 |
| EU/1/02/224/001/NO-005/NO | Ambirix | Norway | 8.1.2003 |
| EU/1/02/226/001/IS | InductOs | Iceland | 19.3.2003 |
| EU/1/02/233/001-015 | Insulatard | Liechtenstein | 31.1.2003 |
| EU/1/02/238/001 | Zavesca | Liechtenstein | 31.1.2003 |
| EU/1/02/239/001/NO-024/NO | Bextra | Norway | 9.4.2003 |
| EU/1/02/239/001-010/IS | Bextra tablets 10 mg* | Iceland | 22.5.2003 |
| EU/1/02/239/001-024 | Bextra | Liechtenstein | 31.5.2003 |
| EU/1/02/239/011-020/IS | Bextra tablets 20 mg* | Iceland | 22.5.2003 |
| EU/1/02/239/021-024/IS | Bextra tablets 40 mg* | Iceland | 22.5.2003 |
| EU/1/02/240/001-003 | Somavert | Liechtenstein | 31.1.2003 |
| EU/1/02/242/001/NO-024/NO | Valdyn | Norway | 9.4.2003 |
| EU/1/02/242/001-024 | Valdyn | Liechtenstein | 31.5.2003 |
| EU/1/02/244/001/NO-024/NO | Kudeq | Norway | 9.4.2003 |
| EU/1/02/244/001-024 | Kudeq | Liechtenstein | 31.5.2003 |
| EU/1/02/245/001 | Theryttrex | Liechtenstein | 31.1.2003 |
| EU/1/02/245/001-002/IS | Theryttrex radioact. precursor | Iceland | 7.2.2002 |
| EU/1/02/246/001/IS | Carbaglu dispersible tabl. | Iceland | 17.2.2003 |
| EU/1/02/246/001/NO-002/NO | Carbaglu | Norway | 6.3.2003 |
| EU/1/03/248/001/NO-012/NO | Levitra | Norway | 10.3.2003 |
| EU/1/03/248/001-004/IS | Levitra 5 mg | Iceland | 24.3.2003 |
| EU/1/03/248/001-012 | Levitra | Liechtenstein | 31.3.2003 |
| EU/1/03/248/005-008/IS | Levitra 10 mg | Iceland | 24.3.2003 |
| EU/1/03/248/009-012/IS | Levitra 20 mg | Iceland | 24.3.2003 |
| EU/1/03/249/001/NO-012/NO | Vivanza | Norway | 26.5.2003 |
| EU/1/03/249/001-004/IS | Vivanza tabl. 5 mg | Iceland | 24.3.2003 |
| EU/1/03/249/001-012 | Vivanza | Liechtenstein | 31.3.2003 |
| EU/1/03/249/005-008/IS | Vivanza tabl. 10 mg | Iceland | 24.3.2003 |
| EU/1/03/249/009-012/IS | Vivanza tabl. 20 mg | Iceland | 24.3.2003 |
| EU/1/03/250/001 | Ytracis | Liechtenstein | 31.5.2003 |
| EU/1/03/250/001/IS | Ytracis 1850 MBq/ml | Iceland | 16.4.2003 |
| EU/1/03/250/001/NO | Ytracis 1850 MBq/ml | Norway | 22.4.2003 |
| EU/1/03/251/001 | Hepsera | Liechtenstein | 31.3.2003 |
| EU/1/03/251/001/IS | Hepsera tabl. 10 mg | Iceland | 4.4.2003 |
| EU/1/03/251/001/NO | Hepsera | Norway | 26.3.2003 |
| EU/1/03/252/001/NO-003/NO | Fuzeon | Norway | 5.6.2003 |
| EU/1/03/252/001-002/IS | Fuzeon powder and solv. for sol. for inj. | Iceland | 20.6.2003 |
| EU/1/03/252/003/IS | Fuzeon powder for sol. for inj. | Iceland | 20.6.2003 |
| EU/1/96/007/021-028 | Humalog | Liechtenstein | 31.1.2003 |
| EU/1/96/011/001-004 | Caelyx | Liechtenstein | 31.3.2003 |
| EU/1/97/054/001 and 003-005 | Viracept | Liechtenstein | 31.3.2003 |
| EU/1/98/069/004a, 4b | Plavix | Liechtenstein | 31.3.2003 |
| EU/1/98/070/004a, 4b | Iscover | Liechtenstein | 31.3.2003 |
| EU/1/98/084/002 | Simulect | Liechtenstein | 31.3.2003 |
| EU/1/99/103/004 | ReFacto | Liechtenstein | 31.1.2003 |
| EU/2/00/021/001/NO-002/NO | Rabigen | Norway | 19.5.2003 |
| EU/2/00/022/001/NO-004/NO | Ibaflin | Norway | 19.5.2003 |
| EU/2/00/022/001a, b, 002a, b | Ibaflin | Liechtenstein | 31.3.2003 |
| EU/2/00/022/003a, b, 004a, b | Ibaflin | Liechtenstein | 31.3.2003 |
| EU/2/00/022/005-012 | Ibaflin | Liechtenstein | 31.3.2003 |
| EU/2/00/024/001/NO | Pruban | Norway | 6.5.2003 |
| EU/2.2.20033/001/NO | Dexdomitor | Norway | 16.1.2003 |
| EU/2.2.20034/001/IS | Nobivac Bb cat | Iceland | 21.1.2003 |
| EU/2.2.20035/001-006 | SevoFlo | Liechtenstein | 31.1.2003 |
| EU/2.2.20036/001-002 | Nobilis OR inac | Liechtenstein | 31.1.2003 |
| EU/2.2.20036/001-002 | Nobilis OR inac | Norway | 31.1.2003 |
| EU/2.3.20037/001/NO-004/NO | ProteqFlu | Norway | 24.4.2003 |
| EU/2.3.20037/001-004 | ProteqFlu | Liechtenstein | 31.3.2003 |
| EU/2.3.20038/001/NO-004/NO | ProteqFlu-Te | Norway | 24.4.2003 |
| EU/2.3.20038/001-004 | ProteqFlu-Te | Liechtenstein | 31.3.2003 |
| EU/2.3.20039/001-012 | Advocate | Liechtenstein | 31.5.2003 |
| EU/2.3.20039/013/NO-018/NO | Advocate | Norway | 25.6.2003 |
| EU/2/97/004/001 and 003-008 | Metacam | Liechtenstein | 31.3.2003 |
| EU/2/97/005/008-009 | Quadrisol | Liechtenstein | 31.1.2003 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/131/031-050

PegIntron

Liechtenstein

31.1.2003

EU/1/00/134/013-021

Lantus

Liechtenstein

31.5.2003

EU/1/00/146/027

Keppra

Liechtenstein

31.3.2003

EU/1/00/147/001/NO-008/NO

Hexavac

Norway

30.1.2003

EU/1/01/171/009-010

Rapamune

Liechtenstein

31.1.2003

EU/1/01/176/004-006

Zometa

Liechtenstein

31.5.2003

EU/1/01/179/001/NO

Osteogent Protein 1

Norway

24.4.2003

EU/1/01/183/001/NO-017/NO

HBVAXPRO

Norway

5.3.2003

EU/1/01/188/004-006

Fabrazyme

Liechtenstein

31.1.2003

EU/1/01/195/008-015

Liprolog

Liechtenstein

31.3.2003

EU/1/02/201/005-006

Protopic

Liechtenstein

31.5.2003

EU/1/02/202/005-006

Protopy

Liechtenstein

31.5.2003

EU/1/02/216/002

Invanz

Liechtenstein

31.5.2003

EU/1/02/224/001/NO-005/NO

Ambirix

Norway

8.1.2003

EU/1/02/226/001/IS

InductOs

Iceland

19.3.2003

EU/1/02/233/001-015

Insulatard

Liechtenstein

31.1.2003

EU/1/02/238/001

Zavesca

Liechtenstein

31.1.2003

EU/1/02/239/001/NO-024/NO

Bextra

Norway

9.4.2003

EU/1/02/239/001-010/IS

Bextra tablets 10 mg*

Iceland

22.5.2003

EU/1/02/239/001-024

Bextra

Liechtenstein

31.5.2003

EU/1/02/239/011-020/IS

Bextra tablets 20 mg*

Iceland

22.5.2003

EU/1/02/239/021-024/IS

Bextra tablets 40 mg*

Iceland

22.5.2003

EU/1/02/240/001-003

Somavert

Liechtenstein

31.1.2003

EU/1/02/242/001/NO-024/NO

Valdyn

Norway

9.4.2003

EU/1/02/242/001-024

Valdyn

Liechtenstein

31.5.2003

EU/1/02/244/001/NO-024/NO

Kudeq

Norway

9.4.2003

EU/1/02/244/001-024

Kudeq

Liechtenstein

31.5.2003

EU/1/02/245/001

Theryttrex

Liechtenstein

31.1.2003

EU/1/02/245/001-002/IS

Theryttrex radioact. precursor

Iceland

7.2.2002

EU/1/02/246/001/IS

Carbaglu dispersible tabl.

Iceland

17.2.2003

EU/1/02/246/001/NO-002/NO

Carbaglu

Norway

6.3.2003

EU/1/03/248/001/NO-012/NO

Levitra

Norway

10.3.2003

EU/1/03/248/001-004/IS

Levitra 5 mg

Iceland

24.3.2003

EU/1/03/248/001-012

Levitra

Liechtenstein

31.3.2003

EU/1/03/248/005-008/IS

Levitra 10 mg

Iceland

24.3.2003

EU/1/03/248/009-012/IS

Levitra 20 mg

Iceland

24.3.2003

EU/1/03/249/001/NO-012/NO

Vivanza

Norway

26.5.2003

EU/1/03/249/001-004/IS

Vivanza tabl. 5 mg

Iceland

24.3.2003

EU/1/03/249/001-012

Vivanza

Liechtenstein

31.3.2003

EU/1/03/249/005-008/IS

Vivanza tabl. 10 mg

Iceland

24.3.2003

EU/1/03/249/009-012/IS

Vivanza tabl. 20 mg

Iceland

24.3.2003

EU/1/03/250/001

Ytracis

Liechtenstein

31.5.2003

EU/1/03/250/001/IS

Ytracis 1850 MBq/ml

Iceland

16.4.2003

EU/1/03/250/001/NO

Ytracis 1850 MBq/ml

Norway

22.4.2003

EU/1/03/251/001

Hepsera

Liechtenstein

31.3.2003

EU/1/03/251/001/IS

Hepsera tabl. 10 mg

Iceland

4.4.2003

EU/1/03/251/001/NO

Hepsera

Norway

26.3.2003

EU/1/03/252/001/NO-003/NO

Fuzeon

Norway

5.6.2003

EU/1/03/252/001-002/IS

Fuzeon powder and solv. for sol. for inj.

Iceland

20.6.2003

EU/1/03/252/003/IS

Fuzeon powder for sol. for inj.

Iceland

20.6.2003

EU/1/96/007/021-028

Humalog

Liechtenstein

31.1.2003

EU/1/96/011/001-004

Caelyx

Liechtenstein

31.3.2003

EU/1/97/054/001 and 003-005

Viracept

Liechtenstein

31.3.2003

EU/1/98/069/004a, 4b

Plavix

Liechtenstein

31.3.2003

EU/1/98/070/004a, 4b

Iscover

Liechtenstein

31.3.2003

EU/1/98/084/002

Simulect

Liechtenstein

31.3.2003

EU/1/99/103/004

ReFacto

Liechtenstein

31.1.2003

EU/2/00/021/001/NO-002/NO

Rabigen

Norway

19.5.2003

EU/2/00/022/001/NO-004/NO

Ibaflin

Norway

19.5.2003

EU/2/00/022/001a, b, 002a, b

Ibaflin

Liechtenstein

31.3.2003

EU/2/00/022/003a, b, 004a, b

Ibaflin

Liechtenstein

31.3.2003

EU/2/00/022/005-012

Ibaflin

Liechtenstein

31.3.2003

EU/2/00/024/001/NO

Pruban

Norway

6.5.2003

EU/2.2.20033/001/NO

Dexdomitor

Norway

16.1.2003

EU/2.2.20034/001/IS

Nobivac Bb cat

Iceland

21.1.2003

EU/2.2.20035/001-006

SevoFlo

Liechtenstein

31.1.2003

EU/2.2.20036/001-002

Nobilis OR inac

Liechtenstein

31.1.2003

EU/2.2.20036/001-002

Nobilis OR inac

Norway

31.1.2003

EU/2.3.20037/001/NO-004/NO

ProteqFlu

Norway

24.4.2003

EU/2.3.20037/001-004

ProteqFlu

Liechtenstein

31.3.2003

EU/2.3.20038/001/NO-004/NO

ProteqFlu-Te

Norway

24.4.2003

EU/2.3.20038/001-004

ProteqFlu-Te

Liechtenstein

31.3.2003

EU/2.3.20039/001-012

Advocate

Liechtenstein

31.5.2003

EU/2.3.20039/013/NO-018/NO

Advocate

Norway

25.6.2003

EU/2/97/004/001 and 003-008

Metacam

Liechtenstein

31.3.2003

EU/2/97/005/008-009

Quadrisol

Liechtenstein

31.1.2003

---

ANNEX II

2.   Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January — 30 June 2003:

| EU-Number | Product | Country | Date of renewal |
| --- | --- | --- | --- |
| EU/1/96/006/001/NO-003/NO | NovoSeven | Norway | 14.1.2003 |
| EU/1/96/015/001/NO-002/NO | Epivir | Norway | 31.1.2003 |
| EU/1/97/032/001/IS | LeukoScan p.f. sol. for inj. | Iceland | 29.1.2003 |
| EU/1/97/039/001/NO-004/NO | Cystagon | Norway | 3.3.2003 |
| EU/1/97/039/001-002/IS | Cystagon capsule, hard | Iceland | 29.1.2003 |
| EU/1/97/039/003-004/IS | Cystagon capsule, hard | Iceland | 29.1.2003 |
| EU/1/97/040/001-002/IS | Teslascan 0,01 mmol/ml solution for infusion | Iceland | 12.5.2003 |
| EU/1/97/045/001, 006-007/IS | Helicobacter INFAI powder for oral solution, 75 mg | Iceland | 12.5.2003 |
| EU/1/97/045/008/IS | Helicobacter INFAI powder for oral solution, 45 mg | Iceland | 12.5.2003 |
| EU/1/97/046/001-003, -010, -013/IS | Aprovel tabl. 75 mg | Iceland | 18.2.2003 |
| EU/1/97/046/004-006, -011, -014/IS | Aprovel tabl. 150 mg | Iceland | 18.2.2003 |
| EU/1/97/046/007-009, 026, 030, 033/IS | Aprovel tabl. 300 mg | Iceland | 18.2.2003 |
| EU/1/97/047/001/IS | BeneFix powd. and solv. inj. 250 IU | Iceland | 15.4.2003 |
| EU/1/97/047/001-003 | BeneFix | Liechtenstein | 31.3.2003 |
| EU/1/97/047/002/IS | BeneFix powd. and solv. inj. 500 IU | Iceland | 15.4.2003 |
| EU/1/97/047/003/IS | BeneFix powd. and solv. inj. 1000 IU | Iceland | 15.4.2003 |
| EU/1/97/048/001-014 | Infanrix HepB | Liechtenstein | 31.1.2003 |
| EU/1/97/048/001-014/IS | Infanrix HepB | Iceland | 11.2.2003 |
| EU/1/97/049/001-003, -010, 013/IS | Karvea tabl. 75 mg | Iceland | 12.2.2003 |
| EU/1/97/049/004-006, -012, 015/IS | Karvea tabl. 300 mg | Iceland | 12.2.2003 |
| EU/1/97/049/004-006, -011, 014/IS | Karvea tabl. 150 mg | Iceland | 12.2.2003 |
| EU/1/97/050/001/NO | Sifrol | Norway | 6.1.2003 |
| EU/1/97/050/009/NO-012/NO | Sifrol | Norway | 6.1.2003 |
| EU/1/97/051/001-002/IS | Mirapexin tab. 0,088 mg | Iceland | 31.1.2003 |
| EU/1/97/051/003-004/IS | Mirapexin tab. 0,18 mg | Iceland | 31.1.2003 |
| EU/1/97/051/005-006/IS | Mirapexin tab. 0,035 mg | Iceland | 31.1.2003 |
| EU/1/97/051/007-008/IS | Mirapexin tab. 0,7 mg | Iceland | 31.1.2003 |
| EU/1/97/051/009-010/IS | Mirapexin tab. 1,1 mg | Iceland | 31.1.2003 |
| EU/1/97/052/001/NO-006/NO | Daquiran | Norway | 28.1.2003 |
| EU/1/97/052/009/NO-010/NO | Daquiran | Norway | 28.1.2003 |
| EU/1/97/053/001/NO-005/NO | Cerezyme | Norway | 6.1.2003 |
| EU/1/97/053/001-002/IS | Cerezyme 200U | Iceland | 10.2.2003 |
| EU/1/97/053/001-005 | Cerezyme | Liechtenstein | 31.1.2003 |
| EU/1/97/053/003-005/IS | Cerezyme 400U | Iceland | 10.2.2003 |
| EU/1/97/054/001/IS | Viracept 50 mg/g oral powder | Iceland | 13.5.2003 |
| EU/1/97/054/001/NO | Viracept | Norway | 18.2.2003 |
| EU/1/97/054/003/IS | Viracept tablets 250 mg | Iceland | 13.5.2003 |
| EU/1/97/054/003/NO-005/NO | Viracept | Norway | 18.2.2003 |
| EU/1/97/054/005/IS | Viracept film coated tablets 250 mg | Iceland | 13.5.2003 |
| EU/1/97/055/001/IS | Viramune tabl. 200 mg | Iceland | 10.4.2003 |
| EU/1/97/055/001/NO-002/NO | Viramune | Norway | 6.3.2003 |
| EU/1/97/055/001-002 | Viramune | Liechtenstein | 31.3.2003 |
| EU/1/97/055/002/IS | Viramune mixt. susp. 50 mg/5ml | Iceland | 10.4.2003 |
| EU/1/97/057/001 | Quadramet | Liechtenstein | 31.3.2003 |
| EU/1/97/057/001/IS | Quadramet solution for injection 1,3 GB/ml | Iceland | 16.5.2003 |
| EU/1/97/057/001/NO | Quadramet | Norway | 5.5.2003 |
| EU/1/98/065/001/NO-002/NO | Optison | Norway | 20.6.2003 |
| EU/1/98/065/001-002 | Optison | Liechtenstein | 31.5.2003 |
| EU/1/98/065/001-002/IS | Optison, solution for injection | Iceland | 25.6.2003 |
| EU/2/98/007/001-003 | Clomicalm | Liechtenstein | 31.5.2003 |
| EU/2/98/008/001/NO-004/NO | Neocolipor | Norway | 18.6.2003 |
| EU/2/98/008/001-004 | Neocolipor | Liechtenstein | 31.5.2003 |

EU-Number

Product

Country

Date of renewal

EU/1/96/006/001/NO-003/NO

NovoSeven

Norway

14.1.2003

EU/1/96/015/001/NO-002/NO

Epivir

Norway

31.1.2003

EU/1/97/032/001/IS

LeukoScan p.f. sol. for inj.

Iceland

29.1.2003

EU/1/97/039/001/NO-004/NO

Cystagon

Norway

3.3.2003

EU/1/97/039/001-002/IS

Cystagon capsule, hard

Iceland

29.1.2003

EU/1/97/039/003-004/IS

Cystagon capsule, hard

Iceland

29.1.2003

EU/1/97/040/001-002/IS

Teslascan 0,01 mmol/ml solution for infusion

Iceland

12.5.2003

EU/1/97/045/001, 006-007/IS

Helicobacter INFAI powder for oral solution, 75 mg

Iceland

12.5.2003

EU/1/97/045/008/IS

Helicobacter INFAI powder for oral solution, 45 mg

Iceland

12.5.2003

EU/1/97/046/001-003, -010, -013/IS

Aprovel tabl. 75 mg

Iceland

18.2.2003

EU/1/97/046/004-006, -011, -014/IS

Aprovel tabl. 150 mg

Iceland

18.2.2003

EU/1/97/046/007-009, 026, 030, 033/IS

Aprovel tabl. 300 mg

Iceland

18.2.2003

EU/1/97/047/001/IS

BeneFix powd. and solv. inj. 250 IU

Iceland

15.4.2003

EU/1/97/047/001-003

BeneFix

Liechtenstein

31.3.2003

EU/1/97/047/002/IS

BeneFix powd. and solv. inj. 500 IU

Iceland

15.4.2003

EU/1/97/047/003/IS

BeneFix powd. and solv. inj. 1000 IU

Iceland

15.4.2003

EU/1/97/048/001-014

Infanrix HepB

Liechtenstein

31.1.2003

EU/1/97/048/001-014/IS

Infanrix HepB

Iceland

11.2.2003

EU/1/97/049/001-003, -010, 013/IS

Karvea tabl. 75 mg

Iceland

12.2.2003

EU/1/97/049/004-006, -012, 015/IS

Karvea tabl. 300 mg

Iceland

12.2.2003

EU/1/97/049/004-006, -011, 014/IS

Karvea tabl. 150 mg

Iceland

12.2.2003

EU/1/97/050/001/NO

Sifrol

Norway

6.1.2003

EU/1/97/050/009/NO-012/NO

Sifrol

Norway

6.1.2003

EU/1/97/051/001-002/IS

Mirapexin tab. 0,088 mg

Iceland

31.1.2003

EU/1/97/051/003-004/IS

Mirapexin tab. 0,18 mg

Iceland

31.1.2003

EU/1/97/051/005-006/IS

Mirapexin tab. 0,035 mg

Iceland

31.1.2003

EU/1/97/051/007-008/IS

Mirapexin tab. 0,7 mg

Iceland

31.1.2003

EU/1/97/051/009-010/IS

Mirapexin tab. 1,1 mg

Iceland

31.1.2003

EU/1/97/052/001/NO-006/NO

Daquiran

Norway

28.1.2003

EU/1/97/052/009/NO-010/NO

Daquiran

Norway

28.1.2003

EU/1/97/053/001/NO-005/NO

Cerezyme

Norway

6.1.2003

EU/1/97/053/001-002/IS

Cerezyme 200U

Iceland

10.2.2003

EU/1/97/053/001-005

Cerezyme

Liechtenstein

31.1.2003

EU/1/97/053/003-005/IS

Cerezyme 400U

Iceland

10.2.2003

EU/1/97/054/001/IS

Viracept 50 mg/g oral powder

Iceland

13.5.2003

EU/1/97/054/001/NO

Viracept

Norway

18.2.2003

EU/1/97/054/003/IS

Viracept tablets 250 mg

Iceland

13.5.2003

EU/1/97/054/003/NO-005/NO

Viracept

Norway

18.2.2003

EU/1/97/054/005/IS

Viracept film coated tablets 250 mg

Iceland

13.5.2003

EU/1/97/055/001/IS

Viramune tabl. 200 mg

Iceland

10.4.2003

EU/1/97/055/001/NO-002/NO

Viramune

Norway

6.3.2003

EU/1/97/055/001-002

Viramune

Liechtenstein

31.3.2003

EU/1/97/055/002/IS

Viramune mixt. susp. 50 mg/5ml

Iceland

10.4.2003

EU/1/97/057/001

Quadramet

Liechtenstein

31.3.2003

EU/1/97/057/001/IS

Quadramet solution for injection 1,3 GB/ml

Iceland

16.5.2003

EU/1/97/057/001/NO

Quadramet

Norway

5.5.2003

EU/1/98/065/001/NO-002/NO

Optison

Norway

20.6.2003

EU/1/98/065/001-002

Optison

Liechtenstein

31.5.2003

EU/1/98/065/001-002/IS

Optison, solution for injection

Iceland

25.6.2003

EU/2/98/007/001-003

Clomicalm

Liechtenstein

31.5.2003

EU/2/98/008/001/NO-004/NO

Neocolipor

Norway

18.6.2003

EU/2/98/008/001-004

Neocolipor

Liechtenstein

31.5.2003

---

ANNEX III

3.   Extended Marketing Authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January — 30 June 2003:

| EU-Number | Product | Country | Date of extention |
| --- | --- | --- | --- |
| EU/1/00/146/027/NO | Keppra | Norway | 18.3.2003 |
| EU/1/01/171/009-010/IS | Rapamune filmc. tablets 2 mg | Iceland | 11.6.2003 |
| EU/1/01/171/009-010/NO | Rapamune | Norway | 29.1.2003 |
| EU/1/01/176/004/NO-006/NO | Zometa | Norway | 29.4.2003 |
| EU/1/01/176/004-006/IS | Zometa, concentrate for sol. for infus | Iceland | 22.3.2003 |
| EU/1/96/015/003/NO | Epivir | Norway | 4.2.2003 |
| EU/1/98/084/002/NO | Simulect | Norway | 18.3.2003 |
| EU/1/99/103/004/NO | ReFacto | Norway | 13.3.2003 |
| EU/1/99/127/040/NO-044/NO | Introna | Norway | 21.1.2003 |
| EU/2/00/022/009/NO-12/NO | Ibaflin | Norway | 18.6.2003 |

EU-Number

Product

Country

Date of extention

EU/1/00/146/027/NO

Keppra

Norway

18.3.2003

EU/1/01/171/009-010/IS

Rapamune filmc. tablets 2 mg

Iceland

11.6.2003

EU/1/01/171/009-010/NO

Rapamune

Norway

29.1.2003

EU/1/01/176/004/NO-006/NO

Zometa

Norway

29.4.2003

EU/1/01/176/004-006/IS

Zometa, concentrate for sol. for infus

Iceland

22.3.2003

EU/1/96/015/003/NO

Epivir

Norway

4.2.2003

EU/1/98/084/002/NO

Simulect

Norway

18.3.2003

EU/1/99/103/004/NO

ReFacto

Norway

13.3.2003

EU/1/99/127/040/NO-044/NO

Introna

Norway

21.1.2003

EU/2/00/022/009/NO-12/NO

Ibaflin

Norway

18.6.2003

---

ANNEX IV

4.   Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January — 30 June 2003:

| EU-Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/00/142/003/IS | Novomix 30 Penfill | Iceland | 1.1.2003 |
| EU/1/00/142/003/NO | Novomix 30 Penfil | Norway | 12.3.2003 |
| EU/1/00/142/006/IS | Novomix 30 Novolet | Iceland | 1.1.2003 |
| EU/1/00/142/006/NO | Novomix 30 Novolet | Norway | 12.3.2003 |
| EU/1/96/021/001/NO-010/NO | Olansek | Norway | 27.5.2003 |
| EU/1/96/021/001-010 | Olansek | Liechtenstein | 31.3.2003 |
| EU/2/00/019/004 | Eurifel FelV | Liechtenstein | 31.5.2003 |
| EU/2/00/019/004/NO | Eurifel FelV | Norway | 27.5.2003 |

EU-Number

Product

Country

Date of withdrawal

EU/1/00/142/003/IS

Novomix 30 Penfill

Iceland

1.1.2003

EU/1/00/142/003/NO

Novomix 30 Penfil

Norway

12.3.2003

EU/1/00/142/006/IS

Novomix 30 Novolet

Iceland

1.1.2003

EU/1/00/142/006/NO

Novomix 30 Novolet

Norway

12.3.2003

EU/1/96/021/001/NO-010/NO

Olansek

Norway

27.5.2003

EU/1/96/021/001-010

Olansek

Liechtenstein

31.3.2003

EU/2/00/019/004

Eurifel FelV

Liechtenstein

31.5.2003

EU/2/00/019/004/NO

Eurifel FelV

Norway

27.5.2003

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/28 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/28

---

List of marketing authorisations granted by the EEA EFTA States for the second half of 2003

(2006/C 233/09)

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note, at the meeting on 10 March 2006, the following lists concerning marketing authorisations for medicinal products for the period 1 July — 31 December 2003:

| Annex I | List of new marketing authorisations |
| --- | --- |

Annex I

| Annex II | List of renewed marketing authorisations |
| --- | --- |

Annex II

| Annex III | List of extended marketing authorisations |
| --- | --- |

Annex III

| Annex IV | List of withdrawn marketing authorisations |
| --- | --- |

Annex IV

---

ANNEX I

1.   New Marketing Authorisations:

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July — 31 December 2003:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/141/001/IS | Myocet conc. F. inf. Liposomes | Iceland | 31.7.2003 |
| EU/1/00/150/011-015 | Actos | Liechtenstein | 30.9.2003 |
| EU/1/00/151/009-013 | Glustin | Liechtenstein | 30.9.2003 |
| EU/1/00/165/007 | Ovitrelle | Liechtenstein | 30.11.2003 |
| EU/1/02/206/005-008 | Arixtra | Liechtenstein | 30.11.2003 |
| EU/1/02/207/005-008 | Quixidar | Liechtenstein | 30.11.2003 |
| EU/1/02/219/010-013 | Ebixa | Liechtenstein | 30.9.2003 |
| EU/1/02/229/036-037 | Actraphane | Liechtenstein | 30.9.2003 |
| EU/1/02/230/016-017 | Actrapid | Liechtenstein | 30.9.2003 |
| EU/1/02/231/036-037 | Mixtard | Liechtenstein | 30.9.2003 |
| EU/1/02/232/003 | Velosulin | Liechtenstein | 30.9.2003 |
| EU/1/02/233/016-017 | Insulatard | Liechtenstein | 30.9.2003 |
| EU/1/02/234/016-017 | Protaphane | Liechtenstein | 30.9.2003 |
| EU/1/02/240/004 | Somavert | Liechtenstein | 30.9.2003 |
| EU/1/02/242/001-010/IS | Valdyn tablets 10 mg | Iceland | 1.7.2003 |
| EU/1/02/242/011-020/IS | Valdyn tablets 20 mg | Iceland | 1.7.2003 |
| EU/1/02/242/021-024/IS | Valdyn tablets 40 mg | Iceland | 1.7.2003 |
| EU/1/02/244/001-010/IS | Kudeq tablets 10 mg | Iceland | 1.7.2003 |
| EU/1/02/244/011-020/IS | Kudeq tablets 20 mg | Iceland | 1.7.2003 |
| EU/1/02/244/021-024/IS | Kudeq tablets 40 mg | Iceland | 1.7.2003 |
| EU/1/03/247/001-002 | Forsteo | Liechtenstein | 31.7.2003 |
| EU/1/03/247/001-002/IS | Forsteo sol for inj. in prefilled pen | Iceland | 8.7.2003 |
| EU/1/03/252/001-003 | Fuzeon | Liechtenstein | 31.7.2003 |
| EU/1/03/253/001-003 | Aldurazyme | Liechtenstein | 31.7.2003 |
| EU/1/03/253/001-003/IS | Aldurazyme conc. for sol. f. inf. 100 U/ml | Iceland | 21.7.2003 |
| EU/1/03/254/001 | Busilvex | Liechtenstein | 30.9.2003 |
| EU/1/03/254/001/IS | Busilvex 6 mg/ml conc.f. sol. f.inf. | Iceland | 22.7.2003 |
| EU/1/03/254/001/NO | Busilvex | Norway | 17.7.2003 |
| EU/1/03/255/001/NO-003/NO | Ventavis | Norway | 30.10.2003 |
| EU/1/03/255/001-003/IS | Ventavis Nebul. sol.- Inhal. 10 microg/ml | Iceland | 15.10.2003 |
| EU/1/03/256/001/NO-006/NO | Humira | Norway | 11.9.2003 |
| EU/1/03/256/001-006 | Humira | Liechtenstein | 30.9.2003 |
| EU/1/03/256/001-006/IS | Humira solution for injection | Iceland | 25.9.2003 |
| EU/1/03/257/001/NO-006/NO | Trudexa | Norway | 17.9.2003 |
| EU/1/03/257/001-006 | Trudexa | Liechtenstein | 30.9.2003 |
| EU/1/03/257/001-006/IS | Trudexa solution for injection | Iceland | 29.9.2003 |
| EU/1/03/258/001/NO-006/NO | Avandamet | Norway | 18.11.2003 |
| EU/1/03/258/001-003/IS | Avandamet tabl. 1mg/500 mg | Iceland | 19.11.2003 |
| EU/1/03/258/001-006 | Avandamet | Liechtenstein | 30.11.2003 |
| EU/1/03/258/004-006/IS | Avandamet tabl. 2mg/500mg | Iceland | 19.11.2003 |
| EU/1/03/259/001/NO-006/NO | Onsenal | Norway | 5.11.2003 |
| EU/1/03/259/001-004/IS | Onsenal Hard capsules 200 mg | Iceland | 16.12.2003 |
| EU/1/03/259/001-006 | Onsenal | Liechtenstein | 30.11.2003 |
| EU/1/03/259/005-006/IS | Onsenal Hard capsules 400 mg | Iceland | 16.12.2003 |
| EU/1/03/260/001/NO-012/NO | Stalevo | Norway | 5.11.2003 |
| EU/1/03/260/001-004/IS | Stalevo tabl. 50/12.5/200 mg | Iceland | 31.10.2003 |
| EU/1/03/260/001-012 | Stalevo | Liechtenstein | 30.11.2003 |
| EU/1/03/260/005-008/IS | Stalevo tab. 100/25/200 mg | Iceland | 31.10.2003 |
| EU/1/03/260/009-012/IS | Stalevo tabl. 150/37.5/200 mg | Iceland | 31.10.2003 |
| EU/1/03/261/001/NO-003/NO | Emtriva | Norway | 5.11.2003 |
| EU/1/03/261/001-002/IS | Emtriva hard caps. 200 mg | Iceland | 8.11.2003 |
| EU/1/03/261/001-003 | Emtriva | Liechtenstein | 30.11.2003 |
| EU/1/03/261/003/IS | Emtriva oral sol. 10mg/ml | Iceland | 8.11.2003 |
| EU/1/03/262/001/NO-006/NO | Emend | Norway | 15.12.2003 |
| EU/1/03/262/001-003/IS | Emend hard caps. 80 mg | Iceland | 11.12.2003 |
| EU/1/03/262/004-006/IS | Emend hard caps. 80 mg and 125 mg (comb.) | Iceland | 11.12.2003 |
| EU/1/03/262/005/IS | Emend hard caps. 125 mg | Iceland | 11.12.2003 |
| EU/1/96/012/001-013 | Bondronat | Liechtenstein | 30.11.2003 |
| EU/1/96/015/004-005 | Epivir | Liechtenstein | 30.9.2003 |
| EU/1/97/033/003 | Avonex | Liechtenstein | 31.7.2003 |
| EU/1/98/064/001/NO | Pylobactell | Norway | 1.7.2003 |
| EU/1/98/076/001/NO-002/NO,
  004/NO-009/NO | NovoNorm | Norway | 15.8.2003 |
| EU/1/98/076/011/NO-016/NO,
  018/NO-021/NO | NovoNorm | Norway | 15.8.2003 |
| EU/1/99/119/012-014 | NovoRapid | Liechtenstein | 31.7.2003 |
| EU/2/00/025/001/NO-006/NO | Bayovac CSF E2 | Norway | 8.9.2003 |
| EU/2/00/027/001/NO-003/NO | Pirsue | Norway | 2.9.2003 |
| EU/2/01/030/001/IS | Virbagen Omega powd. & solv. for susp. f. inj. 5 MU | Iceland | 10.12.2003 |
| EU/2/01/030/002/IS | Virbagen Omega powd. & solv. for susp. f. inj. 10 MU | Iceland | 10.12.2003 |
| EU/2/02/035/001/NO-006/NO | SevoFlo | Norway | 2.9.2003 |
| EU/2/02/035/001-006/IS | SevoFlo Inhalation vapour, liquid for dogs | Iceland | 1.8.2003 |
| EU/2/03/039/001-004 & 013-014/IS | Advocate spot on sol. for cats | Iceland | 25.9.2003 |
| EU/2/03/039/005-012 & 015-018/IS | Advocate spot on sol for dogs | Iceland | 25.9.2003 |
| EU/2/03/039/013-018 | Advocate | Liechtenstein | 31.7.2003 |
| EU/2/03/040/001 | Gonazon | Liechtenstein | 30.9.2003 |
| EU/2/03/040/001/IS | Gonazon solution injection 1.600 microg/ml | Iceland | 30.10.2003 |
| EU/2/03/040/001/NO | Gonazon | Norway | 18.8.2003 |
| EU/2/03/041/001/NO-005/NO | Draxxin | Norway | 10.12.2003 |
| EU/2/03/041/001-005 | Draxxin | Liechtenstein | 30.11.2003 |
| EU/2/03/041/001-005/IS | Draxxin sol for injection, cattle and pigs | Iceland | 12.12.2003 |
| EU/2/97/003/001-018 | Dicural | Liechtenstein | 30.9.2003 |
| EU/2/97/004/009 | Metacam | Liechtenstein | 30.11.2003 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/141/001/IS

Myocet conc. F. inf. Liposomes

Iceland

31.7.2003

EU/1/00/150/011-015

Actos

Liechtenstein

30.9.2003

EU/1/00/151/009-013

Glustin

Liechtenstein

30.9.2003

EU/1/00/165/007

Ovitrelle

Liechtenstein

30.11.2003

EU/1/02/206/005-008

Arixtra

Liechtenstein

30.11.2003

EU/1/02/207/005-008

Quixidar

Liechtenstein

30.11.2003

EU/1/02/219/010-013

Ebixa

Liechtenstein

30.9.2003

EU/1/02/229/036-037

Actraphane

Liechtenstein

30.9.2003

EU/1/02/230/016-017

Actrapid

Liechtenstein

30.9.2003

EU/1/02/231/036-037

Mixtard

Liechtenstein

30.9.2003

EU/1/02/232/003

Velosulin

Liechtenstein

30.9.2003

EU/1/02/233/016-017

Insulatard

Liechtenstein

30.9.2003

EU/1/02/234/016-017

Protaphane

Liechtenstein

30.9.2003

EU/1/02/240/004

Somavert

Liechtenstein

30.9.2003

EU/1/02/242/001-010/IS

Valdyn tablets 10 mg

Iceland

1.7.2003

EU/1/02/242/011-020/IS

Valdyn tablets 20 mg

Iceland

1.7.2003

EU/1/02/242/021-024/IS

Valdyn tablets 40 mg

Iceland

1.7.2003

EU/1/02/244/001-010/IS

Kudeq tablets 10 mg

Iceland

1.7.2003

EU/1/02/244/011-020/IS

Kudeq tablets 20 mg

Iceland

1.7.2003

EU/1/02/244/021-024/IS

Kudeq tablets 40 mg

Iceland

1.7.2003

EU/1/03/247/001-002

Forsteo

Liechtenstein

31.7.2003

EU/1/03/247/001-002/IS

Forsteo sol for inj. in prefilled pen

Iceland

8.7.2003

EU/1/03/252/001-003

Fuzeon

Liechtenstein

31.7.2003

EU/1/03/253/001-003

Aldurazyme

Liechtenstein

31.7.2003

EU/1/03/253/001-003/IS

Aldurazyme conc. for sol. f. inf. 100 U/ml

Iceland

21.7.2003

EU/1/03/254/001

Busilvex

Liechtenstein

30.9.2003

EU/1/03/254/001/IS

Busilvex 6 mg/ml conc.f. sol. f.inf.

Iceland

22.7.2003

EU/1/03/254/001/NO

Busilvex

Norway

17.7.2003

EU/1/03/255/001/NO-003/NO

Ventavis

Norway

30.10.2003

EU/1/03/255/001-003/IS

Ventavis Nebul. sol.- Inhal. 10 microg/ml

Iceland

15.10.2003

EU/1/03/256/001/NO-006/NO

Humira

Norway

11.9.2003

EU/1/03/256/001-006

Humira

Liechtenstein

30.9.2003

EU/1/03/256/001-006/IS

Humira solution for injection

Iceland

25.9.2003

EU/1/03/257/001/NO-006/NO

Trudexa

Norway

17.9.2003

EU/1/03/257/001-006

Trudexa

Liechtenstein

30.9.2003

EU/1/03/257/001-006/IS

Trudexa solution for injection

Iceland

29.9.2003

EU/1/03/258/001/NO-006/NO

Avandamet

Norway

18.11.2003

EU/1/03/258/001-003/IS

Avandamet tabl. 1mg/500 mg

Iceland

19.11.2003

EU/1/03/258/001-006

Avandamet

Liechtenstein

30.11.2003

EU/1/03/258/004-006/IS

Avandamet tabl. 2mg/500mg

Iceland

19.11.2003

EU/1/03/259/001/NO-006/NO

Onsenal

Norway

5.11.2003

EU/1/03/259/001-004/IS

Onsenal Hard capsules 200 mg

Iceland

16.12.2003

EU/1/03/259/001-006

Onsenal

Liechtenstein

30.11.2003

EU/1/03/259/005-006/IS

Onsenal Hard capsules 400 mg

Iceland

16.12.2003

EU/1/03/260/001/NO-012/NO

Stalevo

Norway

5.11.2003

EU/1/03/260/001-004/IS

Stalevo tabl. 50/12.5/200 mg

Iceland

31.10.2003

EU/1/03/260/001-012

Stalevo

Liechtenstein

30.11.2003

EU/1/03/260/005-008/IS

Stalevo tab. 100/25/200 mg

Iceland

31.10.2003

EU/1/03/260/009-012/IS

Stalevo tabl. 150/37.5/200 mg

Iceland

31.10.2003

EU/1/03/261/001/NO-003/NO

Emtriva

Norway

5.11.2003

EU/1/03/261/001-002/IS

Emtriva hard caps. 200 mg

Iceland

8.11.2003

EU/1/03/261/001-003

Emtriva

Liechtenstein

30.11.2003

EU/1/03/261/003/IS

Emtriva oral sol. 10mg/ml

Iceland

8.11.2003

EU/1/03/262/001/NO-006/NO

Emend

Norway

15.12.2003

EU/1/03/262/001-003/IS

Emend hard caps. 80 mg

Iceland

11.12.2003

EU/1/03/262/004-006/IS

Emend hard caps. 80 mg and 125 mg (comb.)

Iceland

11.12.2003

EU/1/03/262/005/IS

Emend hard caps. 125 mg

Iceland

11.12.2003

EU/1/96/012/001-013

Bondronat

Liechtenstein

30.11.2003

EU/1/96/015/004-005

Epivir

Liechtenstein

30.9.2003

EU/1/97/033/003

Avonex

Liechtenstein

31.7.2003

EU/1/98/064/001/NO

Pylobactell

Norway

1.7.2003

EU/1/98/076/001/NO-002/NO,

004/NO-009/NO

NovoNorm

Norway

15.8.2003

EU/1/98/076/011/NO-016/NO,

018/NO-021/NO

NovoNorm

Norway

15.8.2003

EU/1/99/119/012-014

NovoRapid

Liechtenstein

31.7.2003

EU/2/00/025/001/NO-006/NO

Bayovac CSF E2

Norway

8.9.2003

EU/2/00/027/001/NO-003/NO

Pirsue

Norway

2.9.2003

EU/2/01/030/001/IS

Virbagen Omega powd. & solv. for susp. f. inj. 5 MU

Iceland

10.12.2003

EU/2/01/030/002/IS

Virbagen Omega powd. & solv. for susp. f. inj. 10 MU

Iceland

10.12.2003

EU/2/02/035/001/NO-006/NO

SevoFlo

Norway

2.9.2003

EU/2/02/035/001-006/IS

SevoFlo Inhalation vapour, liquid for dogs

Iceland

1.8.2003

EU/2/03/039/001-004 & 013-014/IS

Advocate spot on sol. for cats

Iceland

25.9.2003

EU/2/03/039/005-012 & 015-018/IS

Advocate spot on sol for dogs

Iceland

25.9.2003

EU/2/03/039/013-018

Advocate

Liechtenstein

31.7.2003

EU/2/03/040/001

Gonazon

Liechtenstein

30.9.2003

EU/2/03/040/001/IS

Gonazon solution injection 1.600 microg/ml

Iceland

30.10.2003

EU/2/03/040/001/NO

Gonazon

Norway

18.8.2003

EU/2/03/041/001/NO-005/NO

Draxxin

Norway

10.12.2003

EU/2/03/041/001-005

Draxxin

Liechtenstein

30.11.2003

EU/2/03/041/001-005/IS

Draxxin sol for injection, cattle and pigs

Iceland

12.12.2003

EU/2/97/003/001-018

Dicural

Liechtenstein

30.9.2003

EU/2/97/004/009

Metacam

Liechtenstein

30.11.2003

---

ANNEX II

2.   Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July — 31 December 2003:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/162/001-006/IS | Prandin 0.5 mg tablets | Iceland | 25.9.2003 |
| EU/1/00/162/001-018 | Prandin | Liechtenstein | 30.9.2003 |
| EU/1/00/162/001-018/NO | Prandin | Norway | 15.8.2003 |
| EU/1/00/162/007-012/IS | Prandin 1 mg tablets | Iceland | 25.9.2003 |
| EU/1/00/162/013-018/IS | Prandin 2 mg tablets | Iceland | 25.9.2003 |
| EU/1/97/047/001/NO-003/NO | Benefix | Norway | 30.12.2003 |
| EU/1/97/048/001/NO-014/NO | InfanrixHep B | Norway | 20.11.2003 |
| EU/1/97/051/001/NO-006/NO,
  009/NO-012/NO | Mirapexin | Norway | 1.9.2003 |
| EU/1/98/058/001-002 | Combivir | Liechtenstein | 31.7.2003 |
| EU/1/98/058/001-002/IS | Combivir 150/300 mg film coated tablets | Iceland | 16.9.2003 |
| EU/1/98/058/001-002/NO | Combivir | Norway | 7.7.2003 |
| EU/1/98/063/001-003/IS | Rebif 22 microg/0.5 ml. solution for injection | Iceland | 18.9.2003 |
| EU/1/98/063/001-006 | Rebif | Liechtenstein | 31.7.2003 |
| EU/1/98/063/001-006/NO | Rebif | Norway | 19.8.2003 |
| EU/1/98/063/004-006/IS | Rebif 44 microg/0.5 ml. solution for injection | Iceland | 18.9.2003 |
| EU/1/98/064/001 | Pylobactell | Liechtenstein | 31.7.2003 |
| EU/1/98/064/001/IS | Pylobactell 100 mg soluble tablet | Iceland | 21.10.2003 |
| EU/1/98/066/001-003/IS | Exelon capsules hard, 1.5 mg | Iceland | 26.8.2003 |
| EU/1/98/066/001-013 | Exelon | Liechtenstein | 31.7.2003 |
| EU/1/98/066/001-013/NO | Exelon | Norway | 15.7.2003 |
| EU/1/98/066/004-006/IS | Exelon capsules hard, 3 mg | Iceland | 26.8.2003 |
| EU/1/98/066/007-009/IS | Exelon capsules hard, 4.5 mg | Iceland | 26.8.2003 |
| EU/1/98/066/010-012/IS | Exelon capsules hard, 6 mg | Iceland | 26.8.2003 |
| EU/1/98/066/013/IS | Exelon oral solution 2 mg/ml | Iceland | 26.8.2003 |
| EU/1/98/067/001/IS | MabThera Concentrate for solution for infusion 100 mg | Iceland | 13.10.2003 |
| EU/1/98/067/001-002 | Mabthera | Liechtenstein | 30.9.2003 |
| EU/1/98/067/001-002/NO | Mabthera | Norway | 6.8.2003 |
| EU/1/98/067/002/IS | MabThera Concentrate for solution for infusion 500 mg | Iceland | 13.10.2003 |
| EU/1/98/069/001-004/IS | Plavix tablets 75 mg | Iceland | 20.11.2003 |
| EU/1/98/069/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b | Plavix | Liechtenstein | 30.11.2003 |
| EU/1/98/069/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b/NO | Plavix | Norway | 7.11.2003 |
| EU/1/98/070/001-004/IS | Iscover tablets 75 mg | Iceland | 20.11.2003 |
| EU/1/98/070/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b | Iscover | Liechtenstein | 30.11.2003 |
| EU/1/98/070/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b/NO | Iscover | Norway | 7.11.2003 |
| EU/1/98/071/001-006 | Xenical | Liechtenstein | 30.11.2003 |
| EU/1/98/071/001-006/IS | Xenical hard capsules 120 mg | Iceland | 1.12.2003 |
| EU/1/98/071/001-006/NO | Xenical | Norway | 24.10.2003 |
| EU/1/98/073/001-004 | Evista | Liechtenstein | 30.9.2003 |
| EU/1/98/073/001-004/IS | Evista film coated tablets 60 mg | Iceland | 18.9.2003 |
| EU/1/98/073/001-004/NO | Evista | Norway | 1.8.2003 |
| EU/1/98/074/001-004 | Optruma | Liechtenstein | 30.9.2003 |
| EU/1/98/074/001-004/IS | Optruma film coated tablets 60 mg | Iceland | 18.9.2003 |
| EU/1/98/074/001-004/NO | Optruma | Norway | 1.8.2003 |
| EU/1/98/075/001-002 | Fortovase | Liechtenstein | 30.9.2003 |
| EU/1/98/075/001-002/IS | Fortovase soft capsule 200 mg | Iceland | 19.11.2003 |
| EU/1/98/075/001-002/NO | Fortovase | Norway | 8.10.2003 |
| EU/1/98/076/001-002, 004-007/IS | NovoNorm 0.5 mg tablets | Iceland | 25.9.2003 |
| EU/1/98/076/001-002, 004-009 | NovoNorm | Liechtenstein | 30.9.2003 |
| EU/1/98/076/008-009, 011-014/IS | NovoNorm 1 mg tablets | Iceland | 25.9.2003 |
| EU/1/98/076/011-016, 018-021 | NovoNorm | Liechtenstein | 30.9.2003 |
| EU/1/98/076/015-016, 018-021/IS | NovoNorm 2 mg tablets | Iceland | 25.9.2003 |
| EU/1/98/077/001-012 | Viagra | Liechtenstein | 30.11.2003 |
| EU/1/98/077/001-012/NO | Viagra | Norway | 11.12.2003 |
| EU/1/98/080/001 | Aldara | Liechtenstein | 30.11.2003 |
| EU/1/98/080/001/IS | Aldara cream 5% | Iceland | 3.12.2003 |
| EU/1/98/080/001/NO | Aldara | Norway | 14.11.2003 |
| EU/1/98/081/001-004 | Comtan | Liechtenstein | 30.11.2003 |
| EU/1/98/081/001-004/IS | Comtan filmcoated tablets | Iceland | 16.12.2003 |
| EU/1/98/081/001-004/NO | Comtan | Norway | 3.11.2003 |
| EU/1/98/082/001-004 | Comtess | Liechtenstein | 30.11.2003 |
| EU/1/98/082/001-004/IS | Comtess filmcoated tablets | Iceland | 27.11.2003 |
| EU/1/98/082/001-004/NO | Comtess | Norway | 14.11.2003 |
| EU/1/98/084/001-002 | Simulect | Liechtenstein | 30.11.2003 |
| EU/1/98/084/001-002/NO | Simulect | Norway | 18.11.2003 |
| EU/1/98/085/001/NO-010/NO | Karvezide | Norway | 18.12.2003 |
| EU/1/98/086/001/NO-010/NO | CoAprovel | Norway | 19.12.2003 |
| EU/1/98/092/001-003/IS | Prometax capsules hard 1.5 mg | Iceland | 29.8.2003 |
| EU/1/98/092/001-013 | Prometax | Liechtenstein | 31.7.2003 |
| EU/1/98/092/001-013/NO | Prometax | Norway | 15.7.2003 |
| EU/1/98/092/004-006/IS | Prometax capsules hard, 3 mg | Iceland | 29.8.2003 |
| EU/1/98/092/007-009/IS | Prometax capsules hard, 4.5 mg | Iceland | 29.8.2003 |
| EU/1/98/092/010-012/IS | Prometax capsules hard, 6 mg | Iceland | 29.8.2003 |
| EU/1/98/092/013/IS | Prometax oral solution 2mg/ml | Iceland | 29.8.2003 |
| EU/2/96/002/001-003/IS | Fevaxyn Pentofelsol. for inject. | Iceland | 15.10.2003 |
| EU/2/97/003/001-003/IS | Dicural 100 mg/ml oral solution | Iceland | 12.10.2003 |
| EU/2/97/003/001-018/NO | Dicural | Norway | 21.8.2003 |
| EU/2/97/003/004-015/IS | Dicural 15 mg, 50 mg, 100 mg, 150 mg film coated tablets | Iceland | 12.10.2003 |
| EU/2/97/003/016-018/IS | Dicural 50 mg/ml solution for inject. | Iceland | 12.10.2003 |
| EU/2/97/004/001/IS | Metacam 5 mg/ml solution for injection for cattle | Iceland | 8.7.2003 |
| EU/2/97/004/003-005/IS | Metacam 1.5 mg/ml oral suspension for dogs | Iceland | 8.7.2003 |
| EU/2/97/004/006/IS | Metacam 5 mg/ml solution for injection for dogs and cats | Iceland | 8.7.2003 |
| EU/2/97/004/007-008/IS | Metacam 20 mg/ml solution for injection for cattle | Iceland | 8.7.2003 |
| EU/2/97/005/001, 005/IS | Quadrisol oral gel for horses 100 mg/ml | Iceland | 27.10.2003 |
| EU/2/97/005/002-003, 006-007/IS | Quadrisol oral gel for dogs 5 mg/ml | Iceland | 27.10.2003 |
| EU/2/97/005/004/IS | Quadrisol sol. for injection | Iceland | 27.10.2003 |
| EU/2/97/005/008-009/IS | Quadrisol oral gel for dogs 1 mg/ml | Iceland | 27.10.2003 |
| EU/2/98/006/001-010 | Nobilis IB 4-91 | Liechtenstein | 30.9.2003 |
| EU/2/98/006/001-010/IS | Nobilis IB 4-91 sol. for injection | Iceland | 21.10.2003 |
| EU/2/98/006/001-010/NO | Nobilis IB 4-91 | Norway | 8.8.2003 |
| EU/2/98/007/00/NO-003/NO | Clomicalm | Norway | 1.9.2003 |
| EU/2/98/007/001-003/IS | Clomicalm tablets 5 mg, 20 mg, 80 mg | Iceland | 27.10.2003 |
| EU/2/98/008/001-004/IS | Neocolipor suspension for injection | Iceland | 22.10.2003 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/162/001-006/IS

Prandin 0.5 mg tablets

Iceland

25.9.2003

EU/1/00/162/001-018

Prandin

Liechtenstein

30.9.2003

EU/1/00/162/001-018/NO

Prandin

Norway

15.8.2003

EU/1/00/162/007-012/IS

Prandin 1 mg tablets

Iceland

25.9.2003

EU/1/00/162/013-018/IS

Prandin 2 mg tablets

Iceland

25.9.2003

EU/1/97/047/001/NO-003/NO

Benefix

Norway

30.12.2003

EU/1/97/048/001/NO-014/NO

InfanrixHep B

Norway

20.11.2003

EU/1/97/051/001/NO-006/NO,

009/NO-012/NO

Mirapexin

Norway

1.9.2003

EU/1/98/058/001-002

Combivir

Liechtenstein

31.7.2003

EU/1/98/058/001-002/IS

Combivir 150/300 mg film coated tablets

Iceland

16.9.2003

EU/1/98/058/001-002/NO

Combivir

Norway

7.7.2003

EU/1/98/063/001-003/IS

Rebif 22 microg/0.5 ml. solution for injection

Iceland

18.9.2003

EU/1/98/063/001-006

Rebif

Liechtenstein

31.7.2003

EU/1/98/063/001-006/NO

Rebif

Norway

19.8.2003

EU/1/98/063/004-006/IS

Rebif 44 microg/0.5 ml. solution for injection

Iceland

18.9.2003

EU/1/98/064/001

Pylobactell

Liechtenstein

31.7.2003

EU/1/98/064/001/IS

Pylobactell 100 mg soluble tablet

Iceland

21.10.2003

EU/1/98/066/001-003/IS

Exelon capsules hard, 1.5 mg

Iceland

26.8.2003

EU/1/98/066/001-013

Exelon

Liechtenstein

31.7.2003

EU/1/98/066/001-013/NO

Exelon

Norway

15.7.2003

EU/1/98/066/004-006/IS

Exelon capsules hard, 3 mg

Iceland

26.8.2003

EU/1/98/066/007-009/IS

Exelon capsules hard, 4.5 mg

Iceland

26.8.2003

EU/1/98/066/010-012/IS

Exelon capsules hard, 6 mg

Iceland

26.8.2003

EU/1/98/066/013/IS

Exelon oral solution 2 mg/ml

Iceland

26.8.2003

EU/1/98/067/001/IS

MabThera Concentrate for solution for infusion 100 mg

Iceland

13.10.2003

EU/1/98/067/001-002

Mabthera

Liechtenstein

30.9.2003

EU/1/98/067/001-002/NO

Mabthera

Norway

6.8.2003

EU/1/98/067/002/IS

MabThera Concentrate for solution for infusion 500 mg

Iceland

13.10.2003

EU/1/98/069/001-004/IS

Plavix tablets 75 mg

Iceland

20.11.2003

EU/1/98/069/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b

Plavix

Liechtenstein

30.11.2003

EU/1/98/069/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b/NO

Plavix

Norway

7.11.2003

EU/1/98/070/001-004/IS

Iscover tablets 75 mg

Iceland

20.11.2003

EU/1/98/070/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b

Iscover

Liechtenstein

30.11.2003

EU/1/98/070/001a, 1b, 2a, 2b, 3a, 3b, 4a, 4b/NO

Iscover

Norway

7.11.2003

EU/1/98/071/001-006

Xenical

Liechtenstein

30.11.2003

EU/1/98/071/001-006/IS

Xenical hard capsules 120 mg

Iceland

1.12.2003

EU/1/98/071/001-006/NO

Xenical

Norway

24.10.2003

EU/1/98/073/001-004

Evista

Liechtenstein

30.9.2003

EU/1/98/073/001-004/IS

Evista film coated tablets 60 mg

Iceland

18.9.2003

EU/1/98/073/001-004/NO

Evista

Norway

1.8.2003

EU/1/98/074/001-004

Optruma

Liechtenstein

30.9.2003

EU/1/98/074/001-004/IS

Optruma film coated tablets 60 mg

Iceland

18.9.2003

EU/1/98/074/001-004/NO

Optruma

Norway

1.8.2003

EU/1/98/075/001-002

Fortovase

Liechtenstein

30.9.2003

EU/1/98/075/001-002/IS

Fortovase soft capsule 200 mg

Iceland

19.11.2003

EU/1/98/075/001-002/NO

Fortovase

Norway

8.10.2003

EU/1/98/076/001-002, 004-007/IS

NovoNorm 0.5 mg tablets

Iceland

25.9.2003

EU/1/98/076/001-002, 004-009

NovoNorm

Liechtenstein

30.9.2003

EU/1/98/076/008-009, 011-014/IS

NovoNorm 1 mg tablets

Iceland

25.9.2003

EU/1/98/076/011-016, 018-021

NovoNorm

Liechtenstein

30.9.2003

EU/1/98/076/015-016, 018-021/IS

NovoNorm 2 mg tablets

Iceland

25.9.2003

EU/1/98/077/001-012

Viagra

Liechtenstein

30.11.2003

EU/1/98/077/001-012/NO

Viagra

Norway

11.12.2003

EU/1/98/080/001

Aldara

Liechtenstein

30.11.2003

EU/1/98/080/001/IS

Aldara cream 5%

Iceland

3.12.2003

EU/1/98/080/001/NO

Aldara

Norway

14.11.2003

EU/1/98/081/001-004

Comtan

Liechtenstein

30.11.2003

EU/1/98/081/001-004/IS

Comtan filmcoated tablets

Iceland

16.12.2003

EU/1/98/081/001-004/NO

Comtan

Norway

3.11.2003

EU/1/98/082/001-004

Comtess

Liechtenstein

30.11.2003

EU/1/98/082/001-004/IS

Comtess filmcoated tablets

Iceland

27.11.2003

EU/1/98/082/001-004/NO

Comtess

Norway

14.11.2003

EU/1/98/084/001-002

Simulect

Liechtenstein

30.11.2003

EU/1/98/084/001-002/NO

Simulect

Norway

18.11.2003

EU/1/98/085/001/NO-010/NO

Karvezide

Norway

18.12.2003

EU/1/98/086/001/NO-010/NO

CoAprovel

Norway

19.12.2003

EU/1/98/092/001-003/IS

Prometax capsules hard 1.5 mg

Iceland

29.8.2003

EU/1/98/092/001-013

Prometax

Liechtenstein

31.7.2003

EU/1/98/092/001-013/NO

Prometax

Norway

15.7.2003

EU/1/98/092/004-006/IS

Prometax capsules hard, 3 mg

Iceland

29.8.2003

EU/1/98/092/007-009/IS

Prometax capsules hard, 4.5 mg

Iceland

29.8.2003

EU/1/98/092/010-012/IS

Prometax capsules hard, 6 mg

Iceland

29.8.2003

EU/1/98/092/013/IS

Prometax oral solution 2mg/ml

Iceland

29.8.2003

EU/2/96/002/001-003/IS

Fevaxyn Pentofelsol. for inject.

Iceland

15.10.2003

EU/2/97/003/001-003/IS

Dicural 100 mg/ml oral solution

Iceland

12.10.2003

EU/2/97/003/001-018/NO

Dicural

Norway

21.8.2003

EU/2/97/003/004-015/IS

Dicural 15 mg, 50 mg, 100 mg, 150 mg film coated tablets

Iceland

12.10.2003

EU/2/97/003/016-018/IS

Dicural 50 mg/ml solution for inject.

Iceland

12.10.2003

EU/2/97/004/001/IS

Metacam 5 mg/ml solution for injection for cattle

Iceland

8.7.2003

EU/2/97/004/003-005/IS

Metacam 1.5 mg/ml oral suspension for dogs

Iceland

8.7.2003

EU/2/97/004/006/IS

Metacam 5 mg/ml solution for injection for dogs and cats

Iceland

8.7.2003

EU/2/97/004/007-008/IS

Metacam 20 mg/ml solution for injection for cattle

Iceland

8.7.2003

EU/2/97/005/001, 005/IS

Quadrisol oral gel for horses 100 mg/ml

Iceland

27.10.2003

EU/2/97/005/002-003, 006-007/IS

Quadrisol oral gel for dogs 5 mg/ml

Iceland

27.10.2003

EU/2/97/005/004/IS

Quadrisol sol. for injection

Iceland

27.10.2003

EU/2/97/005/008-009/IS

Quadrisol oral gel for dogs 1 mg/ml

Iceland

27.10.2003

EU/2/98/006/001-010

Nobilis IB 4-91

Liechtenstein

30.9.2003

EU/2/98/006/001-010/IS

Nobilis IB 4-91 sol. for injection

Iceland

21.10.2003

EU/2/98/006/001-010/NO

Nobilis IB 4-91

Norway

8.8.2003

EU/2/98/007/00/NO-003/NO

Clomicalm

Norway

1.9.2003

EU/2/98/007/001-003/IS

Clomicalm tablets 5 mg, 20 mg, 80 mg

Iceland

27.10.2003

EU/2/98/008/001-004/IS

Neocolipor suspension for injection

Iceland

22.10.2003

---

ANNEX III

3.   Extended Marketing Authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July — 31 December 2003:

| EU-Number | Product | Country | Date of extention |
| --- | --- | --- | --- |
| EU/1/00/146/027/IS | Keppra oral solution | Iceland | 19.8.2003 |
| EU/1/00/150/011/NO-015/NO | Actos | Norway | 25.9.2003 |
| EU/1/00/150/011-015/IS | Actos tablets 45 mg | Iceland | 27.11.2003 |
| EU/1/00/165/007/IS | Ovitrelle, sol. for inj. 250 microg/0.5 ml | Iceland | 16.12.2003 |
| EU/1/00/165/007/NO | Ovitrelle | Norway | 7.11.2003 |
| EU/1/02/206/005/NO-008/NO | Arixtra | Norway | 21.11.2003 |
| EU/1/02/206/005-008/IS | Arixtra solution for injection, 1.5 mg/0.3 ml. | Iceland | 4.12.2003 |
| EU/1/02/207/00/NO-008/NO | Quixidar | Norway | 21.11.2003 |
| EU/1/02/207/005-009/IS | Quixidar solution for injection, 1.5 mg/0.3 ml | Iceland | 4.12.2003 |
| EU/1/96/009/010-017/IS | Zerit caps. prolonged release | Iceland | 9.10.2003 |
| EU/1/96/012/009/NO-013/NO | Bondronat | Norway | 5.11.2003 |
| EU/1/96/015/003/NO,
  EU/1/96/015/004/NO-005/NO | Epivir | Norway | 29.7.2003 |
| EU/1/97/033/003/IS | Avonex sol. for injection 30 microg/0.5 ml | Iceland | 7.11.2003 |
| EU/1/97/033/003/NO | Avonex | Norway | 4.7.2003 |
| EU/2/97/004/009/IS | Metacam oral suspention for horses | Iceland | 29.10.2003 |
| EU/2/97/004/009/NO | Metacam | Norway | 24.10.2003 |

EU-Number

Product

Country

Date of extention

EU/1/00/146/027/IS

Keppra oral solution

Iceland

19.8.2003

EU/1/00/150/011/NO-015/NO

Actos

Norway

25.9.2003

EU/1/00/150/011-015/IS

Actos tablets 45 mg

Iceland

27.11.2003

EU/1/00/165/007/IS

Ovitrelle, sol. for inj. 250 microg/0.5 ml

Iceland

16.12.2003

EU/1/00/165/007/NO

Ovitrelle

Norway

7.11.2003

EU/1/02/206/005/NO-008/NO

Arixtra

Norway

21.11.2003

EU/1/02/206/005-008/IS

Arixtra solution for injection, 1.5 mg/0.3 ml.

Iceland

4.12.2003

EU/1/02/207/00/NO-008/NO

Quixidar

Norway

21.11.2003

EU/1/02/207/005-009/IS

Quixidar solution for injection, 1.5 mg/0.3 ml

Iceland

4.12.2003

EU/1/96/009/010-017/IS

Zerit caps. prolonged release

Iceland

9.10.2003

EU/1/96/012/009/NO-013/NO

Bondronat

Norway

5.11.2003

EU/1/96/015/003/NO,

EU/1/96/015/004/NO-005/NO

Epivir

Norway

29.7.2003

EU/1/97/033/003/IS

Avonex sol. for injection 30 microg/0.5 ml

Iceland

7.11.2003

EU/1/97/033/003/NO

Avonex

Norway

4.7.2003

EU/2/97/004/009/IS

Metacam oral suspention for horses

Iceland

29.10.2003

EU/2/97/004/009/NO

Metacam

Norway

24.10.2003

---

ANNEX IV

4.   Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July — 31 December 2003:

| EU-Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/96/021/001-010/IS | Olansek | Iceland | 1.7.2003 |

EU-Number

Product

Country

Date of withdrawal

EU/1/96/021/001-010/IS

Olansek

Iceland

1.7.2003

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/37 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/37

---

List of marketing authorisations granted by the EEA EFTA States for the first half of 2004

(2006/C 233/10)

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note, at the meeting on 10 March 2006, the following lists concerning marketing authorisations for medicinal products for the period 1 January — 30 June 2004:

| Annex I | List of new marketing authorisations |
| --- | --- |

Annex I

| Annex II | List of renewed marketing authorisations |
| --- | --- |

Annex II

| Annex III | List of extended marketing authorisations |
| --- | --- |

Annex III

| Annex IV | List of withdrawn marketing authorisations |
| --- | --- |

Annex IV

| Annex V | List of suspended marketing authorisations |
| --- | --- |

Annex V

---

ANNEX I

1.   New Marketing Authorisations:

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January — 30 June 2004:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/141/001/NO | Myocet | Norway | 22.1.2004 |
| EU/1/00/164/003-005 | NutropinAq | Liechtenstein | 31.3.2004 |
| EU/1/02/212/026 | Vfend | Liechtenstein | 31.3.2004 |
| EU/1/02/215/001-010/IS | PritorPlus tablets 40 mg and 80 mg | Iceland | 10.2.2004 |
| EU/1/03/263/001/NO-003/NO | Dukoral | Norway | 11.5.2004 |
| EU/1/03/263/001-003 | Dukoral | Liechtenstein | 31.5.2004 |
| EU/1/03/264/001 | Zevalin | Liechtenstein | 31.1.2004 |
| EU/1/03/264/001/IS | Zevalin 1.6 mg/ml kit for radiopharmaceut. prep. | Iceland | 13.2.2004 |
| EU/1/03/264/001/NO | Zevalin | Norway | 2.2.2004 |
| EU/1/03/265/001/NO-002/NO | Bonviva | Norway | 24.3.2004 |
| EU/1/03/265/001-002 | Bonviva | Liechtenstein | 31.5.2004 |
| EU/1/03/265/001-002/IS | Bonviva filmc. tabl. 2.5 mg | Iceland | 23.3.2004 |
| EU/1/03/266/001/NO-002/NO | Ibandronic Acid Roche | Norway | 24.3.2004 |
| EU/1/03/266/001-002 | Ibandronic Acid Roche | Liechtenstein | 31.5.2004 |
| EU/1/03/266/001-002/IS | Ibandronic Acid Roche film. tabl. 2.5 mg | Iceland | 23.3.2004 |
| EU/1/03/267/001/NO-007/NO | Reyataz | Norway | 26.3.2004 |
| EU/1/03/267/001-006/IS | Reyataz capsule hard 100 mg, 150 mg, 200 mg | Iceland | 30.3.2004 |
| EU/1/03/267/001-007 | Reyataz | Liechtenstein | 31.3.2004 |
| EU/1/03/267/007/IS | Reyataz oral powder 50 mg/1.5 g | Iceland | 30.3.2004 |
| EU/1/03/268/001/NO-003/NO | Cholestagel | Norway | 24.3.2004 |
| EU/1/03/268/001-003 | Cholestagel | Liechtenstein | 31.3.2004 |
| EU/1/03/268/001-003/IS | Cholestagel filmc. tabl. 625 mg | Iceland | 5.4.2004 |
| EU/1/03/269/001/IS | Faslodex | Iceland | 7.4.2004 |
| EU/1/03/269/001/NO | Faslodex | Norway | 6.4.2004 |
| EU/1/03/270/001/NO-002/NO | Oxybutynin Nicobrand | Norway | 28.6.2004 |
| EU/1/03/271/001/IS | Advate powder for sol. for inj. 250 IU, 500 IU, 1000 IU, 150 | Iceland | 1.4.2004 |
| EU/1/03/271/001/NO-004/NO | Advate | Norway | 29.3.2004 |
| EU/1/03/271/001-004 | Advate | Liechtenstein | 31.5.2004 |
| EU/1/04/272/001/NO-002/NO | Photo Barr | Norway | 23.4.2004 |
| EU/1/04/272/001-002 | Photo Barr | Liechtenstein | 31.5.2004 |
| EU/1/04/272/002/IS | Photo Barr Powder for sol. for inj. 15 or 75 mg | Iceland | 23.4.2004 |
| EU/1/04/273/001 | Lysodren | Liechtenstein | 31.5.2004 |
| EU/1/04/273/001/IS | Lysodren tablets 500 mg | Iceland | 19.5.2004 |
| EU/1/04/273/001/NO | Lysodren | Norway | 26.5.2004 |
| EU/1/04/274/001 | Velcade | Liechtenstein | 31.5.2004 |
| EU/1/04/274/001/IS | Velcade powder for sol. for inj. 3.5 mg | Iceland | 26.5.2004 |
| EU/1/04/274/001/NO | Velcade | Norway | 25.5.2004 |
| EU/1/04/275/001/NO-002/NO | Litak | Norway | 14.5.2004 |
| EU/1/04/275/001-002 | Litak | Liechtenstein | 31.5.2004 |
| EU/1/04/275/001-002/IS | Litak Solution for inj. 2 mg/ml | Iceland | 14.5.2004 |
| EU/1/04/276/001/NO-020/NO | Abilify | Norway | 24.6.2004 |
| EU/1/04/278/001/NO-009/NO | Levemir | Norway | 14.6.2004 |
| EU/1/04/278/001-009/IS | Levemir Penfill/FlexPen/InnoLet, sol f. inj. | Iceland | 25.6.2004 |
| EU/1/95/001/032 | Gonal | Liechtenstein | 31.1.2004 |
| EU/1/95/001/033-035 | Gonal f | Liechtenstein | 31.3.2004 |
| EU/1/97/031/045-046 | NeoRecormon | Liechtenstein | 31.3.2004 |
| EU/1/97/046/016-030 | Aprovel | Liechtenstein | 31.5.2004 |
| EU/1/97/049/016-030 | Karvea | Liechtenstein | 31.5.2004 |
| EU/1/97/054/006 | Viracept | Liechtenstein | 31.5.2004 |
| EU/1/98/066/014-018 | Exelon | Liechtenstein | 31.3.2004 |
| EU/1/98/085/011-020 | Karvezide | Liechtenstein | 31.5.2004 |
| EU/1/98/086/011-020 | CoAprovel | Liechtenstein | 31.5.2004 |
| EU/1/98/091/001-014 | Kinzalmono | Liechtenstein | 31.1.2004 |
| EU/1/98/092/014-018 | Prometax | Liechtenstein | 31.3.2004 |
| EU/1/99/099/001-006 | Zerene | Liechtenstein | 31.5.2004 |
| EU/1/99/113/003-004 | Paxene | Liechtenstein | 31.1.2004 |
| EU/2/00/022/009-012/IS | Ibaflin oral gel 3% and 7.5% | Iceland | 22.1.2004 |
| EU/2/00/022/013-017 | Ibaflin | Liechtenstein | 31.3.2004 |
| EU/2/02/032/001/IS | Gallivac HVT IDB Frosen susp. And diluent for inj. | Iceland | 13.4.2004 |
| EU/2/04/042/001/NO-004/NO | Novem | Norway | 10.5.2004 |
| EU/2/04/042/001-002/IS | Novem sol. for inj. 5 mg/ml | Iceland | 31.3.2004 |
| EU/2/04/042/001-004 | Novem | Liechtenstein | 31.5.2004 |
| EU/2/04/042/003-004/IS | Novem sol. for inj. 20 mg/ml | Iceland | 31.3.2004 |
| EU/2/04/043/001/IS | Equilis StrepE lyophilisate and solvent for suspension | Iceland | 11.6.2004 |
| EU/2/97/004/010 | Metacam | Liechtenstein | 31.3.2004 |
| EU/2/98/010/001-024 | Econor | Liechtenstein | 31.5.2004 |
| EU/2/99/011/001 | Locatim | Liechtenstein | 31.5.2004 |
| EU/2/99/014/001-011 | Stronghold | Liechtenstein | 31.3.2004 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/141/001/NO

Myocet

Norway

22.1.2004

EU/1/00/164/003-005

NutropinAq

Liechtenstein

31.3.2004

EU/1/02/212/026

Vfend

Liechtenstein

31.3.2004

EU/1/02/215/001-010/IS

PritorPlus tablets 40 mg and 80 mg

Iceland

10.2.2004

EU/1/03/263/001/NO-003/NO

Dukoral

Norway

11.5.2004

EU/1/03/263/001-003

Dukoral

Liechtenstein

31.5.2004

EU/1/03/264/001

Zevalin

Liechtenstein

31.1.2004

EU/1/03/264/001/IS

Zevalin 1.6 mg/ml kit for radiopharmaceut. prep.

Iceland

13.2.2004

EU/1/03/264/001/NO

Zevalin

Norway

2.2.2004

EU/1/03/265/001/NO-002/NO

Bonviva

Norway

24.3.2004

EU/1/03/265/001-002

Bonviva

Liechtenstein

31.5.2004

EU/1/03/265/001-002/IS

Bonviva filmc. tabl. 2.5 mg

Iceland

23.3.2004

EU/1/03/266/001/NO-002/NO

Ibandronic Acid Roche

Norway

24.3.2004

EU/1/03/266/001-002

Ibandronic Acid Roche

Liechtenstein

31.5.2004

EU/1/03/266/001-002/IS

Ibandronic Acid Roche film. tabl. 2.5 mg

Iceland

23.3.2004

EU/1/03/267/001/NO-007/NO

Reyataz

Norway

26.3.2004

EU/1/03/267/001-006/IS

Reyataz capsule hard 100 mg, 150 mg, 200 mg

Iceland

30.3.2004

EU/1/03/267/001-007

Reyataz

Liechtenstein

31.3.2004

EU/1/03/267/007/IS

Reyataz oral powder 50 mg/1.5 g

Iceland

30.3.2004

EU/1/03/268/001/NO-003/NO

Cholestagel

Norway

24.3.2004

EU/1/03/268/001-003

Cholestagel

Liechtenstein

31.3.2004

EU/1/03/268/001-003/IS

Cholestagel filmc. tabl. 625 mg

Iceland

5.4.2004

EU/1/03/269/001/IS

Faslodex

Iceland

7.4.2004

EU/1/03/269/001/NO

Faslodex

Norway

6.4.2004

EU/1/03/270/001/NO-002/NO

Oxybutynin Nicobrand

Norway

28.6.2004

EU/1/03/271/001/IS

Advate powder for sol. for inj. 250 IU, 500 IU, 1000 IU, 150

Iceland

1.4.2004

EU/1/03/271/001/NO-004/NO

Advate

Norway

29.3.2004

EU/1/03/271/001-004

Advate

Liechtenstein

31.5.2004

EU/1/04/272/001/NO-002/NO

Photo Barr

Norway

23.4.2004

EU/1/04/272/001-002

Photo Barr

Liechtenstein

31.5.2004

EU/1/04/272/002/IS

Photo Barr Powder for sol. for inj. 15 or 75 mg

Iceland

23.4.2004

EU/1/04/273/001

Lysodren

Liechtenstein

31.5.2004

EU/1/04/273/001/IS

Lysodren tablets 500 mg

Iceland

19.5.2004

EU/1/04/273/001/NO

Lysodren

Norway

26.5.2004

EU/1/04/274/001

Velcade

Liechtenstein

31.5.2004

EU/1/04/274/001/IS

Velcade powder for sol. for inj. 3.5 mg

Iceland

26.5.2004

EU/1/04/274/001/NO

Velcade

Norway

25.5.2004

EU/1/04/275/001/NO-002/NO

Litak

Norway

14.5.2004

EU/1/04/275/001-002

Litak

Liechtenstein

31.5.2004

EU/1/04/275/001-002/IS

Litak Solution for inj. 2 mg/ml

Iceland

14.5.2004

EU/1/04/276/001/NO-020/NO

Abilify

Norway

24.6.2004

EU/1/04/278/001/NO-009/NO

Levemir

Norway

14.6.2004

EU/1/04/278/001-009/IS

Levemir Penfill/FlexPen/InnoLet, sol f. inj.

Iceland

25.6.2004

EU/1/95/001/032

Gonal

Liechtenstein

31.1.2004

EU/1/95/001/033-035

Gonal f

Liechtenstein

31.3.2004

EU/1/97/031/045-046

NeoRecormon

Liechtenstein

31.3.2004

EU/1/97/046/016-030

Aprovel

Liechtenstein

31.5.2004

EU/1/97/049/016-030

Karvea

Liechtenstein

31.5.2004

EU/1/97/054/006

Viracept

Liechtenstein

31.5.2004

EU/1/98/066/014-018

Exelon

Liechtenstein

31.3.2004

EU/1/98/085/011-020

Karvezide

Liechtenstein

31.5.2004

EU/1/98/086/011-020

CoAprovel

Liechtenstein

31.5.2004

EU/1/98/091/001-014

Kinzalmono

Liechtenstein

31.1.2004

EU/1/98/092/014-018

Prometax

Liechtenstein

31.3.2004

EU/1/99/099/001-006

Zerene

Liechtenstein

31.5.2004

EU/1/99/113/003-004

Paxene

Liechtenstein

31.1.2004

EU/2/00/022/009-012/IS

Ibaflin oral gel 3% and 7.5%

Iceland

22.1.2004

EU/2/00/022/013-017

Ibaflin

Liechtenstein

31.3.2004

EU/2/02/032/001/IS

Gallivac HVT IDB Frosen susp. And diluent for inj.

Iceland

13.4.2004

EU/2/04/042/001/NO-004/NO

Novem

Norway

10.5.2004

EU/2/04/042/001-002/IS

Novem sol. for inj. 5 mg/ml

Iceland

31.3.2004

EU/2/04/042/001-004

Novem

Liechtenstein

31.5.2004

EU/2/04/042/003-004/IS

Novem sol. for inj. 20 mg/ml

Iceland

31.3.2004

EU/2/04/043/001/IS

Equilis StrepE lyophilisate and solvent for suspension

Iceland

11.6.2004

EU/2/97/004/010

Metacam

Liechtenstein

31.3.2004

EU/2/98/010/001-024

Econor

Liechtenstein

31.5.2004

EU/2/99/011/001

Locatim

Liechtenstein

31.5.2004

EU/2/99/014/001-011

Stronghold

Liechtenstein

31.3.2004

---

ANNEX II

2.   Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January — 30 June 2004:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/97/037/001/NO | Vistide | Norway | 31.3.2004 |
| EU/1/98/084/001/IS | Simulect, powder and solvent for sol. for injection, 20 mg | Iceland | 27.1.2004 |
| EU/1/98/084/002/IS | Simulect, powder and solvent for sol. for injection, 10 mg | Iceland | 27.1.2004 |
| EU/1/98/085/001-010 | Karvezide | Liechtenstein | 31.1.2004 |
| EU/1/98/086/001-003,007 and 009/IS | CoAprovel, tablets, 150 mg/12,5 mg | Iceland | 23.1.2004 |
| EU/1/98/086/004-006,008 and 010/IS | CoAprovel, tablets, 300 mg/12,5 mg | Iceland | 23.1.2004 |
| EU/1/98/086/001-010 | CoAprovel | Liechtenstein | 31.1.2004 |
| EU/1/98/087/001/NO-003/NO | Infergen | Norway | 23.4.2004 |
| EU/1/98/087/001-003 | Infergen | Liechtenstein | 31.5.2004 |
| EU/1/98/087/001-003/IS | Infergen solution for injection, 9 micrograms | Iceland | 21.6.2004 |
| EU/1/98/089/001-016/IS | Pritor tablets, 20, 40 and 80 mg | Iceland | 2.2.2004 |
| EU/1/98/089/001-016/NO | Pritor tablets, 20, 40 and 80 mg | Norway | 30.1.2004 |
| EU/1/98/089/001-016 | Pritor | Liechtenstein | 31.1.2004 |
| EU/1/98/090/001/NO-014/NO | Micardis | Norway | 30.1.2004 |
| EU/1/98/090/001-014 | Micardis | Liechtenstein | 31.1.2004 |
| EU/1/98/090/001-014/IS | Micardis tablets, 20, 40 and 80 mg | Iceland | 2.2.2004 |
| EU/1/98/091/001/NO-014/NO | Kinzalmono | Norway | 30.1.2004 |
| EU/1/98/091/001-014/IS | Kinzalmono tablets, 20, 40 and 80 mg | Iceland | 2.2.2004 |
| EU/1/98/095/001/NO-002/NO | Emadine | Norway | 5.4.2004 |
| EU/1/98/095/001-004 | Emadine | Liechtenstein | 31.3.2004 |
| EU/1/98/095/001-004/IS | Emadine, eye drops, solution, 0,5 mg/ml | Iceland | 1.4.2004 |
| EU/1/98/096/001-002/IS | Temodal, capsule, hard, 5 mg | Iceland | 7.4.2004 |
| EU/1/98/096/001/NO-008/NO | Temodal | Norway | 6.4.2004 |
| EU/1/98/096/001-008 | Temodal | Liechtenstein | 31.3.2004 |
| EU/1/98/096/003-004/IS | Temodal, capsule, hard, 20 mg | Iceland | 7.4.2004 |
| EU/1/98/096/005-006/IS | Temodal, capsule, hard, 100 mg | Iceland | 7.4.2004 |
| EU/1/98/096/007-008/IS | Temodal, capsule, hard, 250 mg | Iceland | 7.4.2004 |
| EU/1/99/097/001/NO | Beromun | Norway | 8.6.2004 |
| EU/1/99/098/001/NO-002/NO | Zenapax | Norway | 14.5.2004 |
| EU/1/99/098/001-002 | Zenapax | Liechtenstein | 31.5.2004 |
| EU/1/99/098/001-002/IS | Zenepax concentrate for solution for infusion | Iceland | 23.6.2004 |
| EU/1/99/099/001-003/IS | Zerene, capsule, hard, 5 mg | Iceland | 28.4.2004 |
| EU/1/99/099/004-006/IS | Zerene, capsule, hard, 10 mg | Iceland | 28.4.2004 |
| EU/1/99/099/001-006/NO | Zerene 5 mg, 10 mg capsules | Norway | 29.4.2004 |
| EU/1/99/101/001/NO | Regranex | Norway | 30.4.2004 |
| EU/1/99/101/001 | Regranex | Liechtenstein | 31.5.2004 |
| EU/1/99/101/001/IS | Regranex, gel, 100 mcg/g | Iceland | 30.4.2004 |
| EU/1/99/102/001-003 and 007/IS | Sonata, capsule, hard, 5 mg | Iceland | 29.4.2004 |
| EU/1/99/102/001/NO-008/NO | Sonata | Norway | 29.4.2004 |
| EU/1/99/102/001-008 | Sonata | Liechtenstein | 31.5.2004 |
| EU/1/99/102/004-006 and 008/IS | Sonata, capsule, hard, 10 mg | Iceland | 29.4.2004 |
| EU/1/99/110/001/NO-009/NO | Sustiva | Norway | 24.5.2004 |
| EU/1/99/110/001-009 | Sustiva | Liechtenstein | 31.5.2004 |
| EU/1/99/110/001-009/IS | Sustiva filmcoated tablets, capsules and oral sol. | Iceland | 28.5.2004 |
| EU/1/99/111/001-009/IS | Stocrin tablets, capsules and oral sol. | Iceland | 21.5.2004 |
| EU/1/99/111/001/NO-009/NO | Stocrin | Norway | 24.5.2004 |
| EU/1/99/111/001-009 | Stocrin | Liechtenstein | 31.5.2004 |
| EU/1/99/111/002/IS | Stocrin, capsule, hard, 100 mg | Iceland | 21.5.2004 |
| EU/1/99/111/003-004/IS | Stocrin, capsule, hard, 200 mg | Iceland | 21.5.2004 |
| EU/1/99/111/005/IS | Stocrin, oral solution, 30 mg/ml | Iceland | 21.5.2004 |
| EU/1/99/111/006-007/IS | Stocrin, film-coated tablet, 300 mg | Iceland | 21.5.2004 |
| EU/1/98/085/004-006, 008, 010, 017-020/IS | Karvezide, tablets, 150 mg/12,5 mg | Iceland | 22.1.2004 |
| EU/1/98/085/001-003, 007, 009, 011-015/IS | Karvezide, tablets, 300 mg/12,5 mg | Iceland | 22.1.2004 |
| EU/2/98/009/001/NO-006/NO | Suvaxyn Aujeszky 783+ O/W | Norway | 14.4.2004 |
| EU/2/98/009/001-006 | Suvaxyn Aujeszky 783+ O/W | Liechtenstein | 31.3.2004 |
| EU/2/99/011/001/IS | Locatim oral solution | Iceland | 27.5.2004 |
| EU/2/99/011/001/NO | Locatim | Norway | 28.5.2004 |

EU-Number

Product

Country

Date of authorisation

EU/1/97/037/001/NO

Vistide

Norway

31.3.2004

EU/1/98/084/001/IS

Simulect, powder and solvent for sol. for injection, 20 mg

Iceland

27.1.2004

EU/1/98/084/002/IS

Simulect, powder and solvent for sol. for injection, 10 mg

Iceland

27.1.2004

EU/1/98/085/001-010

Karvezide

Liechtenstein

31.1.2004

EU/1/98/086/001-003,007 and 009/IS

CoAprovel, tablets, 150 mg/12,5 mg

Iceland

23.1.2004

EU/1/98/086/004-006,008 and 010/IS

CoAprovel, tablets, 300 mg/12,5 mg

Iceland

23.1.2004

EU/1/98/086/001-010

CoAprovel

Liechtenstein

31.1.2004

EU/1/98/087/001/NO-003/NO

Infergen

Norway

23.4.2004

EU/1/98/087/001-003

Infergen

Liechtenstein

31.5.2004

EU/1/98/087/001-003/IS

Infergen solution for injection, 9 micrograms

Iceland

21.6.2004

EU/1/98/089/001-016/IS

Pritor tablets, 20, 40 and 80 mg

Iceland

2.2.2004

EU/1/98/089/001-016/NO

Pritor tablets, 20, 40 and 80 mg

Norway

30.1.2004

EU/1/98/089/001-016

Pritor

Liechtenstein

31.1.2004

EU/1/98/090/001/NO-014/NO

Micardis

Norway

30.1.2004

EU/1/98/090/001-014

Micardis

Liechtenstein

31.1.2004

EU/1/98/090/001-014/IS

Micardis tablets, 20, 40 and 80 mg

Iceland

2.2.2004

EU/1/98/091/001/NO-014/NO

Kinzalmono

Norway

30.1.2004

EU/1/98/091/001-014/IS

Kinzalmono tablets, 20, 40 and 80 mg

Iceland

2.2.2004

EU/1/98/095/001/NO-002/NO

Emadine

Norway

5.4.2004

EU/1/98/095/001-004

Emadine

Liechtenstein

31.3.2004

EU/1/98/095/001-004/IS

Emadine, eye drops, solution, 0,5 mg/ml

Iceland

1.4.2004

EU/1/98/096/001-002/IS

Temodal, capsule, hard, 5 mg

Iceland

7.4.2004

EU/1/98/096/001/NO-008/NO

Temodal

Norway

6.4.2004

EU/1/98/096/001-008

Temodal

Liechtenstein

31.3.2004

EU/1/98/096/003-004/IS

Temodal, capsule, hard, 20 mg

Iceland

7.4.2004

EU/1/98/096/005-006/IS

Temodal, capsule, hard, 100 mg

Iceland

7.4.2004

EU/1/98/096/007-008/IS

Temodal, capsule, hard, 250 mg

Iceland

7.4.2004

EU/1/99/097/001/NO

Beromun

Norway

8.6.2004

EU/1/99/098/001/NO-002/NO

Zenapax

Norway

14.5.2004

EU/1/99/098/001-002

Zenapax

Liechtenstein

31.5.2004

EU/1/99/098/001-002/IS

Zenepax concentrate for solution for infusion

Iceland

23.6.2004

EU/1/99/099/001-003/IS

Zerene, capsule, hard, 5 mg

Iceland

28.4.2004

EU/1/99/099/004-006/IS

Zerene, capsule, hard, 10 mg

Iceland

28.4.2004

EU/1/99/099/001-006/NO

Zerene 5 mg, 10 mg capsules

Norway

29.4.2004

EU/1/99/101/001/NO

Regranex

Norway

30.4.2004

EU/1/99/101/001

Regranex

Liechtenstein

31.5.2004

EU/1/99/101/001/IS

Regranex, gel, 100 mcg/g

Iceland

30.4.2004

EU/1/99/102/001-003 and 007/IS

Sonata, capsule, hard, 5 mg

Iceland

29.4.2004

EU/1/99/102/001/NO-008/NO

Sonata

Norway

29.4.2004

EU/1/99/102/001-008

Sonata

Liechtenstein

31.5.2004

EU/1/99/102/004-006 and 008/IS

Sonata, capsule, hard, 10 mg

Iceland

29.4.2004

EU/1/99/110/001/NO-009/NO

Sustiva

Norway

24.5.2004

EU/1/99/110/001-009

Sustiva

Liechtenstein

31.5.2004

EU/1/99/110/001-009/IS

Sustiva filmcoated tablets, capsules and oral sol.

Iceland

28.5.2004

EU/1/99/111/001-009/IS

Stocrin tablets, capsules and oral sol.

Iceland

21.5.2004

EU/1/99/111/001/NO-009/NO

Stocrin

Norway

24.5.2004

EU/1/99/111/001-009

Stocrin

Liechtenstein

31.5.2004

EU/1/99/111/002/IS

Stocrin, capsule, hard, 100 mg

Iceland

21.5.2004

EU/1/99/111/003-004/IS

Stocrin, capsule, hard, 200 mg

Iceland

21.5.2004

EU/1/99/111/005/IS

Stocrin, oral solution, 30 mg/ml

Iceland

21.5.2004

EU/1/99/111/006-007/IS

Stocrin, film-coated tablet, 300 mg

Iceland

21.5.2004

EU/1/98/085/004-006, 008, 010, 017-020/IS

Karvezide, tablets, 150 mg/12,5 mg

Iceland

22.1.2004

EU/1/98/085/001-003, 007, 009, 011-015/IS

Karvezide, tablets, 300 mg/12,5 mg

Iceland

22.1.2004

EU/2/98/009/001/NO-006/NO

Suvaxyn Aujeszky 783+ O/W

Norway

14.4.2004

EU/2/98/009/001-006

Suvaxyn Aujeszky 783+ O/W

Liechtenstein

31.3.2004

EU/2/99/011/001/IS

Locatim oral solution

Iceland

27.5.2004

EU/2/99/011/001/NO

Locatim

Norway

28.5.2004

---

ANNEX III

3.   Extended Marketing Authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January — 30 June 2004:

| EU-Number | Product | Country | Date of extention |
| --- | --- | --- | --- |
| EU/1/01/198/007/NO-010/NO | Glivec | Norway | 5.1.2004 |
| EU/1/01/198/007-010/IS | Glivec 100 mg and 400 mg filmcoated tablets | Iceland | 15.1.2004 |
| EU/1/02/212/026/IS | Vfend, powder for oral suspension 40 mg/ml | Iceland | 18.6.2004 |
| EU/1/02/212/026/NO | Vfend | Norway | 5.3.2004 |
| EU/1/95/001/033/NO-035/NO | Gonal-f | Norway | 24.3.2004 |
| EU/1/95/001/033-035/IS | GONAL-f, solution for injection in prefilled pen | Iceland | 19.3.2004 |
| EU/1/96/012/009-010/IS | Bondronat, film coated tablets 50 mg | Iceland | 7.1.2004 |
| EU/1/97/031/045/NO-046/NO | NeoRecormon | Norway | 23.3.2004 |
| EU/1/97/031/045-046/IS | NeoRecormon 30.000 IU Sol. for injection pref.syr. | Iceland | 30.3.2004 |
| EU/1/97/046/016/NO-030/NO | Aprovel | Norway | 30.3.2004 |
| EU/1/97/049/016/NO-030/NO | Karvea | Norway | 30.3.2004 |
| EU/1/97/054/006/IS | Viracept 625 mg film-coated tablets | Iceland | 28.5.2004 |
| EU/1/97/054/006/NO | Viracept | Norway | 21.5.2004 |
| EU/1/98/085/011/NO-020/NO | Karvezide | Norway | 23.6.2004 |
| EU/1/98/086/011/NO-020/NO | CoAprovel | Norway | 23.6.2004 |
| EU/2/00/022/013/NO-017/NO | Ibaflin | Norway | 24.3.2004 |
| EU/2/97/004/010/NO | Metacam | Norway | 11.5.2004 |

EU-Number

Product

Country

Date of extention

EU/1/01/198/007/NO-010/NO

Glivec

Norway

5.1.2004

EU/1/01/198/007-010/IS

Glivec 100 mg and 400 mg filmcoated tablets

Iceland

15.1.2004

EU/1/02/212/026/IS

Vfend, powder for oral suspension 40 mg/ml

Iceland

18.6.2004

EU/1/02/212/026/NO

Vfend

Norway

5.3.2004

EU/1/95/001/033/NO-035/NO

Gonal-f

Norway

24.3.2004

EU/1/95/001/033-035/IS

GONAL-f, solution for injection in prefilled pen

Iceland

19.3.2004

EU/1/96/012/009-010/IS

Bondronat, film coated tablets 50 mg

Iceland

7.1.2004

EU/1/97/031/045/NO-046/NO

NeoRecormon

Norway

23.3.2004

EU/1/97/031/045-046/IS

NeoRecormon 30.000 IU Sol. for injection pref.syr.

Iceland

30.3.2004

EU/1/97/046/016/NO-030/NO

Aprovel

Norway

30.3.2004

EU/1/97/049/016/NO-030/NO

Karvea

Norway

30.3.2004

EU/1/97/054/006/IS

Viracept 625 mg film-coated tablets

Iceland

28.5.2004

EU/1/97/054/006/NO

Viracept

Norway

21.5.2004

EU/1/98/085/011/NO-020/NO

Karvezide

Norway

23.6.2004

EU/1/98/086/011/NO-020/NO

CoAprovel

Norway

23.6.2004

EU/2/00/022/013/NO-017/NO

Ibaflin

Norway

24.3.2004

EU/2/97/004/010/NO

Metacam

Norway

11.5.2004

---

ANNEX IV

4.   Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January — 30 June 2004:

| EU-Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/00/158/001/NO-034/NO | Opulis | Norway | 29.3.2004 |
| EU/1/00/158/001-034 | Opulis | Liechtenstein | 31.3.2004 |
| EU/1/00/159/001/NO-034/NO | Allex | Norway | 29.3.2004 |
| EU/1/00/159/001-034 | Allex | Liechtenstein | 31.3.2004 |
| EU/1/00/159/001-034/IS | Allex | Iceland | 10.3.2004 |
| EU/1/02/208/001/NO-008/NO | Xapit | Norway | 29.3.2004 |
| EU/1/02/208/001-008 | Xapit | Liechtenstein | 31.3.2004 |
| EU/1/02/242/001/NO-024/NO | Valdyn | Norway | 29.3.2004 |
| EU/1/99/106/001-003 | Cotronak | Liechtenstein | 31.3.2004 |

EU-Number

Product

Country

Date of withdrawal

EU/1/00/158/001/NO-034/NO

Opulis

Norway

29.3.2004

EU/1/00/158/001-034

Opulis

Liechtenstein

31.3.2004

EU/1/00/159/001/NO-034/NO

Allex

Norway

29.3.2004

EU/1/00/159/001-034

Allex

Liechtenstein

31.3.2004

EU/1/00/159/001-034/IS

Allex

Iceland

10.3.2004

EU/1/02/208/001/NO-008/NO

Xapit

Norway

29.3.2004

EU/1/02/208/001-008

Xapit

Liechtenstein

31.3.2004

EU/1/02/242/001/NO-024/NO

Valdyn

Norway

29.3.2004

EU/1/99/106/001-003

Cotronak

Liechtenstein

31.3.2004

---

ANNEX V

5.   Suspended Marketing Authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January — 30 June 2004:

| EU-Number | Product | Country | Date of suspension |
| --- | --- | --- | --- |
| EU/1/98/093/002 | Forcaltonin | Liechtenstein | 31.5.2004 |

EU-Number

Product

Country

Date of suspension

EU/1/98/093/002

Forcaltonin

Liechtenstein

31.5.2004

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/45 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/45

---

List of marketing authorisations granted by the EEA EFTA States for the second half of 2004

(2006/C 233/11)

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note, at the meeting on 10 March 2006, the following lists concerning marketing authorisations for medicinal products for the period 1 July — 31 December 2004:

| Annex I | List of new marketing authorisations |
| --- | --- |

Annex I

| Annex II | List of renewed marketing authorisations |
| --- | --- |

Annex II

| Annex III | List of extended marketing authorisations |
| --- | --- |

Annex III

| Annex IV | List of withdrawn marketing authorisations |
| --- | --- |

Annex IV

---

ANNEX I

1.   New Marketing Authorisations:

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July — 31 December 2004:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/134/022-029 | Lantus | Liechtenstein | 30.9.2004 |
| EU/1/00/138/001/NO-012/NO | Venvia | Norway | 30.7.2004 |
| EU/1/00/139/001/NO-012/NO | Nyracta | Norway | 30.7.2004 |
| EU/1/00/143/004-006 | Kogenate Bayer | Liechtenstein | 30.9.2004 |
| EU/1/01/178/001/NO | Targretin | Norway | 13.7.2004 |
| EU/1/01/184/033-044 | Nespo | Liechtenstein | 30.11.2004 |
| EU/1/01/185/033-044 | Aranesp | Liechtenstein | 30.11.2004 |
| EU/1/01/189/004-006 | Replagal | Liechtenstein | 30.9.2004 |
| EU/1/01/191/005 | Ketek | Liechtenstein | 30.11.2004 |
| EU/1/01/192/005 | Levviax | Liechtenstein | 30.11.2004 |
| EU/1/01/193/002 | MabCampath | Liechtenstein | 30.11.2004 |
| EU/1/02/206/009-017 | Arixtra | Liechtenstein | 30.11.2004 |
| EU/1/02/207/009-017 | Quixidar | Liechtenstein | 30.11.2004 |
| EU/1/02/221/009-010 | Pegasys | Liechtenstein | 30.11.2004 |
| EU/1/03/258/007-012 | Avandamet | Liechtenstein | 30.9.2004 |
| EU/1/03/270/001-002 | Oxybutynin | Liechtenstein | 31.7.2004 |
| EU/1/03/270/001-002/IS | Oxybutynin Nicobrand transderm. patches, 3,9 mg/24hours | Iceland | 28.7.2004 |
| EU/1/04/276/001-005/IS | Abilify, tablets, 5 mg | Iceland | 1.7.2004 |
| EU/1/04/276/001-020 | Abilify | Liechtenstein | 31.7.2004 |
| EU/1/04/276/006-010/IS | Abilify, tablets,10 mg | Iceland | 1.7.2004 |
| EU/1/04/276/011-015/IS | Abilify, tablets, 15 mg | Iceland | 1.7.2004 |
| EU/1/04/276/016-020/IS | Abilify, tablets, 30 mg | Iceland | 1.7.2004 |
| EU/1/04/277/001/IS | TachoSil, medicated sponge, 5,5 mg + 2,0 IU | Iceland | 8.7.2004 |
| EU/1/04/277/001/NO-004/NO | TachoSil | Norway | 5.7.2004 |
| EU/1/04/277/001-004 | TachoSil | Liechtenstein | 31.7.2004 |
| EU/1/04/278/001-009 | Levemir | Liechtenstein | 31.7.2004 |
| EU/1/04/279/001/NO-025/NO | Lyrica | Norway | 4.8.2004 |
| EU/1/04/279/001-005/IS | LYRICA, capsule, hard, 25 mg | Iceland | 26.8.2004 |
| EU/1/04/279/001-025 | Lyrica | Liechtenstein | 30.9.2004 |
| EU/1/04/279/006-010/IS | LYRICA, capsule, hard, 50 mg | Iceland | 26.8.2004 |
| EU/1/04/279/011-013/IS | LYRICA, capsule, hard, 75 mg | Iceland | 26.8.2004 |
| EU/1/04/279/014-016/IS | LYRICA, capsule, hard, 150 mg | Iceland | 26.8.2004 |
| EU/1/04/279/017-019/IS | LYRICA, capsule, hard, 300 mg | Iceland | 26.8.2004 |
| EU/1/04/279/020-022/IS | LYRICA, capsule, hard, 100 mg | Iceland | 26.8.2004 |
| EU/1/04/279/023-025/IS | LYRICA, capsule, hard, 200 mg | Iceland | 26.8.2004 |
| EU/1/04/280/001/IS | Yentreve, gastro-resistant capsule, hard, 20 mg | Iceland | 9.9.2004 |
| EU/1/04/280/001/NO-006/NO | Yentreve | Norway | 26.8.2004 |
| EU/1/04/280/001-006 | Yentreve | Liechtenstein | 30.9.2004 |
| EU/1/04/280/002-006/IS | Yentreve, gastro-resistant capsule, hard, 40 mg | Iceland | 9.9.2004 |
| EU/1/04/281/001 | Erbitux | Liechtenstein | 31.7.2004 |
| EU/1/04/281/001/IS | Erbitux, solution for infusion, 2 mg/ml | Iceland | 26.7.2004 |
| EU/1/04/281/001/NO | Erbitux | Norway | 9.7.2004 |
| EU/1/04/282/001/NO-002/NO | Telzir | Norway | 19.7.2004 |
| EU/1/04/282/001-002 | Telzir | Liechtenstein | 30.9.2004 |
| EU/1/04/282/001-002/IS | Telzir tablets and oral susp. | Iceland | 10.8.2004 |
| EU/1/04/283/001/IS | Ariclaim, gastro-resistant capsule, hard, 20 mg | Iceland | 11.9.2004 |
| EU/1/04/283/001/NO-006/NO | Ariclaim | Norway | 27.8.2004 |
| EU/1/04/283/001-006 | Ariclaim | Liechtenstein | 30.9.2004 |
| EU/1/04/283/002-006/IS | Ariclaim, gastro-resistant capsule, hard, 40 mg | Iceland | 11.9.2004 |
| EU/1/04/284/001 | Pedea | Liechtenstein | 30.9.2004 |
| EU/1/04/284/001/IS | Pedea, solution for injection, 5mg/ml | Iceland | 12.8.2004 |
| EU/1/04/284/001/NO | Pedea | Norway | 18.8.2004 |
| EU/1/04/285/001/NO-020/NO | Apidra | Norway | 25.10.2004 |
| EU/1/04/285/001-004/IS | Apidra, solution for injection,vial, 100 units/ml | Iceland | 27.10.2004 |
| EU/1/04/285/001-020 | Apidra | Liechtenstein | 30.11.2004 |
| EU/1/04/285/005/012/IS | Apidra, solution for injection,cartridge, 100 units/ml | Iceland | 27.10.2004 |
| EU/1/04/285/013-020/IS | Apidra, solution for injection, pre-filled pen, 100 units/ml | Iceland | 27.10.2004 |
| EU/1/04/286/001/IS | Wilzin, capsule, hard, 25 mg | Iceland | 11.11.2004 |
| EU/1/04/286/001/NO-002/NO | Wilzin | Norway | 12.11.2004 |
| EU/1/04/286/001-002 | Wilzin | Liechtenstein | 30.11.2004 |
| EU/1/04/286/002/IS | Wilzin, capsule, hard, 50 mg | Iceland | 11.11.2004 |
| EU/1/04/287/001/NO-006/NO | Osseor | Norway | 18.10.2004 |
| EU/1/04/287/001-006 | Osseor | Liechtenstein | 30.11.2004 |
| EU/1/04/287/001-006/IS | Osseor, powder for oral suspension, 2g | Iceland | 27.10.2004 |
| EU/1/04/288/001/NO-006/NO | Protelos | Norway | 18.10.2004 |
| EU/1/04/288/001-006 | Protelos | Liechtenstein | 30.11.2004 |
| EU/1/04/288/001-006/IS | Protelos, powder for oral suspension, 2g | Iceland | 20.10.2004 |
| EU/1/04/289/001 | Angiox | Liechtenstein | 30.9.2004 |
| EU/1/04/289/001/NO | Angiox | Norway | 8.10.2004 |
| EU/1/04/290/001 | Alimta | Liechtenstein | 30.9.2004 |
| EU/1/04/290/001/IS | Alimta, concentrate for solution for infusion, 500 mg | Iceland | 19.10.2004 |
| EU/1/04/290/001/NO | Alimta, concentrate for solution for infusion, 500 mg | Norway | 19.10.2004 |
| EU/1/04/291/001/NO-002/NO | Raptiva | Norway | 30.9.2004 |
| EU/1/04/291/001-001/IS | Raptiva 100 mg/ml Powder and solvent for solution for injection | Iceland | 18.10.2004 |
| EU/1/04/291/001-002 | Raptiva | Liechtenstein | 30.9.2004 |
| EU/1/04/292/001/NO-012/NO | Mimpara | Norway | 11.11.2004 |
| EU/1/04/292/001-004/IS | Mimpara, film-coated tablet, 30 mg | Iceland | 19.11.2004 |
| EU/1/04/292/001-012 | Mimpara | Liechtenstein | 30.11.2004 |
| EU/1/04/292/005-008/IS | Mimpara, film-coated tablet, 60 mg | Iceland | 19.11.2004 |
| EU/1/04/292/009-012/IS | Mimpara, film-coated tablet, 90 mg | Iceland | 19.11.2004 |
| EU/1/04/293/001/NO-012/NO | Parareg | Norway | 11.11.2004 |
| EU/1/04/293/001-004/IS | Parareg, film-coated tablet, 30 mg | Iceland | 18.11.2004 |
| EU/1/04/293/001-012 | Parareg | Liechtenstein | 30.11.2004 |
| EU/1/04/293/005-008/IS | Parareg, film-coated tablet, 60 mg | Iceland | 18.11.2004 |
| EU/1/04/293/009-012/IS | Parareg, film-coated tablet, 90 mg | Iceland | 18.11.2004 |
| EU/1/04/294/001/NO-012/NO | Emselex | Norway | 16.11.2004 |
| EU/1/04/294/001-006/IS | Emselex 7,5 mg prolonged release tablets | Iceland | 24.11.2004 |
| EU/1/04/294/001-012 | Emselex | Liechtenstein | 30.11.2004 |
| EU/1/04/294/007-012/IS | Emselex 15 mg prolonged release tablets | Iceland | 24.11.2004 |
| EU/1/04/295/001 | Xagrid | Liechtenstein | 30.11.2004 |
| EU/1/04/295/001/IS | Xagrid, Capsules, hard, 0,5 mg | Iceland | 29.12.2004 |
| EU/1/04/295/001/NO | Xagrid | Norway | 15.12.2004 |
| EU/1/96/008/040-041 | Puregon | Liechtenstein | 30.9.2004 |
| EU/1/96/013/001-004 | Destara | Liechtenstein | 31.7.2004 |
| EU/1/96/022/019-022 | Zyprexa | Liechtenstein | 30.11.2004 |
| EU/1/97/044/001-006 | Tasmar | Liechtenstein | 30.11.2004 |
| EU/1/99/104/001/NO | Procomvax | Norway | 17.9.2004 |
| EU/2/04/043/001/NO | Equilis StrepE | Norway | 13.9.2004 |
| EU/2/04/044/001/IS | Aivlozin 42,5 mg/g premix for medicated feeding stuff for pigs | Iceland | 22.9.2004 |
| EU/2/04/044/001/NO | Aivlosin | Norway | 8.10.2004 |
| EU/2/04/045/001/NO-004/NO | Previcox | Norway | 13.10.2004 |
| EU/2/04/045/001-002/IS | Previcox, chewable tablet, 57 mg | Iceland | 4.10.2004 |
| EU/2/04/045/001-004 | Previcox | Liechtenstein | 30.9.2004 |
| EU/2/04/045/003-004/IS | Previcox, chewable tablet, 227 mg | Iceland | 4.10.2004 |
| EU/2/04/046/001/NO-003/NO | Nobivac Piro | Norway | 2.10.2004 |
| EU/2/04/046/001-003 | Nobivac Piro-606 | Liechtenstein | 30.9.2004 |
| EU/2/96/001/009-010 | Porcilis Porcoli | Liechtenstein | 30.9.2004 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/134/022-029

Lantus

Liechtenstein

30.9.2004

EU/1/00/138/001/NO-012/NO

Venvia

Norway

30.7.2004

EU/1/00/139/001/NO-012/NO

Nyracta

Norway

30.7.2004

EU/1/00/143/004-006

Kogenate Bayer

Liechtenstein

30.9.2004

EU/1/01/178/001/NO

Targretin

Norway

13.7.2004

EU/1/01/184/033-044

Nespo

Liechtenstein

30.11.2004

EU/1/01/185/033-044

Aranesp

Liechtenstein

30.11.2004

EU/1/01/189/004-006

Replagal

Liechtenstein

30.9.2004

EU/1/01/191/005

Ketek

Liechtenstein

30.11.2004

EU/1/01/192/005

Levviax

Liechtenstein

30.11.2004

EU/1/01/193/002

MabCampath

Liechtenstein

30.11.2004

EU/1/02/206/009-017

Arixtra

Liechtenstein

30.11.2004

EU/1/02/207/009-017

Quixidar

Liechtenstein

30.11.2004

EU/1/02/221/009-010

Pegasys

Liechtenstein

30.11.2004

EU/1/03/258/007-012

Avandamet

Liechtenstein

30.9.2004

EU/1/03/270/001-002

Oxybutynin

Liechtenstein

31.7.2004

EU/1/03/270/001-002/IS

Oxybutynin Nicobrand transderm. patches, 3,9 mg/24hours

Iceland

28.7.2004

EU/1/04/276/001-005/IS

Abilify, tablets, 5 mg

Iceland

1.7.2004

EU/1/04/276/001-020

Abilify

Liechtenstein

31.7.2004

EU/1/04/276/006-010/IS

Abilify, tablets,10 mg

Iceland

1.7.2004

EU/1/04/276/011-015/IS

Abilify, tablets, 15 mg

Iceland

1.7.2004

EU/1/04/276/016-020/IS

Abilify, tablets, 30 mg

Iceland

1.7.2004

EU/1/04/277/001/IS

TachoSil, medicated sponge, 5,5 mg + 2,0 IU

Iceland

8.7.2004

EU/1/04/277/001/NO-004/NO

TachoSil

Norway

5.7.2004

EU/1/04/277/001-004

TachoSil

Liechtenstein

31.7.2004

EU/1/04/278/001-009

Levemir

Liechtenstein

31.7.2004

EU/1/04/279/001/NO-025/NO

Lyrica

Norway

4.8.2004

EU/1/04/279/001-005/IS

LYRICA, capsule, hard, 25 mg

Iceland

26.8.2004

EU/1/04/279/001-025

Lyrica

Liechtenstein

30.9.2004

EU/1/04/279/006-010/IS

LYRICA, capsule, hard, 50 mg

Iceland

26.8.2004

EU/1/04/279/011-013/IS

LYRICA, capsule, hard, 75 mg

Iceland

26.8.2004

EU/1/04/279/014-016/IS

LYRICA, capsule, hard, 150 mg

Iceland

26.8.2004

EU/1/04/279/017-019/IS

LYRICA, capsule, hard, 300 mg

Iceland

26.8.2004

EU/1/04/279/020-022/IS

LYRICA, capsule, hard, 100 mg

Iceland

26.8.2004

EU/1/04/279/023-025/IS

LYRICA, capsule, hard, 200 mg

Iceland

26.8.2004

EU/1/04/280/001/IS

Yentreve, gastro-resistant capsule, hard, 20 mg

Iceland

9.9.2004

EU/1/04/280/001/NO-006/NO

Yentreve

Norway

26.8.2004

EU/1/04/280/001-006

Yentreve

Liechtenstein

30.9.2004

EU/1/04/280/002-006/IS

Yentreve, gastro-resistant capsule, hard, 40 mg

Iceland

9.9.2004

EU/1/04/281/001

Erbitux

Liechtenstein

31.7.2004

EU/1/04/281/001/IS

Erbitux, solution for infusion, 2 mg/ml

Iceland

26.7.2004

EU/1/04/281/001/NO

Erbitux

Norway

9.7.2004

EU/1/04/282/001/NO-002/NO

Telzir

Norway

19.7.2004

EU/1/04/282/001-002

Telzir

Liechtenstein

30.9.2004

EU/1/04/282/001-002/IS

Telzir tablets and oral susp.

Iceland

10.8.2004

EU/1/04/283/001/IS

Ariclaim, gastro-resistant capsule, hard, 20 mg

Iceland

11.9.2004

EU/1/04/283/001/NO-006/NO

Ariclaim

Norway

27.8.2004

EU/1/04/283/001-006

Ariclaim

Liechtenstein

30.9.2004

EU/1/04/283/002-006/IS

Ariclaim, gastro-resistant capsule, hard, 40 mg

Iceland

11.9.2004

EU/1/04/284/001

Pedea

Liechtenstein

30.9.2004

EU/1/04/284/001/IS

Pedea, solution for injection, 5mg/ml

Iceland

12.8.2004

EU/1/04/284/001/NO

Pedea

Norway

18.8.2004

EU/1/04/285/001/NO-020/NO

Apidra

Norway

25.10.2004

EU/1/04/285/001-004/IS

Apidra, solution for injection,vial, 100 units/ml

Iceland

27.10.2004

EU/1/04/285/001-020

Apidra

Liechtenstein

30.11.2004

EU/1/04/285/005/012/IS

Apidra, solution for injection,cartridge, 100 units/ml

Iceland

27.10.2004

EU/1/04/285/013-020/IS

Apidra, solution for injection, pre-filled pen, 100 units/ml

Iceland

27.10.2004

EU/1/04/286/001/IS

Wilzin, capsule, hard, 25 mg

Iceland

11.11.2004

EU/1/04/286/001/NO-002/NO

Wilzin

Norway

12.11.2004

EU/1/04/286/001-002

Wilzin

Liechtenstein

30.11.2004

EU/1/04/286/002/IS

Wilzin, capsule, hard, 50 mg

Iceland

11.11.2004

EU/1/04/287/001/NO-006/NO

Osseor

Norway

18.10.2004

EU/1/04/287/001-006

Osseor

Liechtenstein

30.11.2004

EU/1/04/287/001-006/IS

Osseor, powder for oral suspension, 2g

Iceland

27.10.2004

EU/1/04/288/001/NO-006/NO

Protelos

Norway

18.10.2004

EU/1/04/288/001-006

Protelos

Liechtenstein

30.11.2004

EU/1/04/288/001-006/IS

Protelos, powder for oral suspension, 2g

Iceland

20.10.2004

EU/1/04/289/001

Angiox

Liechtenstein

30.9.2004

EU/1/04/289/001/NO

Angiox

Norway

8.10.2004

EU/1/04/290/001

Alimta

Liechtenstein

30.9.2004

EU/1/04/290/001/IS

Alimta, concentrate for solution for infusion, 500 mg

Iceland

19.10.2004

EU/1/04/290/001/NO

Alimta, concentrate for solution for infusion, 500 mg

Norway

19.10.2004

EU/1/04/291/001/NO-002/NO

Raptiva

Norway

30.9.2004

EU/1/04/291/001-001/IS

Raptiva 100 mg/ml Powder and solvent for solution for injection

Iceland

18.10.2004

EU/1/04/291/001-002

Raptiva

Liechtenstein

30.9.2004

EU/1/04/292/001/NO-012/NO

Mimpara

Norway

11.11.2004

EU/1/04/292/001-004/IS

Mimpara, film-coated tablet, 30 mg

Iceland

19.11.2004

EU/1/04/292/001-012

Mimpara

Liechtenstein

30.11.2004

EU/1/04/292/005-008/IS

Mimpara, film-coated tablet, 60 mg

Iceland

19.11.2004

EU/1/04/292/009-012/IS

Mimpara, film-coated tablet, 90 mg

Iceland

19.11.2004

EU/1/04/293/001/NO-012/NO

Parareg

Norway

11.11.2004

EU/1/04/293/001-004/IS

Parareg, film-coated tablet, 30 mg

Iceland

18.11.2004

EU/1/04/293/001-012

Parareg

Liechtenstein

30.11.2004

EU/1/04/293/005-008/IS

Parareg, film-coated tablet, 60 mg

Iceland

18.11.2004

EU/1/04/293/009-012/IS

Parareg, film-coated tablet, 90 mg

Iceland

18.11.2004

EU/1/04/294/001/NO-012/NO

Emselex

Norway

16.11.2004

EU/1/04/294/001-006/IS

Emselex 7,5 mg prolonged release tablets

Iceland

24.11.2004

EU/1/04/294/001-012

Emselex

Liechtenstein

30.11.2004

EU/1/04/294/007-012/IS

Emselex 15 mg prolonged release tablets

Iceland

24.11.2004

EU/1/04/295/001

Xagrid

Liechtenstein

30.11.2004

EU/1/04/295/001/IS

Xagrid, Capsules, hard, 0,5 mg

Iceland

29.12.2004

EU/1/04/295/001/NO

Xagrid

Norway

15.12.2004

EU/1/96/008/040-041

Puregon

Liechtenstein

30.9.2004

EU/1/96/013/001-004

Destara

Liechtenstein

31.7.2004

EU/1/96/022/019-022

Zyprexa

Liechtenstein

30.11.2004

EU/1/97/044/001-006

Tasmar

Liechtenstein

30.11.2004

EU/1/99/104/001/NO

Procomvax

Norway

17.9.2004

EU/2/04/043/001/NO

Equilis StrepE

Norway

13.9.2004

EU/2/04/044/001/IS

Aivlozin 42,5 mg/g premix for medicated feeding stuff for pigs

Iceland

22.9.2004

EU/2/04/044/001/NO

Aivlosin

Norway

8.10.2004

EU/2/04/045/001/NO-004/NO

Previcox

Norway

13.10.2004

EU/2/04/045/001-002/IS

Previcox, chewable tablet, 57 mg

Iceland

4.10.2004

EU/2/04/045/001-004

Previcox

Liechtenstein

30.9.2004

EU/2/04/045/003-004/IS

Previcox, chewable tablet, 227 mg

Iceland

4.10.2004

EU/2/04/046/001/NO-003/NO

Nobivac Piro

Norway

2.10.2004

EU/2/04/046/001-003

Nobivac Piro-606

Liechtenstein

30.9.2004

EU/2/96/001/009-010

Porcilis Porcoli

Liechtenstein

30.9.2004

---

ANNEX II

2.   Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July — 31 December 2004:

| EU-Number | Product | Country | Date of renewal |
| --- | --- | --- | --- |
| EU/1/99/119/009/IS-011/IS | NovoRapid FlexPen, solution for injection, 100 units/ml | Iceland | 11.11.2004 |
| EU/1/99/097/001 | Beromun | Liechtenstein | 31.7.2004 |
| EU/1/99/097/001/IS | Beromun, powder and solvent for solution for infusion, 1 mg | Iceland | 9.8.2004 |
| EU/1/99/100/001-002/IS | Cetrotide, powder for solution for injection, 0,25 mg | Iceland | 15.9.2004 |
| EU/1/99/100/001-003 | Cetrotide | Liechtenstein | 30.9.2004 |
| EU/1/99/100/003/IS | Cetrotide, powder for solution for injection, 3 mg | Iceland | 15.9.2004 |
| EU/1/99/103/001/IS | Refacto, powder and solvent for sol. for injection, 250 a.e. | Iceland | 19.8.2004 |
| EU/1/99/103/001/NO-004/NO | ReFacto | Norway | 16.8.2004 |
| EU/1/99/103/001-004 | ReFacto | Liechtenstein | 30.9.2004 |
| EU/1/99/103/002/IS | Refacto, powder and solvent for sol. for injection, 500 a.e. | Iceland | 19.8.2004 |
| EU/1/99/103/003/IS | Refacto, powder and solvent for sol. for injection, 1 000 a.e. | Iceland | 19.8.2004 |
| EU/1/99/103/004/IS | Refacto, powder and solvent for sol. for injection, 2 000 a.e. | Iceland | 19.8.2004 |
| EU/1/99/104/001 | Procomvax | Liechtenstein | 30.9.2004 |
| EU/1/99/104/001/IS | Procomvax, suspension for injection | Iceland | 2.9.2004 |
| EU/1/99/107/001/IS | Rebetol, capsule, hard, 200 mg | Iceland | 29.9.2004 |
| EU/1/99/107/001/NO-003/NO | Rebetol | Norway | 28.9.2004 |
| EU/1/99/107/001-003 | Rebetol | Liechtenstein | 30.9.2004 |
| EU/1/99/108/001 | Ferriprox | Liechtenstein | 30.9.2004 |
| EU/1/99/108/001/IS | Ferriprox, film coated tablet, 500 mg | Iceland | 22.9.2004 |
| EU/1/99/108/001/NO | Ferriprox | Norway | 27.9.2004 |
| EU/1/99/109/001/IS | Integrilin, solution for infusion, 0,75 mg/ml | Iceland | 1.10.2004 |
| EU/1/99/109/001/NO-002/NO | Integrilin | Norway | 28.9.2004 |
| EU/1/99/109/001-002 | Integrilin | Liechtenstein | 30.9.2004 |
| EU/1/99/109/002/IS | Integrilin, solution for injection, 2 mg/ml | Iceland | 1.10.2004 |
| EU/1/99/111/001-009 | Stocrin | Liechtenstein | 31.7.2004 |
| EU/1/99/112/001/IS | Ziagen, film-coated tablet, 300 mg | Iceland | 16.9.2004 |
| EU/1/99/112/001/NO-002/NO | Ziagen | Norway | 18.9.2004 |
| EU/1/99/112/002/IS | Ziagen, oral liquid, 20 mg/ml | Iceland | 16.9.2004 |
| EU/1/99/113/001/NO-004/NO | Paxene | Norway | 11.11.2004 |
| EU/1/99/113/001-004 | Paxene | Liechtenstein | 30.11.2004 |
| EU/1/99/113/001-004/IS | Paxene, concentrate foer solution for infusion, 6 mg/ml | Iceland | 23.11.2004 |
| EU/1/99/114/001/NO-003/NO | Zeffix | Norway | 18.11.2004 |
| EU/1/99/114/001-002/IS | Zeffix, film-coated tablet, 100 mg | Iceland | 19.11.2004 |
| EU/1/99/114/001-003 | Zeffix | Liechtenstein | 30.11.2004 |
| EU/1/99/114/003/IS | Zeffix, oral solution, 5 mg/ml | Iceland | 19.11.2004 |
| EU/1/99/116/001/NO-003/NO | Remicade | Norway | 11.10.2004 |
| EU/1/99/116/001-003 | Remicade | Liechtenstein | 30.9.2004 |
| EU/1/99/117/001/IS | Synagis, powder and solvent fol sol. for injection, 50 mg/hgl | Iceland | 7.10.2004 |
| EU/1/99/117/001/NO-002/NO | Synagis | Norway | 8.10.2004 |
| EU/1/99/117/001-002 | Synagis | Liechtenstein | 30.9.2004 |
| EU/1/99/117/002/IS | Synagis, powder and solvent fol sol. for injection, 100 mg/hgl | Iceland | 7.10.2004 |
| EU/1/99/118/001/NO-010/NO | Arava | Norway | 4.11.2004 |
| EU/1/99/118/001-004/IS | Arava, tablet, 10 mg | Iceland | 8.11.2004 |
| EU/1/99/118/001-010 | Arava | Liechtenstein | 30.11.2004 |
| EU/1/99/118/005-009/IS | Arava, tablet, 20 mg | Iceland | 8.11.2004 |
| EU/1/99/118/009/IS | Arava, tablet, 100 mg | Iceland | 8.11.2004 |
| EU/1/99/119/001 | NovoRapid | Liechtenstein | 30.11.2004 |
| EU/1/99/119/001/IS and 008/IS | NovoRapid, solution for injection, 100 units/ml | Iceland | 11.11.2004 |
| EU/1/99/119/001/NO
  EU/1/99/119/003/NO
  EU/1/99/119/005/NO-014/NO | NovoRapid | Norway | 4.11.2004 |
| EU/1/99/119/003 | NovoRapid | Liechtenstein | 30.11.2004 |
| EU/1/99/119/003/IS and 006/IS | NovoRapid Penfill, solution for injection, 100 units/ml | Iceland | 11.11.2004 |
| EU/1/99/119/005/IS and 007/IS | NovoRapid NovoLet, solution for injection, 100 units/ml | Iceland | 11.11.2004 |
| EU/1/99/119/005-014 | NovoRapid | Liechtenstein | 30.11.2004 |
| EU/1/99/119/012-014/IS | NovoRapid InnoLet, solution for injection, 100 units/ml | Iceland | 11.11.2004 |
| EU/1/99/125/001/NO-008/NO | Zyprexa Velotab | Norway | 4.12.2004 |
| EU/1/99/125/001-004/IS | Zyprexa Velotab, orodispersible tablet | Iceland | 1.12.2004 |
| EU/2/98/009/001-006/IS | Suvaxyn Aujezky 738+O/W, emulsion for injection, | Iceland | 6.8.2004 |
| EU/2/99/013/001/NO-002/NO | Halocur | Norway | 21.12.2004 |

EU-Number

Product

Country

Date of renewal

EU/1/99/119/009/IS-011/IS

NovoRapid FlexPen, solution for injection, 100 units/ml

Iceland

11.11.2004

EU/1/99/097/001

Beromun

Liechtenstein

31.7.2004

EU/1/99/097/001/IS

Beromun, powder and solvent for solution for infusion, 1 mg

Iceland

9.8.2004

EU/1/99/100/001-002/IS

Cetrotide, powder for solution for injection, 0,25 mg

Iceland

15.9.2004

EU/1/99/100/001-003

Cetrotide

Liechtenstein

30.9.2004

EU/1/99/100/003/IS

Cetrotide, powder for solution for injection, 3 mg

Iceland

15.9.2004

EU/1/99/103/001/IS

Refacto, powder and solvent for sol. for injection, 250 a.e.

Iceland

19.8.2004

EU/1/99/103/001/NO-004/NO

ReFacto

Norway

16.8.2004

EU/1/99/103/001-004

ReFacto

Liechtenstein

30.9.2004

EU/1/99/103/002/IS

Refacto, powder and solvent for sol. for injection, 500 a.e.

Iceland

19.8.2004

EU/1/99/103/003/IS

Refacto, powder and solvent for sol. for injection, 1 000 a.e.

Iceland

19.8.2004

EU/1/99/103/004/IS

Refacto, powder and solvent for sol. for injection, 2 000 a.e.

Iceland

19.8.2004

EU/1/99/104/001

Procomvax

Liechtenstein

30.9.2004

EU/1/99/104/001/IS

Procomvax, suspension for injection

Iceland

2.9.2004

EU/1/99/107/001/IS

Rebetol, capsule, hard, 200 mg

Iceland

29.9.2004

EU/1/99/107/001/NO-003/NO

Rebetol

Norway

28.9.2004

EU/1/99/107/001-003

Rebetol

Liechtenstein

30.9.2004

EU/1/99/108/001

Ferriprox

Liechtenstein

30.9.2004

EU/1/99/108/001/IS

Ferriprox, film coated tablet, 500 mg

Iceland

22.9.2004

EU/1/99/108/001/NO

Ferriprox

Norway

27.9.2004

EU/1/99/109/001/IS

Integrilin, solution for infusion, 0,75 mg/ml

Iceland

1.10.2004

EU/1/99/109/001/NO-002/NO

Integrilin

Norway

28.9.2004

EU/1/99/109/001-002

Integrilin

Liechtenstein

30.9.2004

EU/1/99/109/002/IS

Integrilin, solution for injection, 2 mg/ml

Iceland

1.10.2004

EU/1/99/111/001-009

Stocrin

Liechtenstein

31.7.2004

EU/1/99/112/001/IS

Ziagen, film-coated tablet, 300 mg

Iceland

16.9.2004

EU/1/99/112/001/NO-002/NO

Ziagen

Norway

18.9.2004

EU/1/99/112/002/IS

Ziagen, oral liquid, 20 mg/ml

Iceland

16.9.2004

EU/1/99/113/001/NO-004/NO

Paxene

Norway

11.11.2004

EU/1/99/113/001-004

Paxene

Liechtenstein

30.11.2004

EU/1/99/113/001-004/IS

Paxene, concentrate foer solution for infusion, 6 mg/ml

Iceland

23.11.2004

EU/1/99/114/001/NO-003/NO

Zeffix

Norway

18.11.2004

EU/1/99/114/001-002/IS

Zeffix, film-coated tablet, 100 mg

Iceland

19.11.2004

EU/1/99/114/001-003

Zeffix

Liechtenstein

30.11.2004

EU/1/99/114/003/IS

Zeffix, oral solution, 5 mg/ml

Iceland

19.11.2004

EU/1/99/116/001/NO-003/NO

Remicade

Norway

11.10.2004

EU/1/99/116/001-003

Remicade

Liechtenstein

30.9.2004

EU/1/99/117/001/IS

Synagis, powder and solvent fol sol. for injection, 50 mg/hgl

Iceland

7.10.2004

EU/1/99/117/001/NO-002/NO

Synagis

Norway

8.10.2004

EU/1/99/117/001-002

Synagis

Liechtenstein

30.9.2004

EU/1/99/117/002/IS

Synagis, powder and solvent fol sol. for injection, 100 mg/hgl

Iceland

7.10.2004

EU/1/99/118/001/NO-010/NO

Arava

Norway

4.11.2004

EU/1/99/118/001-004/IS

Arava, tablet, 10 mg

Iceland

8.11.2004

EU/1/99/118/001-010

Arava

Liechtenstein

30.11.2004

EU/1/99/118/005-009/IS

Arava, tablet, 20 mg

Iceland

8.11.2004

EU/1/99/118/009/IS

Arava, tablet, 100 mg

Iceland

8.11.2004

EU/1/99/119/001

NovoRapid

Liechtenstein

30.11.2004

EU/1/99/119/001/IS and 008/IS

NovoRapid, solution for injection, 100 units/ml

Iceland

11.11.2004

EU/1/99/119/001/NO

EU/1/99/119/003/NO

EU/1/99/119/005/NO-014/NO

NovoRapid

Norway

4.11.2004

EU/1/99/119/003

NovoRapid

Liechtenstein

30.11.2004

EU/1/99/119/003/IS and 006/IS

NovoRapid Penfill, solution for injection, 100 units/ml

Iceland

11.11.2004

EU/1/99/119/005/IS and 007/IS

NovoRapid NovoLet, solution for injection, 100 units/ml

Iceland

11.11.2004

EU/1/99/119/005-014

NovoRapid

Liechtenstein

30.11.2004

EU/1/99/119/012-014/IS

NovoRapid InnoLet, solution for injection, 100 units/ml

Iceland

11.11.2004

EU/1/99/125/001/NO-008/NO

Zyprexa Velotab

Norway

4.12.2004

EU/1/99/125/001-004/IS

Zyprexa Velotab, orodispersible tablet

Iceland

1.12.2004

EU/2/98/009/001-006/IS

Suvaxyn Aujezky 738+O/W, emulsion for injection,

Iceland

6.8.2004

EU/2/99/013/001/NO-002/NO

Halocur

Norway

21.12.2004

---

ANNEX III

3.   Extended Marketing Authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July — 31 December 2004:

| EU-Number | Product | Country | Date of extention |
| --- | --- | --- | --- |
| EU/03/258/007-009/IS | Avandamet 2 mg/1 000 mg, film-coated tablets | Iceland | 20.10.2004 |
| EU/03/258/010-012/IS | Avandamet 4 mg/1 000 mg, film-coated tablets | Iceland | 20.10.2004 |
| EU/1/00/143/004/IS | KOGENATE Bayer 250 IU Powder and solvent for solution for injection | Iceland | 23.10.2004 |
| EU/1/00/143/004/NO-006/NO | Kogenate | Norway | 21.10.2004 |
| EU/1/00/143/005/IS | KOGENATE Bayer 500 IU Powder and solvent for solution for injection | Iceland | 23.10.2004 |
| EU/1/00/143/006/IS | KOGENATE Bayer 1 000 IU Powder and solvent for solution for injection | Iceland | 23.10.2004 |
| EU/1/01/193/002/IS | MabCampath, conc. for sol. for inf. 30 mg/ml | Iceland | 26.11.2004 |
| EU/1/02/206/009/NO-017/NO | Arixtra | Norway | 8.12.2004 |
| EU/1/02/207/009/NO-017/NO | Quixidar | Norway | 8.12.2004 |
| EU/1/03/258/007/NO-012/NO | Avandamet | Norway | 24.9.2004 |
| EU/1/97/046/016-030/IS | Aprovel 75, 150 and 300 mg film-coated tablets | Iceland | 25.8.2004 |
| EU/1/97/049/016-030/IS | Karvea 75, 150 and 300 mg film-coated tablets | Iceland | 25.8.2004 |
| EU/1/98/085/011-020/IS | Karvezide, 150 mg/12,5 mg and 300 mg/12,5 mg film-coated tablets | Iceland | 25.8.2004 |
| EU/1/98/086/011-020/IS | CoAprovel 150 mg/12,5 mg and 300 mg/12,5 mg film-coated tablets | Iceland | 25.8.2004 |

EU-Number

Product

Country

Date of extention

EU/03/258/007-009/IS

Avandamet 2 mg/1 000 mg, film-coated tablets

Iceland

20.10.2004

EU/03/258/010-012/IS

Avandamet 4 mg/1 000 mg, film-coated tablets

Iceland

20.10.2004

EU/1/00/143/004/IS

KOGENATE Bayer 250 IU Powder and solvent for solution for injection

Iceland

23.10.2004

EU/1/00/143/004/NO-006/NO

Kogenate

Norway

21.10.2004

EU/1/00/143/005/IS

KOGENATE Bayer 500 IU Powder and solvent for solution for injection

Iceland

23.10.2004

EU/1/00/143/006/IS

KOGENATE Bayer 1 000 IU Powder and solvent for solution for injection

Iceland

23.10.2004

EU/1/01/193/002/IS

MabCampath, conc. for sol. for inf. 30 mg/ml

Iceland

26.11.2004

EU/1/02/206/009/NO-017/NO

Arixtra

Norway

8.12.2004

EU/1/02/207/009/NO-017/NO

Quixidar

Norway

8.12.2004

EU/1/03/258/007/NO-012/NO

Avandamet

Norway

24.9.2004

EU/1/97/046/016-030/IS

Aprovel 75, 150 and 300 mg film-coated tablets

Iceland

25.8.2004

EU/1/97/049/016-030/IS

Karvea 75, 150 and 300 mg film-coated tablets

Iceland

25.8.2004

EU/1/98/085/011-020/IS

Karvezide, 150 mg/12,5 mg and 300 mg/12,5 mg film-coated tablets

Iceland

25.8.2004

EU/1/98/086/011-020/IS

CoAprovel 150 mg/12,5 mg and 300 mg/12,5 mg film-coated tablets

Iceland

25.8.2004

---

ANNEX IV

4.   Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July — 31 December 2004:

| EU-Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/01/181/001-007 | Ixense | Liechtenstein | 30.11.2004 |
| EU/1/01/181/001-007/IS | Ixense | Iceland | 8.11.2004 |
| EU/1/01/182/001/NO-010/NO | Taluvian | Norway | 10.8.2004 |
| EU/1/01/182/001-010 | Taluvian | Liechtenstein | 30.9.2004 |
| EU/1/01/182/001-010/IS | Taluvian | Iceland | 26.10.2004 |

EU-Number

Product

Country

Date of withdrawal

EU/1/01/181/001-007

Ixense

Liechtenstein

30.11.2004

EU/1/01/181/001-007/IS

Ixense

Iceland

8.11.2004

EU/1/01/182/001/NO-010/NO

Taluvian

Norway

10.8.2004

EU/1/01/182/001-010

Taluvian

Liechtenstein

30.9.2004

EU/1/01/182/001-010/IS

Taluvian

Iceland

26.10.2004

---

| 28.9.2006 | EN | Official Journal of the European Union | C 233/54 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/54

---

List of marketing authorisations granted by the EEA EFTA States for the first half of 2005

(2006/C 233/12)

With reference to EEA Joint Committee Decision No. 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note, at the meeting on 10 March 2006, the following lists concerning marketing authorisations for medicinal products for the period 1 January — 30 June 2005:

| Annex I | List of new marketing authorisations |
| --- | --- |

Annex I

| Annex II | List of renewed marketing authorisations |
| --- | --- |

Annex II

| Annex III | List of extended marketing authorisations |
| --- | --- |

Annex III

| Annex IV | List of withdrawn marketing authorisations |
| --- | --- |

Annex IV

---

ANNEX I

1.   New Marketing Authorisations:

The following marketing authorisations have been granted In the EEA EFTA States during the period 1 January — 30 June 2005:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/146/028-029 | Keppra | Liechtenstein | 31.3.2005 |
| EU/1/00/149/001/NO | Panretin | Norway | 28.2.2005 |
| EU/1/01/171/011-012 | Rapamune | Liechtenstein | 31.3.2005 |
| EU/1/01/178/001/IS | Targretin 75 mg, capsule, soft | Iceland | 31.1.2005 |
| EU/1/01/183/019 | HBVAXPRO | Liechtenstein | 31.5.2005 |
| EU/1/01/184/045-056 | Nespo | Liechtenstein | 31.3.2005 |
| EU/1/01/185/045-056 | Aranesp | Liechtenstein | 31.3.2005 |
| EU/1/01/198/011-013 | Glivec | Liechtenstein | 31.1.2005 |
| EU/1/02/227/002 | Neulasta | Liechtenstein | 31.3.2005 |
| EU/1/02/228/002 | Neupopeg | Liechtenstein | 31.3.2005 |
| EU/1/02/237/005 | Cialis | Liechtenstein | 31.1.2005 |
| EU/1/02/239/025-030 | Bextra | Liechtenstein | 31.1.2005 |
| EU/1/02/246/003 | Carbaglu | Liechtenstein | 31.5.2005 |
| EU/1/04/285/021-028 | Apidra | Liechtenstein | 31.5.2005 |
| EU/1/04/296/001/IS | Cymbalta 30 mg, Gastro-resistant capsule, hard | Iceland | 14.1.2005 |
| EU/1/04/296/001/NO-004/NO | Cymbalta | Norway | 11.1.2005 |
| EU/1/04/296/001-004 | Cymbalta | Liechtenstein | 31.1.2005 |
| EU/1/04/296/002-005/IS | Cymbalta 60 mg, Gastro-resistant capsule, hard | Iceland | 14.1.2005 |
| EU/1/04/297/001/IS | Xeristar 30 mg, Gastro-resistant tablet hard | Iceland | 14.1.2005 |
| EU/1/04/297/001/NO-004/NO | Xeristar | Norway | 11.1.2005 |
| EU/1/04/297/001-004 | Xeristar | Liechtenstein | 31.1.2005 |
| EU/1/04/297/002-005/IS | Xeristar 60 mg, Gastro-resistant tablet hard | Iceland | 14.1.2005 |
| EU/1/04/298/001/NO-002/NO | Kivexa | Norway | 11.1.2005 |
| EU/1/04/298/001-002 | Kivexa | Liechtenstein | 31.1.2005 |
| EU/1/04/298/001-002/IS | Kivexa 600 mg, film-coated tablet | Iceland | 11.1.2005 |
| EU/1/04/299/001/NO-003/NO | Fendrix | Norway | 15.2.2005 |
| EU/1/04/299/001-003 | Fendrix | Liechtenstein | 31.3.2005 |
| EU/1/04/299/001-003/IS | Fendrix 20 microg/0,5 ml, suspension for injection | Iceland | 25.2.2005 |
| EU/1/04/300/001/NO-002/NO | Avastin | Norway | 18.1.2005 |
| EU/1/04/300/001-002 | Avastin | Liechtenstein | 31.1.2005 |
| EU/1/04/300/001-002/IS | Avastin 25 mg/ml, concentrate for sol. For infusion | Iceland | 11.2.2005 |
| EU/1/04/301/001/NO-005/NO | Quintanrix | Norway | 1.3.2005 |
| EU/1/04/301/001-005 | Quintanrix | Liechtenstein | 31.3.2005 |
| EU/1/04/301/001-005/IS | Quintanrix, powder and solvent for susp. for injection | Iceland | 14.3.2005 |
| EU/1/04/302/001/NO-003/NO | Prialt | Norway | 17.3.2005 |
| EU/1/04/302/001-003 | Prialt | Liechtenstein | 31.3.2005 |
| EU/1/04/302/001-003/IS | Prialt, solution for injection | Iceland | 18.3.2005 |
| EU/1/04/303/001/IS | Orfadin 2 mg, capsule, hard | Iceland | 19.3.2005 |
| EU/1/04/303/003/IS | Orfadin 10 mg, capsule, hard | Iceland | 19.3.2005 |
| EU/1/04/303/001/NO-003/NO | Orfadin | Norway | 17.3.2005 |
| EU/1/04/303/001-003 | Orfadin | Liechtenstein | 31.3.2005 |
| EU/1/04/303/002/IS | Orfadin 5 mg, capsule, hard | Iceland | 19.3.2005 |
| EU/1/04/304/001/NO-007/NO | Azilect | Norway | 21.3.2005 |
| EU/1/04/304/001-007 | Azilect | Liechtenstein | 31.3.2005 |
| EU/1/04/304/001-007/IS | Azilect 1 mg, tablet | Iceland | 17.3.2005 |
| EU/1/04/305/001 | Truvada | Liechtenstein | 31.3.2005 |
| EU/1/04/305/001/IS | Truvada 245/200 mg, film-coated tablet | Iceland | 16.3.2005 |
| EU/1/04/305/001/NO | Truvada | Norway | 7.3.2005 |
| EU/1/04/306/001 | Aloxi | Liechtenstein | 31.5.2005 |
| EU/1/04/306/001/IS | Aloxi 0,25 mg/5 ml, solution for injection | Iceland | 7.4.2005 |
| EU/1/04/306/001/NO | Aloxi | Norway | 20.4.2005 |
| EU/1/04/307/001/NO-004/NO | Zonegran | Norway | 9.4.2005 |
| EU/1/04/307/001-004 | Zonegran | Liechtenstein | 31.5.2005 |
| EU/1/04/307/003/IS | Zonegran 25 mg, capsule, hard | Iceland | 6.4.2005 |
| EU/1/04/307/003/IS | Zonegran 50 mg, capsule, hard | Iceland | 6.4.2005 |
| EU/1/05/308/001 | Aclasta | Liechtenstein | 31.5.2005 |
| EU/1/05/308/001/IS | Aclasta 5 mg/ml, solution for infusion | Iceland | 9.5.2005 |
| EU/1/05/308/001/NO | Aclasta | Norway | 10.5.2005 |
| EU/1/97/044/001-006/IS | Tasmar | Iceland | 18.1.2005 |
| EU/1/97/045/004 | Helicobacter Test INFAI | Liechtenstein | 31.3.2005 |
| EU/1/99/107/004 | Rebetol | Liechtenstein | 31.3.2005 |
| EU/1/99/120/001/NO-004/NO | Ammonaps | Norway | 21.4.2005 |
| EU/1/99/123/011 | Renagel | Liechtenstein | 31.3.2005 |
| EU/1/99/125/005-008 | Zyprexa Velotab | Liechtenstein | 31.3.2005 |
| EU/1/99/126/004-005 | Enbrel | Liechtenstein | 31.3.2005 |
| EU/1/99/126/006-011 | Enbrel | Liechtenstein | 31.5.2005 |
| EU/2/00/019/005-007 | Eurifel FeLV | Liechtenstein | 31.5.2005 |
| EU/2/03/037/001-004/IS | ProteqFlu, powder and solvent for susp. for inj. | Iceland | 9.5.2005 |
| EU/2/03/038/001-004/IS | ProteqFlu-Te, powder and solvent for susp. for inj. | Iceland | 18.2.2005 |
| EU/2/04/046/001-003/IS | Nobivac Piro, suspension for injection | Iceland | 12.5.2005 |
| EU/2/04/047/001/NO-002/NO | Purevax RCPCh FeLV | Norway | 21.3.2005 |
| EU/2/04/047/001-002 | Purevax RCPCh FeLV | Liechtenstein | 31.3.2005 |
| EU/2/04/047/001-002/IS | Purevax RCPCh Fel V | Iceland | 30.6.2005 |
| EU/2/04/048/001/NO-002/NO | Purevax RCP FeLV | Norway | 21.3.2005 |
| EU/2/04/048/001-002 | Purevax RCP FeLV | Liechtenstein | 31.3.2005 |
| EU/2/04/048/001-002/IS | Purevax RCP FeL V | Iceland | 30.6.2005 |
| EU/2/04/049/001/NO-002/NO | Purevax RCCh | Norway | 21.3.2005 |
| EU/2/04/049/001-002 | Purevax RCCh | Liechtenstein | 31.3.2005 |
| EU/2/04/050/001/NO-002/NO | Purevax RCPCh | Norway | 21.3.2005 |
| EU/2/04/050/001-002 | Purevax RCPCh | Liechtenstein | 31.3.2005 |
| EU/2/04/051/001/NO-002/NO | Purevax RC | Norway | 21.3.2005 |
| EU/2/04/051/001-002 | Purevax RC | Liechtenstein | 31.3.2005 |
| EU/2/04/051/001-002/IS | Purevax RC, powder and solvent for susp. for inj. | Iceland | 30.6.2005 |
| EU/2/04/052/001/NO-002/NO | Purevax RCP | Norway | 21.3.2005 |
| EU/2/04/052/001-002 | Purevax RCP | Liechtenstein | 31.3.2005 |
| EU/2/04/052/001-002/IS | Purevax RCP, powder and solvent for susp. for injection | Iceland | 30.6.2005 |
| EU/2/04/49/001-002/IS | Purevax RCCh, powder and solvent for susp. for inj. | Iceland | 30.6.2005 |
| EU/2/04/50/001-002/IS | Purevax RCPCh, powder and solvent for susp. for inj. | Iceland | 30.6.2005 |
| EU/2/05/053/001/IS | Naxel 100 mg/ml, suspension for injection | Iceland | 9.6.2005 |
| EU/2/05/053/001/NO | Naxcel | Norway | 17.6.2005 |
| EU/2/99/014/012 | Stronghold | Liechtenstein | 31.1.2005 |
| EU/2/99/015/001/NO | Oxyglobin | Norway | 5.1.2005 |
| EU/2/99/017/001-006/IS | Ibraxion, emulsion for injection | Iceland | 10.5.2005 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/146/028-029

Keppra

Liechtenstein

31.3.2005

EU/1/00/149/001/NO

Panretin

Norway

28.2.2005

EU/1/01/171/011-012

Rapamune

Liechtenstein

31.3.2005

EU/1/01/178/001/IS

Targretin 75 mg, capsule, soft

Iceland

31.1.2005

EU/1/01/183/019

HBVAXPRO

Liechtenstein

31.5.2005

EU/1/01/184/045-056

Nespo

Liechtenstein

31.3.2005

EU/1/01/185/045-056

Aranesp

Liechtenstein

31.3.2005

EU/1/01/198/011-013

Glivec

Liechtenstein

31.1.2005

EU/1/02/227/002

Neulasta

Liechtenstein

31.3.2005

EU/1/02/228/002

Neupopeg

Liechtenstein

31.3.2005

EU/1/02/237/005

Cialis

Liechtenstein

31.1.2005

EU/1/02/239/025-030

Bextra

Liechtenstein

31.1.2005

EU/1/02/246/003

Carbaglu

Liechtenstein

31.5.2005

EU/1/04/285/021-028

Apidra

Liechtenstein

31.5.2005

EU/1/04/296/001/IS

Cymbalta 30 mg, Gastro-resistant capsule, hard

Iceland

14.1.2005

EU/1/04/296/001/NO-004/NO

Cymbalta

Norway

11.1.2005

EU/1/04/296/001-004

Cymbalta

Liechtenstein

31.1.2005

EU/1/04/296/002-005/IS

Cymbalta 60 mg, Gastro-resistant capsule, hard

Iceland

14.1.2005

EU/1/04/297/001/IS

Xeristar 30 mg, Gastro-resistant tablet hard

Iceland

14.1.2005

EU/1/04/297/001/NO-004/NO

Xeristar

Norway

11.1.2005

EU/1/04/297/001-004

Xeristar

Liechtenstein

31.1.2005

EU/1/04/297/002-005/IS

Xeristar 60 mg, Gastro-resistant tablet hard

Iceland

14.1.2005

EU/1/04/298/001/NO-002/NO

Kivexa

Norway

11.1.2005

EU/1/04/298/001-002

Kivexa

Liechtenstein

31.1.2005

EU/1/04/298/001-002/IS

Kivexa 600 mg, film-coated tablet

Iceland

11.1.2005

EU/1/04/299/001/NO-003/NO

Fendrix

Norway

15.2.2005

EU/1/04/299/001-003

Fendrix

Liechtenstein

31.3.2005

EU/1/04/299/001-003/IS

Fendrix 20 microg/0,5 ml, suspension for injection

Iceland

25.2.2005

EU/1/04/300/001/NO-002/NO

Avastin

Norway

18.1.2005

EU/1/04/300/001-002

Avastin

Liechtenstein

31.1.2005

EU/1/04/300/001-002/IS

Avastin 25 mg/ml, concentrate for sol. For infusion

Iceland

11.2.2005

EU/1/04/301/001/NO-005/NO

Quintanrix

Norway

1.3.2005

EU/1/04/301/001-005

Quintanrix

Liechtenstein

31.3.2005

EU/1/04/301/001-005/IS

Quintanrix, powder and solvent for susp. for injection

Iceland

14.3.2005

EU/1/04/302/001/NO-003/NO

Prialt

Norway

17.3.2005

EU/1/04/302/001-003

Prialt

Liechtenstein

31.3.2005

EU/1/04/302/001-003/IS

Prialt, solution for injection

Iceland

18.3.2005

EU/1/04/303/001/IS

Orfadin 2 mg, capsule, hard

Iceland

19.3.2005

EU/1/04/303/003/IS

Orfadin 10 mg, capsule, hard

Iceland

19.3.2005

EU/1/04/303/001/NO-003/NO

Orfadin

Norway

17.3.2005

EU/1/04/303/001-003

Orfadin

Liechtenstein

31.3.2005

EU/1/04/303/002/IS

Orfadin 5 mg, capsule, hard

Iceland

19.3.2005

EU/1/04/304/001/NO-007/NO

Azilect

Norway

21.3.2005

EU/1/04/304/001-007

Azilect

Liechtenstein

31.3.2005

EU/1/04/304/001-007/IS

Azilect 1 mg, tablet

Iceland

17.3.2005

EU/1/04/305/001

Truvada

Liechtenstein

31.3.2005

EU/1/04/305/001/IS

Truvada 245/200 mg, film-coated tablet

Iceland

16.3.2005

EU/1/04/305/001/NO

Truvada

Norway

7.3.2005

EU/1/04/306/001

Aloxi

Liechtenstein

31.5.2005

EU/1/04/306/001/IS

Aloxi 0,25 mg/5 ml, solution for injection

Iceland

7.4.2005

EU/1/04/306/001/NO

Aloxi

Norway

20.4.2005

EU/1/04/307/001/NO-004/NO

Zonegran

Norway

9.4.2005

EU/1/04/307/001-004

Zonegran

Liechtenstein

31.5.2005

EU/1/04/307/003/IS

Zonegran 25 mg, capsule, hard

Iceland

6.4.2005

EU/1/04/307/003/IS

Zonegran 50 mg, capsule, hard

Iceland

6.4.2005

EU/1/05/308/001

Aclasta

Liechtenstein

31.5.2005

EU/1/05/308/001/IS

Aclasta 5 mg/ml, solution for infusion

Iceland

9.5.2005

EU/1/05/308/001/NO

Aclasta

Norway

10.5.2005

EU/1/97/044/001-006/IS

Tasmar

Iceland

18.1.2005

EU/1/97/045/004

Helicobacter Test INFAI

Liechtenstein

31.3.2005

EU/1/99/107/004

Rebetol

Liechtenstein

31.3.2005

EU/1/99/120/001/NO-004/NO

Ammonaps

Norway

21.4.2005

EU/1/99/123/011

Renagel

Liechtenstein

31.3.2005

EU/1/99/125/005-008

Zyprexa Velotab

Liechtenstein

31.3.2005

EU/1/99/126/004-005

Enbrel

Liechtenstein

31.3.2005

EU/1/99/126/006-011

Enbrel

Liechtenstein

31.5.2005

EU/2/00/019/005-007

Eurifel FeLV

Liechtenstein

31.5.2005

EU/2/03/037/001-004/IS

ProteqFlu, powder and solvent for susp. for inj.

Iceland

9.5.2005

EU/2/03/038/001-004/IS

ProteqFlu-Te, powder and solvent for susp. for inj.

Iceland

18.2.2005

EU/2/04/046/001-003/IS

Nobivac Piro, suspension for injection

Iceland

12.5.2005

EU/2/04/047/001/NO-002/NO

Purevax RCPCh FeLV

Norway

21.3.2005

EU/2/04/047/001-002

Purevax RCPCh FeLV

Liechtenstein

31.3.2005

EU/2/04/047/001-002/IS

Purevax RCPCh Fel V

Iceland

30.6.2005

EU/2/04/048/001/NO-002/NO

Purevax RCP FeLV

Norway

21.3.2005

EU/2/04/048/001-002

Purevax RCP FeLV

Liechtenstein

31.3.2005

EU/2/04/048/001-002/IS

Purevax RCP FeL V

Iceland

30.6.2005

EU/2/04/049/001/NO-002/NO

Purevax RCCh

Norway

21.3.2005

EU/2/04/049/001-002

Purevax RCCh

Liechtenstein

31.3.2005

EU/2/04/050/001/NO-002/NO

Purevax RCPCh

Norway

21.3.2005

EU/2/04/050/001-002

Purevax RCPCh

Liechtenstein

31.3.2005

EU/2/04/051/001/NO-002/NO

Purevax RC

Norway

21.3.2005

EU/2/04/051/001-002

Purevax RC

Liechtenstein

31.3.2005

EU/2/04/051/001-002/IS

Purevax RC, powder and solvent for susp. for inj.

Iceland

30.6.2005

EU/2/04/052/001/NO-002/NO

Purevax RCP

Norway

21.3.2005

EU/2/04/052/001-002

Purevax RCP

Liechtenstein

31.3.2005

EU/2/04/052/001-002/IS

Purevax RCP, powder and solvent for susp. for injection

Iceland

30.6.2005

EU/2/04/49/001-002/IS

Purevax RCCh, powder and solvent for susp. for inj.

Iceland

30.6.2005

EU/2/04/50/001-002/IS

Purevax RCPCh, powder and solvent for susp. for inj.

Iceland

30.6.2005

EU/2/05/053/001/IS

Naxel 100 mg/ml, suspension for injection

Iceland

9.6.2005

EU/2/05/053/001/NO

Naxcel

Norway

17.6.2005

EU/2/99/014/012

Stronghold

Liechtenstein

31.1.2005

EU/2/99/015/001/NO

Oxyglobin

Norway

5.1.2005

EU/2/99/017/001-006/IS

Ibraxion, emulsion for injection

Iceland

10.5.2005

---

ANNEX II

2.   Renewed Marketing Authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January — 30 June 2005:

| EU-Number | Product | Country | Date of renewal |
| --- | --- | --- | --- |
| EU/1/00/129/001/NO-003/NO | Azopt | Norway | 30.6.2005 |
| EU/1/00/129/001-003/IS | Azopt, eye drops, suspension, 1% | Iceland | 30.6.2005 |
| EU/1/00/130/001/NO-002/NO | Orgalutran | Norway | 4.4.2005 |
| EU/1/00/130/001-002 | Orgalutran | Liechtenstein | 31.3.2005 |
| EU/1/00/130/001-002/IS | Orgalutran | Iceland | 18.4.2005 |
| EU/1/00/131/001/NO-050/NO | PegIntron | Norway | 24.6.2005 |
| EU/1/00/131/001-050/IS | PegIntron | Iceland | 28.6.2005 |
| EU/1/00/132/001/NO-050/NO | ViraferonPeg | Norway | 24.6.2005 |
| EU/1/00/132/001-050/IS | ViraferonPeg | Iceland | 28.6.2005 |
| EU/1/99/100/001/NO-003/NO | Cetrotide | Norway | 4.1.2005 |
| EU/1/99/120/001-002/IS | Ammonaps, tablets, 500 mg | Iceland | 29.4.2005 |
| EU/1/99/120/003-004/IS | Ammonaps 940 mg/g, granules | Iceland | 29.4.2005 |
| EU/1/99/122/001/NO-002/NO | Thyrogen | Norway | 15.4.2005 |
| EU/1/99/122/001-002/IS | Thyrogen, powder for solution for injection, 0,9 mg | Iceland | 14.4.2005 |
| EU/1/99/123/001/NO-011/NO | Renagel | Norway | 4.2.2005 |
| EU/1/99/123/001-004/IS | Renagel, capsule, hard, 403 mg | Iceland | 25.2.2005 |
| EU/1/99/123/001-010 | Renagel | Liechtenstein | 31.3.2005 |
| EU/1/99/123/005-007/IS | Renagel, film-coated tablet, 400 mg | Iceland | 25.2.2005 |
| EU/1/99/123/008-011/IS | Renagel, film-coated tablet, 800 mg | Iceland | 25.2.2005 |
| EU/1/99/124/001/IS | Tractocile, solution for injection, 7,5 mg/ml | Iceland | 1.3.2005 |
| EU/1/99/124/001/NO-002/NO | Tractocile | Norway | 7.3.2005 |
| EU/1/99/124/001-002 | Tractocile | Liechtenstein | 31.3.2005 |
| EU/1/99/124/002/IS | Tractocile, concentrate for solution for infusion, 7,5 mg/ml | Iceland | 1.3.2005 |
| EU/1/99/125/001-004 | Zyprexa Velotab | Liechtenstein | 31.3.2005 |
| EU/1/99/126/001/NO-005/NO | Enbrel | Norway | 6.4.2005 |
| EU/1/99/126/001-003 | Enbrel | Liechtenstein | 31.3.2005 |
| EU/1/99/126/001-005/IS | Enbrel | Iceland | 15.4.2005 |
| EU/1/99/127/001/NO-044/NO | IntronA | Norway | 20.6.2005 |
| EU/1/99/127/001-044/IS | IntronA | Iceland | 27.6.2005 |
| EU/1/99/128/001/NO-037/NO | Viraferon | Norway | 20.6.2005 |
| EU/1/99/128/001-037/IS | Viraferon | Iceland | 27.6.2005 |
| EU/2/00/018/001/IS | Incurin, tablet, 1mg | Iceland | 10.5.2005 |
| EU/2/00/018/001/NO | Incurin | Norway | 16.6.2005 |
| EU/2/00/019/001/NO-003/NO | Eurifel FeLV | Norway | 31.5.2005 |
| EU/2/00/019/001-003 | Eurifel FeLV | Liechtenstein | 31.5.2005 |
| EU/2/00/021/001/NO-002/NO | Rabigen | Norway | 23.5.2005 |
| EU/2/00/021/001-002/IS | RABIGEN SAG2, oral suspension | Iceland | 9.5.2005 |
| EU/2/99/013/001-002 | Halocur | Liechtenstein | 31.1.2005 |
| EU/2/99/013/001-002/IS | Halocur 0.5 mg/ml, oral solution | Iceland | 18.2.2005 |
| EU/2/99/014/001/NO-012/NO | Stronghold | Norway | 6.1.2005 |
| EU/2/99/014/001-011 | Stronghold | Liechtenstein | 31.1.2005 |
| EU/2/99/014/001-012/IS | Stronghold spot on solution 6% and 12% | Iceland | 7.1.2005 |
| EU/2/99/015/001 | Oxyglobin | Liechtenstein | 31.1.2005 |
| EU/2/99/015/001/IS | Oxyglobin 13g/dl, solution for infusion | Iceland | 5.1.2005 |
| EU/2/99/017/001/NO-006/NO | Ibraxion | Norway | 2.6.2005 |
| EU/2/99/017/001-006 | Ibraxion | Liechtenstein | 31.5.2005 |

EU-Number

Product

Country

Date of renewal

EU/1/00/129/001/NO-003/NO

Azopt

Norway

30.6.2005

EU/1/00/129/001-003/IS

Azopt, eye drops, suspension, 1%

Iceland

30.6.2005

EU/1/00/130/001/NO-002/NO

Orgalutran

Norway

4.4.2005

EU/1/00/130/001-002

Orgalutran

Liechtenstein

31.3.2005

EU/1/00/130/001-002/IS

Orgalutran

Iceland

18.4.2005

EU/1/00/131/001/NO-050/NO

PegIntron

Norway

24.6.2005

EU/1/00/131/001-050/IS

PegIntron

Iceland

28.6.2005

EU/1/00/132/001/NO-050/NO

ViraferonPeg

Norway

24.6.2005

EU/1/00/132/001-050/IS

ViraferonPeg

Iceland

28.6.2005

EU/1/99/100/001/NO-003/NO

Cetrotide

Norway

4.1.2005

EU/1/99/120/001-002/IS

Ammonaps, tablets, 500 mg

Iceland

29.4.2005

EU/1/99/120/003-004/IS

Ammonaps 940 mg/g, granules

Iceland

29.4.2005

EU/1/99/122/001/NO-002/NO

Thyrogen

Norway

15.4.2005

EU/1/99/122/001-002/IS

Thyrogen, powder for solution for injection, 0,9 mg

Iceland

14.4.2005

EU/1/99/123/001/NO-011/NO

Renagel

Norway

4.2.2005

EU/1/99/123/001-004/IS

Renagel, capsule, hard, 403 mg

Iceland

25.2.2005

EU/1/99/123/001-010

Renagel

Liechtenstein

31.3.2005

EU/1/99/123/005-007/IS

Renagel, film-coated tablet, 400 mg

Iceland

25.2.2005

EU/1/99/123/008-011/IS

Renagel, film-coated tablet, 800 mg

Iceland

25.2.2005

EU/1/99/124/001/IS

Tractocile, solution for injection, 7,5 mg/ml

Iceland

1.3.2005

EU/1/99/124/001/NO-002/NO

Tractocile

Norway

7.3.2005

EU/1/99/124/001-002

Tractocile

Liechtenstein

31.3.2005

EU/1/99/124/002/IS

Tractocile, concentrate for solution for infusion, 7,5 mg/ml

Iceland

1.3.2005

EU/1/99/125/001-004

Zyprexa Velotab

Liechtenstein

31.3.2005

EU/1/99/126/001/NO-005/NO

Enbrel

Norway

6.4.2005

EU/1/99/126/001-003

Enbrel

Liechtenstein

31.3.2005

EU/1/99/126/001-005/IS

Enbrel

Iceland

15.4.2005

EU/1/99/127/001/NO-044/NO

IntronA

Norway

20.6.2005

EU/1/99/127/001-044/IS

IntronA

Iceland

27.6.2005

EU/1/99/128/001/NO-037/NO

Viraferon

Norway

20.6.2005

EU/1/99/128/001-037/IS

Viraferon

Iceland

27.6.2005

EU/2/00/018/001/IS

Incurin, tablet, 1mg

Iceland

10.5.2005

EU/2/00/018/001/NO

Incurin

Norway

16.6.2005

EU/2/00/019/001/NO-003/NO

Eurifel FeLV

Norway

31.5.2005

EU/2/00/019/001-003

Eurifel FeLV

Liechtenstein

31.5.2005

EU/2/00/021/001/NO-002/NO

Rabigen

Norway

23.5.2005

EU/2/00/021/001-002/IS

RABIGEN SAG2, oral suspension

Iceland

9.5.2005

EU/2/99/013/001-002

Halocur

Liechtenstein

31.1.2005

EU/2/99/013/001-002/IS

Halocur 0.5 mg/ml, oral solution

Iceland

18.2.2005

EU/2/99/014/001/NO-012/NO

Stronghold

Norway

6.1.2005

EU/2/99/014/001-011

Stronghold

Liechtenstein

31.1.2005

EU/2/99/014/001-012/IS

Stronghold spot on solution 6% and 12%

Iceland

7.1.2005

EU/2/99/015/001

Oxyglobin

Liechtenstein

31.1.2005

EU/2/99/015/001/IS

Oxyglobin 13g/dl, solution for infusion

Iceland

5.1.2005

EU/2/99/017/001/NO-006/NO

Ibraxion

Norway

2.6.2005

EU/2/99/017/001-006

Ibraxion

Liechtenstein

31.5.2005

---

ANNEX IV

4.   Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in EEA EFTA States during the period 1 January — 31 June 2005:

| EU-Number | Product | Country | Date of extention |
| --- | --- | --- | --- |
| EU/1/01/171/011/NO-012/NO | Rapamune | Norway | 2.2.2005 |
| EU/1/01/171/011-012/IS | Rapamune 5 mg filmcoated tablets | Iceland | 1.3.2005 |
| EU/1/02/206/009-011/IS | Arixtra 5mg/0,4 ml solution for injection | Iceland | 10.3.2005 |
| EU/1/02/206/012-014/IS | Arixtra 7,5mg/0,6 ml solution for injection | Iceland | 10.3.2005 |
| EU/1/02/206/015-017/IS | Arixtra 10mg/0,8 ml solution for injection | Iceland | 10.3.2005 |
| EU/1/02/207/009-011/IS | Quixidar 5mg/0,4 ml solution for injection | Iceland | 9.3.2005 |
| EU/1/02/207/012-014/IS | Quixidar 7,5mg/0,6 ml solution for injection | Iceland | 9.3.2005 |
| EU/1/02/207/015-017/IS | Quixidar 10mg/0,8 ml solution for injection | Iceland | 9.3.2005 |
| EU/1/96/026/002/NO | Invirase | Norway | 9.6.2005 |
| EU/1/99/107/004/IS | Rebetol, oral solution 40 mg/ml | Iceland | 22.3.2005 |
| EU/1/99/107/004/NO | Rebetol | Norway | 22.2.2005 |
| EU/1/99/126/006/NO-011/NO | Enbrel | Norway | 19.5.2005 |
| EU/1/99/126/006-011/IS | Enbrel, 50 mg | Iceland | 24.5.2005 |
| EU/2/00/019/005/NO-007/NO | Eurifel FeLV | Norway | 15.4.2005 |

EU-Number

Product

Country

Date of extention

EU/1/01/171/011/NO-012/NO

Rapamune

Norway

2.2.2005

EU/1/01/171/011-012/IS

Rapamune 5 mg filmcoated tablets

Iceland

1.3.2005

EU/1/02/206/009-011/IS

Arixtra 5mg/0,4 ml solution for injection

Iceland

10.3.2005

EU/1/02/206/012-014/IS

Arixtra 7,5mg/0,6 ml solution for injection

Iceland

10.3.2005

EU/1/02/206/015-017/IS

Arixtra 10mg/0,8 ml solution for injection

Iceland

10.3.2005

EU/1/02/207/009-011/IS

Quixidar 5mg/0,4 ml solution for injection

Iceland

9.3.2005

EU/1/02/207/012-014/IS

Quixidar 7,5mg/0,6 ml solution for injection

Iceland

9.3.2005

EU/1/02/207/015-017/IS

Quixidar 10mg/0,8 ml solution for injection

Iceland

9.3.2005

EU/1/96/026/002/NO

Invirase

Norway

9.6.2005

EU/1/99/107/004/IS

Rebetol, oral solution 40 mg/ml

Iceland

22.3.2005

EU/1/99/107/004/NO

Rebetol

Norway

22.2.2005

EU/1/99/126/006/NO-011/NO

Enbrel

Norway

19.5.2005

EU/1/99/126/006-011/IS

Enbrel, 50 mg

Iceland

24.5.2005

EU/2/00/019/005/NO-007/NO

Eurifel FeLV

Norway

15.4.2005

---

ANNEX IV

4.   Withdrawn Marketing Authorisations

The following marketing authorisations have been withdrawn in EEA EFTA States during the period 1 January — 31 June 2005:

| EU-Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/00/138/001/NO-012/NO | Venvia | Norway | 4.1.2005 |
| EU/1/00/138/001-012 | Venvia | Liechtenstein | 31.1.2005 |
| EU/1/00/139/001/NO-012/NO | Nyracta | Norway | 4.1.2005 |
| EU/1/00/139/001-012 | Nyracta | Liechtenstein | 31.1.2005 |
| EU/1/01/181/001/NO-007/NO | Ixense | Norway | 6.1.2005 |
| EU/1/97/048/001/NO-014/NO | Infanrix HepB | Norway | 25.5.2005 |
| EU/1/97/048/001-014 | Infanrix HepB | Liechtenstein | 31.5.2005 |
| EU/1/97/048/001-014/IS | Infanrix HepB | Iceland | 15.6.2005 |

EU-Number

Product

Country

Date of withdrawal

EU/1/00/138/001/NO-012/NO

Venvia

Norway

4.1.2005

EU/1/00/138/001-012

Venvia

Liechtenstein

31.1.2005

EU/1/00/139/001/NO-012/NO

Nyracta

Norway

4.1.2005

EU/1/00/139/001-012

Nyracta

Liechtenstein

31.1.2005

EU/1/01/181/001/NO-007/NO

Ixense

Norway

6.1.2005

EU/1/97/048/001/NO-014/NO

Infanrix HepB

Norway

25.5.2005

EU/1/97/048/001-014

Infanrix HepB

Liechtenstein

31.5.2005

EU/1/97/048/001-014/IS

Infanrix HepB

Iceland

15.6.2005

---

III Notices

Commission

| 28.9.2006 | EN | Official Journal of the European Union | C 233/61 |
| --- | --- | --- | --- |

28.9.2006

EN

Official Journal of the European Union

C 233/61

---

Notice of invitation to tender for the reduction in the import duty on maize imported from non-member countries

(2006/C 233/13)

I.   SUBJECT

| 1. | Notice is hereby given of an invitation to tender for the reduction in the duty on imports from non-member countries of maize falling within subheading 1005 90 00 of the Combined Nomenclature. |
| --- | --- |

1.

Notice is hereby given of an invitation to tender for the reduction in the duty on imports from non-member countries of maize falling within subheading 1005 90 00 of the Combined Nomenclature.

| 2. | The total quantity in respect of which the reduction in the import duty may be fixed is 200 000 tonnes. |
| --- | --- |

2.

The total quantity in respect of which the reduction in the import duty may be fixed is 200 000 tonnes.

| 3. | Contracts will be awarded in accordance with the provisions of Commission Regulation (EC) No 1421/2006 (1). |
| --- | --- |

3.

Contracts will be awarded in accordance with the provisions of Commission Regulation (EC) No 1421/2006 (1).

II.   TIME LIMITS

| 1. | The period for submission of tenders for the first weekly invitation begins on 29.9.2006 and expires on 5.10.2006 at 10 a.m. |
| --- | --- |

1.

The period for submission of tenders for the first weekly invitation begins on 29.9.2006 and expires on 5.10.2006 at 10 a.m.

| 2. | The period for submission of tenders for subsequent weekly invitations begins on the Friday of each week and expires on the following Thursday at 10.00.
  This notice is published only in respect of the issue of this invitation to tender. Unless amended or replaced, this notice is valid for all weekly invitations issued during the period of validity of this invitation to tender.
  However, the submission of tenders will be suspended for weeks in which there is no meeting of the Management Committee for Cereals. |
| --- | --- |

2.

The period for submission of tenders for subsequent weekly invitations begins on the Friday of each week and expires on the following Thursday at 10.00.

This notice is published only in respect of the issue of this invitation to tender. Unless amended or replaced, this notice is valid for all weekly invitations issued during the period of validity of this invitation to tender.

However, the submission of tenders will be suspended for weeks in which there is no meeting of the Management Committee for Cereals.

III.   TENDERS

| 1. | Tenders must be submitted in writing and must either be delivered personally against a receipt or be sent by telefax or e-mail, arriving no later than the date and time stated in Title II, to the following address:





  Fondo Español de Garantía Agraria (FEGA) |
| --- | --- |
| C/Beneficencia 8 |
| E-28004 Madrid |
| E-mail: secreint@fega.mapya.es |
| Fax (34) 91 521 98 32, (34) 91 522 43 87 |

1.

Tenders must be submitted in writing and must either be delivered personally against a receipt or be sent by telefax or e-mail, arriving no later than the date and time stated in Title II, to the following address:

Fondo Español de Garantía Agraria (FEGA)

C/Beneficencia 8

E-28004 Madrid

E-mail: secreint@fega.mapya.es

Fax (34) 91 521 98 32, (34) 91 522 43 87

Tenders not submitted by fax or e-mail must be enclosed in a sealed envelope marked ‘Tender for the reduction in the import duty on maize — Regulation (EC) No 1421/2006’. This envelope must itself be enclosed in another sealed envelope bearing the address in question.

Tenders submitted shall remain firm until the Member State concerned informs the interested party that his tender has been successful.

| 2. | The tender and the proof and declaration referred to in Article 6(3) of Commission Regulation (EC) No 1839/95 (2) shall be written in the official language, or one of the official languages, of the Member State whose competent authority has received the tender. |
| --- | --- |

2.

The tender and the proof and declaration referred to in Article 6(3) of Commission Regulation (EC) No 1839/95 (2) shall be written in the official language, or one of the official languages, of the Member State whose competent authority has received the tender.

IV.   SECURITY FOR TENDER

The tendering security shall be made payable to the competent authority.

V.   AWARD OF THE CONTRACT

The award of the contract shall establish:

| (a) | the successful tenderer's entitlement to be issued, in the Member State in which the tender was submitted, with an import licence stating the reduction in the import duty mentioned in the tender and awarded in respect of the quantity in question; |
| --- | --- |

(a)

the successful tenderer's entitlement to be issued, in the Member State in which the tender was submitted, with an import licence stating the reduction in the import duty mentioned in the tender and awarded in respect of the quantity in question;

| (b) | the successful tenderer's obligation to apply, in the Member State referred to in (a), for an import |
| --- | --- |

(b)

the successful tenderer's obligation to apply, in the Member State referred to in (a), for an import

---

(1)  OJ L 269, 28.9.2006, p. 6.

(2)  OJ L 177, 28.7.1995, p. 4. Regulation as last amended by Reg. 1558/2005 (OJ L 249/2005, p. 6)

---